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ABSTRACT	  
	  
Evidence	  suggests	  that	  CD8+	  T-­‐cells	  play	  a	  major	  role	  in	  the	  control	  of	  HIV-­‐1	  viremia	  
and	  apply	  significant	  immune	  pressure	  on	  HIV-­‐1	  replication.	  However,	  the	  presence	  
of	   virus-­‐specific	   CD8+	   T-­‐cells	   in	   individuals	   with	   varying	   levels	   of	   viral	   control	  
suggests	   that	   CD8+	   T-­‐cells	   may	   differ	   in	   their	   antiviral	   function	   or	   efficacy.	   	   The	  
mechanisms	  underlying	  differences	  in	  the	  control	  of	  viremia,	  particularly	  the	  reasons	  
why	  particular	  individuals	  experience	  more	  effective	  acute	  viremia	  resolution,	  which	  
is	  a	  good	  correlate	  of	  the	  subsequent	  rate	  of	  disease	  progression,	  are	  still	  not	  well	  
understood.	   In	   order	   to	   uncover	   some	   of	   the	   features	   of	   CD8+	   T-­‐cell	   subsets	  
responsible	   for	   the	   control	   of	   HIV	   replication,	   particularly	   during	   the	   critical	   early	  
infection	  phase,	  we	  investigated	  the	  patterns	  and	  features	  of	  HIV-­‐1-­‐specific	  CD8+	  T-­‐
cell	   responses	  during	   acute	   and	  primary	  HIV-­‐1	   infection	   and	   their	   association	  with	  
viral	   control.	   	   We	   also	   sought	   to	   determine	   the	   impact	   of	   acute	   phase	   immune	  
activation	   on	   the	   acute	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	   response	   and	   on	   disease	  
progression.	   We	   hypothesized	   that	   protein-­‐specific	   and	   epitope-­‐specific	  
immunodominance	   patterns	   during	   the	   first	   12	   weeks	   of	   HIV-­‐1	   infection	   are	  
associated	  with	  subsequent	  disease	  progression.	  
	  
Our	   data	   show	   the	   presence	   of	   HIV-­‐1	   specific	   CD8+	   T-­‐cells	   with	   limited	   breadth	  
during	  acute	  HIV-­‐1	  infection	  and	  also	  demonstrate	  that	  the	  magnitude	  and	  breadth	  
of	   interferon	   gamma	   (IFN-­‐γ)	   ELISPOT	   assay	   responses	   measured	   within	   12	   weeks	  
post-­‐infection	   are	   unrelated	   to	   the	   course	   of	   disease	   in	   the	   first	   year	   of	   infection.	  	  
During	  the	  first	  weeks	  of	  infection	  Nef	  protein	  was	  most	  frequently	  recognized	  by	  T-­‐
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cells	  and	  was	   the	   target	   for	   the	   earliest	   response.	   Although	   initially	   subdominant,	  
there	  was	  a	  broadening	  of	  the	  Gag-­‐specific	  T-­‐cell	  immune	  response	  such	  that	  these	  
responses	  became	  immunodominant	  by	  one	  year	  post	  infection.	  The	  broadening	  and	  
preservation	  of	  early	  Gag–specific	  T-­‐cell	  responses	  during	  the	  follow	  up	  period	  was	  
associated	  with	  better	   control	  of	   viremia	  and	   lower	   viral	   load	   set	  point.	   	  Although	  
many	   of	   the	   acute/early	   HIV-­‐1-­‐specific	   IFN-­‐γ	   enzyme	   linked	   immunospot	   assay	  
(ELISPOT)	   CD8+	   T-­‐cell	   responses	   targeting	   Gag	   and	   Pol	   persisted,	   the	   majority	   of	  
acute	   and	   early	   T-­‐cell	   responses	   targeting	   Env,	   Nef	   and	   other	   regulatory	   proteins	  
waxed	   and	   waned	   over	   time	   and	   could	   not	   be	   detected	   at	   the	   last	   time	   point	  
evaluated.	   Some	   of	   the	   early	   T-­‐cell	   responses	   which	   where	   no	   longer	   detectable	  
when	  using	  overnight	  ELISPOT	  assay	  were	  detectable	  when	  PBMCs	  were	  stimulated	  
with	   corresponding	   peptides	   and	   cultured	   for	   10	   days	   before	   measuring	   IFN-­‐γ	  
secretion	   via	   the	   ELISPOT	   assay.	   	   The	   presence	   of	   these	   cultured	   ELISPOT	   central	  
memory	   type	   T-­‐cell	   responses	   targeting	   epitopes	   in	   Pol,	   Env,	   Nef,	   Regulatory	   and	  
Accessory	   proteins	  were	  not	   significantly	   associated	  with	   viral	   set	   point.	  However,	  
cultured	   ELISPOT	   Gag-­‐specific	   responses	   correlated	  with	   low	   plasma	   viremia,	   thus	  
further	  providing	  evidence	  for	  the	  favourable	  role	  of	  Gag-­‐specific	  T-­‐cell	  responses	  in	  
the	  control	  of	  viral	  replication.	  We	  also	  show	  that	  three	  cytokines	  IL-­‐10,	  IP-­‐10	  and	  IL-­‐
12	  were	  associated	  with	  changes	  in	  viral	  load	  set	  point	  and/or	  CD4+	  T-­‐cell	  dynamics	  
during	   the	   first	   year	   of	   HIV-­‐1	   infection.	   Interestingly,	   the	   activation	   of	   the	   PD-­‐1	  
inhibitory	   pathway	   in	   acute	   HIV-­‐1	   infection	   was	   associated	   with	   a	   slower	   disease	  
progression.	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The	   data	   indicate	   that	   induction	   and	   preservation	   of	   Gag-­‐specific	   effector	   and	  
central	  memory	  type	  CD8+	  T-­‐cell	   responses	   is	  required	  for	  the	  maintenance	  of	   low	  
viral	   load	   levels	   in	  primary	   infection.	  Our	   study	   suggests	   that	  an	  early	  and	  broadly	  
directed	   Gag-­‐specific	   CD8+	   T-­‐cell	   response	   in	   acute	   infection	   may	   augment	   early	  
control,	   and	   provide	   a	   rational	   goal	   for	   both	   prophylactic	   and	   therapeutic	  
vaccination.	  The	  role	  of	  these	  plasma	  and	  T-­‐cell	  markers	  of	   immune	  activation	  and	  
dysfunction	   as	   early	   independent	   predictors	   of	   rapid	   disease	   progression	   was	  
detected	  despite	   the	  relatively	  small	  number	  of	   subjects	  evaluated,	   supporting	   the	  
predictive	  strength	  of	  these	  markers.	  In	  addition	  to	  or	  in	  combination	  with	  canonical	  
parameters,	  early	  biomarkers,	  which	  are	  indicative	  of	  early	  immune	  dysfunction	  and	  
are	  also	  predictive	  of	  subsequent	  HIV	  disease	  prognosis,	  may	  inform	  approaches	  for	  
evaluating	  the	  ability	  of	  therapeutic	  HIV	  vaccines	  to	  control	  HIV	  infection	  and	  may	  be	  
indicative	   of	   pathways	   that	  may	   be	  manipulated	   to	   achieve	   better	   viral	   control	   in	  
natural	  infection	  or	  following	  vaccination.	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Chapter	   1	   provides	   an	   overview	   of	   the	   HIV	   epidemic,	   acute	   and	   primary	   HIV-­‐1	  
infection	  and	  the	  role	  of	  the	  innate	  and	  adaptive	  immune	  responses	  in	  the	  control	  of	  
HIV-­‐1	  infection.	  	  	  
	  
Chapter	   2	   gives	   a	   detailed	   overview	   of	   CD8+	   T-­‐cell	   responses,	   the	  magnitude	   and	  
breadth	  of	  these	  responses	  and	  their	  targets	  and	  immunodominance	  patterns	  in	  20	  
HIV-­‐1	  subtype	  C	  infected,	  antiretroviral	  naive	  subjects	  from	  4	  weeks	  up	  to	  18	  weeks	  
post	  infection.	  	  
	  
Chapter	  3	  provides	  a	  description	  of	  evolving	  breadth	  of	  CD8+	  T-­‐cell	  responses	  during	  
the	  first	  year	  HIV-­‐1	  of	  infection	  and	  the	  association	  of	  these	  changes	  with	  viral	  load.	  
The	   role	  of	  persistent	   immune	   responses	  and	  central	  memory-­‐type	  CD8+	  T-­‐cells	   in	  
viral	  control	  is	  also	  highlighted.	  
	  
Chapter	   4	   provides	   evidence	   on	   the	   role	   of	   T-­‐cell	   and	  plasma	   immune	  markers	   of	  
activation	  and	  dysfunction	  in	  predicting	  disease	  progression.	  
	  
Chapter	   5	   gives	   an	   overview	   of	   the	   study	   findings	   in	   relation	   the	   current	   body	   of	  
knowledge	  on	  the	  immune	  response	  to	  HIV.	  	  Also	  highlighted	  is	  what	  we	  know	  and	  
what	  we	  should	  know,	   in	  order	   to	   facilitate	   the	  development	  of	  an	  efficacious	  HIV	  
vaccine.	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Chapter	  1 :	  The	  Immune	  Response	  to	  HIV-­‐1	  
	   3	  
1. 	  HIV	  and	  AIDS	  Pandemic:	  	  
1.1. The	  Global	  Perspective	  	  
In	   the	  more	   than	   three	  decades	   since	   the	   first	   clinical	   case	  of	  AIDS	  was	   identified,	  
over	  70	  million	  people	  have	  been	  infected	  with	  the	  human	  immunodeficiency	  virus	  
type	  1	   (HIV-­‐1)	   and	  35	  million	  people	  have	  died	  of	  HIV-­‐1-­‐related	   illnesses	   (UNAIDS,	  
2013).	  	  	  At	  the	  end	  of	  2012,	  it	  was	  estimated	  that	  there	  were	  35.3	  million	  (32.2–38.8	  
million)	  people	  living	  with	  HIV.	  	  Sub-­‐Saharan	  Africa	  remains	  most	  severely	  affected,	  
with	  nearly	  1	  in	  every	  20	  adults	  	  (4.9%)	  living	  with	  HIV	  and	  accounting	  for	  69%	  of	  the	  
people	  living	  with	  HIV	  globally	  (Figure	  1.1)	  and	  in	  this	  region	  women	  account	  for	  at	  
least	  58%	  of	  infections	  (UNAIDS,	  2012,	  UNAIDS,	  2013).	  
	  
	  
Figure	  1.1.	  Global	  view	  of	  the	  estimated	  number	  of	  adults	  living	  with	  HIV/AIDS	  (according	  
to	  region)	  in	  2012	  (WHO,	  2013).	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1.2. HIV	  and	  AIDS:	  South	  Africa	  
Within	   sub-­‐Saharan	  Africa,	   South	  Africa	  with	   5.26	  million	   individuals	   infected	  with	  
HIV	   is	   the	   country	   with	   the	   world’s	   largest	   population	   of	   people	   living	   with	   HIV	  
(UNAIDS,	   2013).	   The	   estimated	   overall	   HIV	   prevalence	   rate	   is	   approximately	   10%,	  
with	   16%	   of	   adults	   aged	   15–49	   years	   and	   17%	   of	   South	   African	   women	   in	   their	  
reproductive	   ages	   HIV	   infected	   (Stats	   SA.,	   2013).	   	   However,	   within	   the	   country,	  

















According	  to	  the	  2011	  National	  Antenatal	  Sentinel	  HIV	  &	  Syphilis	  Prevalence	  Survey,	  
an	  estimated	  29.5%	  of	  the	  antenatal	  population	  is	  HIV	  positive	  with	  the	  province	  of	  
KwaZulu-­‐Natal	   experiencing	   the	   most	   severe	   HIV	   epidemic	   with	   the	   highest	   HIV	  
	   5	  
prevalence	   of	   37.4%	   in	   the	   antenatal	   population	   (South	   African	   Department	   of	  
Health.,	   2011).	   	   Mpumalanga	   follows	   it	   closely	   with	   overall	   prevalence	   rates	   of	  
36.7%,	   and	   the	   Free	   State	   at	   32.5%	   (Figure	   1.2).	   The	  Northern	   Cape	   and	  Western	  
Cape	  provinces	  have	  the	  lowest	  HIV	  prevalence	  rates	  of	  below	  20%	  (Stats	  SA.,	  2013).	  
	  
2. Therapeutic	  strategies	  for	  HIV	  
Although	  declines	  in	  new	  HIV	  infections	  have	  been	  reported	  since	  2011,	  the	  burden	  
of	   disease	   remains	   incredibly	   significant.	   	   So	   far	   the	   best	   results	   at	   curbing	   the	  
epidemic	   have	   been	   the	   development	   of	   antiretroviral	   drugs	   (ARVs)	   that	   inhibit	  
crucial	  HIV-­‐1	  functions.	  	  Whilst	  ARV	  therapy	  has	  significantly	  reduced	  the	  toll	  of	  AIDS	  
related	  deaths,	  a	  significant	  gap	  still	  exists	  between	  those	  on	  therapy	  and	  those	  who	  
need	   it.	   In	  South	  Africa,	  only	  2	  million	  of	   the	  5.26	  million	   individuals	   infected	  with	  
HIV	   are	   on	   therapy	   (UNAIDS,	   2013).	   Furthermore,	   the	   unique	   ability	   of	   HIV-­‐1	   to	  
mutate	   and	   adapt	   (Korber	   et	   al.,	   2001,	   Wain-­‐Hobson,	   1995,	   Ndung'u	   and	   Weiss,	  
2012)	   also	   requires	   the	   use	   of	   multiple	   drug	   treatments	   that	   are	   often	   limited	   in	  
their	  use	  mainly	  because	  of	  their	  side	  effects	  and	  cost	  (Maenza	  and	  Flexner,	  1998).	  	  	  
	  
Arresting	   the	   spread	   of	   the	   HIV/AIDS	   epidemic	   will	   require	   a	   multi-­‐pronged	  
approach,	   which	   consists	   of	   efficient	   HIV-­‐1	   prevention	   strategies,	   improved	   ARV	  
therapy	   access	   for	   individuals	   infected	   with	   HIV-­‐1,	   and	   the	   development	   of	   an	  
efficient	   vaccine	   to	   protect	   people	   from	   HIV-­‐1	   infection	   and/or	   attenuate	   disease	  
progression	   in	   those	   that	   are	   already	   infected.	   In	   order	   to	   facilitate	   the	   design	   of	  
successful	   vaccination	   regimens	   that	   elicit	   specific	   immune	   responses,	   an	   in-­‐depth	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immunological	   knowledge	   as	   well	   as	   an	   enhanced	   understanding	   of	   host-­‐virus	  
interaction	  is	  crucial	  (Virgin	  and	  Walker,	  2010).	  	  
	  
	  Table	  1.1.	  HIV	  vaccine	  products	  tested	  in	  clinical	  efficacy	  trials	  to	  date	  (U.S.	  Department	  of	  
Health	  and	  Human	  Services,	  2013). 
	  
1981 HIV was identified as the cause of AIDS.
1987
The first HIV vaccine clinical trial opened at the National Institutes 
of Health (NIH) Clinical Center. The gp160 subunit vaccine showed 
no serious adverse effects.
1992 NIAID launched the first Phase II HIV vaccine clinical trial.! 
First large scale vaccine trial began: VaxGen initiates Phase III trial 
of AIDSVAX in North America and The Netherlands.
NIAID begins first African preventive HIV vaccine trial in Uganda.
First large scale vaccine trial in a developing country began: 
VaxGen initiates Phase III trial of AIDSVAX in Thailand.
U.S. and Royal Thai governments jointly initiated RV144, a Phase III 
trial to evaluate a novel HIV vaccine strategy commonly referred 
to as "prime-boost."!
2004 VaxGen candidate failed in Phase III trials.
2007 NIAID halted the Phase II Step and Phambili studies due to safety 
concerns.
2009 Phase II HVTN 505 study initiated to evaluate a “prime-boost” 
vaccine regimen developed by the VRC.
2009 Results of Phase III Thai Trial (RV144) show vaccine combination is 
first to demonstrate modest preventive effect in humans.!
Two potent antibodies that prevent most strains of HIV identified by 
the VRC (VRC01 and VRC02).
Establishment of Pox-Protein Public-Private Partnership (P5)
2012
Additional analyses of samples from RV144 provide insight about 
what type of immune response may be needed for an effective 
vaccine.
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2.1. The	  STEP	  and	  Phambili	  trials	  	  
Soon	   after	   HIV-­‐1	   was	   isolated	   and	   confirmed	   as	   the	   cause	   of	   AIDS,	  it	   was	   widely	  
expected	   that	  an	  effective	  vaccine	  would	  be	  developed	   in	  a	   few	  years.	  Over	   thirty	  
years	  later,	  we	  are	  still	  struggling	  to	  develop	  an	  effective	  vaccine.	  	  As	  shown	  in	  Table	  
1.1,	  decades	  of	  effort	  have	  been	  spent,	  and	  continue	  to	  be	  made,	  toward	  developing	  
an	  efficacious	  HIV	  vaccine	   (U.S.	  Department	  of	  Health	  and	  Human	  Services,	  2013).	  
Two	  Phase	  IIb	  trials	  of	  a	  vaccine	  candidate	  created	  by	  the	  pharmaceutical	  company	  
Merck	   were	   halted	   in	   September	   2007.	   The	   STEP	  and	  Phambili	   clinical	   trials	  
evaluated	  Merck’s	   trivalent	   Ad5-­‐HIV-­‐1	   vaccine	   in	   high-­‐risk	  MSM	   and	   heterosexual	  
men	   and	  women	   in	   the	   Americas	   and	   Australia	   (STEP)	   and	   heterosexual	  men	   and	  
women	   in	   South	   Africa	   (Phambili).	   	   Despite	   inducing	   T-­‐cell	   responses	   of	   similar	  
magnitude	   and	   breadth	   to	   those	   observed	   in	   earlier	   trials,	   the	   vaccine	   failed	   to	  
prevent	   infection	   or	   impact	   on	   early	   viraemia	   and	  was	   prematurely	   terminated	   in	  
2007	   on	   grounds	   of	   futility	   (Buchbinder	   et	   al.,	   2008,	  McElrath	   et	   al.,	   2008).	   	   	   The	  
measures	  of	   immunogenicity	   in	  phase	   I/II	   trials	  of	   the	  STEP	  trial	  were	  shown	  to	  be	  
ambiguous	   since	   vaccinees	   who	   acquired	   HIV-­‐1	   infection	   showed	   a	   similar	  
magnitude	   of	   CD8+	   T-­‐cell	   responses	   to	   vaccination	   in	   comparisons	   to	   those	   who	  
were	   not	   vaccinated.	   Furthermore,	   the	   breadth	   of	   responses	   in	   vaccinees	   was	  
particularly	   narrow	  with	   CD8+	   T-­‐cell	   responses	   targeting	   a	  median	   of	   one	   epitope	  
per	  protein	  and	  with	  a	  bias	  towards	  less	  conserved	  epitopes	  (McElrath	  et	  al.,	  2008,	  Li	  
et	  al.,	  2011).	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2.2. The	  Thai	  Phase	  III	  HIV	  vaccine	  clinical	  trial	  
The	  Thai	  HIV	  vaccine	  efficacy	  trial	  (2003-­‐2009),	  known	  as	  RV144,	  tested	  the	  “prime-­‐
boost”	  combination	  of	  two	  vaccines:	  ALVAC-­‐HIV	  recombinant	  canarypox	  vaccine	  (the	  
prime)	  and	  AIDSVAX	  gp120	  B/E	  vaccine	   (the	  boost).	   	   The	  vaccine	  combination	  was	  
based	  on	  HIV	  strains	   that	   commonly	  circulate	   in	  Thailand.	   In	  2009,	   the	  RV144	   trial	  
conducted	   in	   Thailand	   revealed	   an	   estimated	   efficacy	   of	   31%	   with	   the	   ALVAC	  
vCP1521-­‐AIDSVAX	   B/E	   vaccine	   regimen	   (Rerks-­‐Ngarm	   et	   al.,	   2009).	   	   Exploring	   the	  
immune	   correlates	   of	   risk	   for	   HIV-­‐1	   infection	   in	   this	   phase	   IIb	   trial	   led	   to	   the	  
identification	  of	   two	   immune	   correlates	  of	   risk,	   IgG	  antibodies	   to	  HIV-­‐1	  Env	  V1-­‐V2	  
and	  high-­‐titre	  anti-­‐Env	  IgA	  antibodies	  (Haynes	  et	  al.,	  2012).	  Initially,	  IgG	  antibodies	  to	  
HIV-­‐1	   Env	   V1-­‐V2	  were	   shown	   to	   correlate	   inversely	  with	   infection	   risk,	   suggesting	  
that	   antibodies	   binding	   to	   the	   V1V2	   Env	   region	   were	   involved	   somewhat	   in	  
preventing	   infection	  (Liao	  et	  al.,	  2013,	  Haynes	  et	  al.,	  2012).	   	  High	  titer	  anti-­‐Env	   IgA	  
antibodies	  were	  shown	  to	  be	  directly	  correlated	  with	  infection	  risk,	  moreover,	  in	  the	  
presence	   of	   low-­‐titer	   anti-­‐Env	   IgA	   antibodies,	   antibody-­‐dependenT-­‐cell-­‐mediated	  
cytotoxicity	   (ADCC)	   levels	   inversely	   correlated	   with	   infection	   risk	   suggesting	   that	  
anti-­‐Env	  IgA	  antibodies	  could	  lessen	  the	  protective	  effects	  of	  IgG	  antibodies	  (Haynes	  
et	  al.,	  2012,	  Tomaras	  et	  al.,	  2013).	  	  
	  
Although	   attempts	   to	   produce	   a	  vaccine	  that	   prevents	  HIV	  infection	  have	  not	   been	  
wholly	   successful	   to	   date,	   these	   HIV	   vaccine	   clinical	   trials	   have	   provided	   many	  
valuable	   lessons	   towards	   the	   generation	   of	   promising	   HIV	   vaccine	   regimens.	   	   The	  
clues	  gathered	  from	  the	  failed	  clinical	  trials	  and	  the	  partially	  successful	  RV144	  trial,	  
in	   addition	   to	   the	   promising	   ongoing	   preclinical	   vaccine	   data,	   offer	   a	   unique	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opportunity	   to	  build	  on	  efforts	   towards	  an	  effective	  HIV	  vaccine	   (Spearman,	  2003,	  
Day	  and	  Kublin,	  2013).	  
	  
3. Origin	  and	  Structure	  of	  HIV	  
3.1. HIV-­‐1	  types	  
HIV	  belongs	  to	  a	  large	  family	  of	  ribonucleic	  acid	  (RNA)	  viruses	  and	  is	  a	  member	  of	  the	  
genetically	   related	   Lentivirus	   genus	   of	   the	   Retroviridae	   family.	   	   Infection	   with	  
lentiviruses	   is	   characterized	   mainly	   by	   immunosuppression	   with	   a	   long	   period	   of	  
clinical	  latency	  following	  infection	  before	  manifestations	  of	  illness	  become	  apparent	  
(Fauci,	  1993).	  	  It	  has	  long	  been	  suspected	  that	  HIV-­‐1	  is	  of	  chimpanzee	  origin	  derived	  
from	   the	   simian	   immunodeficiency	   virus	   of	   the	   Pan	   troglodytes	   troglodytes	  
subspecies	   of	   chimpanzee	   (SIVcpz)	   (Gao	   et	   al.,	   1999).	   	   In	   2006,	   extracts	   of	   SIVcpz	  
were	  found	  in	  faecal	  samples	  collected	  from	  wild	  chimpanzees,	  thus	  confirming	  that	  
they	  were	  indeed	  a	  reservoir	  of	  SIVcpz	  (Keele	  et	  al.,	  2006).	  	  It	  is	  now	  well	  established	  
that	  SIVs	  from	  chimpanzees	  (Pan	  troglodytes	  troglodytes)	  and	  gorillas	  (Gorilla	  gorilla	  
gorilla)	   in	  West	  central	  Africa	  are	   the	  progenitors	  of	  HIV-­‐1	   (Keele	  et	  al.,	  2006,	  Van	  
Heuverswyn	  et	  al.,	  2006,	  Sharp	  and	  Hahn,	  2011).	  	  
	  
The	  HIV	   isolates	  are	  currently	  grouped	   into	  two	  types,	  HIV	  type	  1	   (HIV-­‐1),	  which	   is	  
the	  main	  causative	  agent	  of	  AIDS	  globally,	  and	  HIV	  type	  2	  (HIV-­‐2),	  which	  is	  restricted	  
to	  some	  regions	  of	  Western	  and	  Central	  Africa	  (Clavel	  et	  al.,	  1986,	  Sharp	  and	  Hahn,	  
2011,	  Whittle	  et	  al.,	  1994).	   	  HIV-­‐1	  comprises	  3	  distinct	  virus	  groups,	  termed	  M	  (the	  
Main	  group),	  O	  (the	  Outlier	  group)	  and	  N	  (the	  Non-­‐M,	  Non-­‐O	  group).	  	  Group	  M	  was	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the	   first	   to	   be	   discovered	   and	   is	   the	   pandemic	   form	   of	   HIV-­‐1	   that	   has	   infected	  
millions	   of	   people	   and	   is	   found	   in	   nearly	   every	   country	   on	   the	   globe	   (Sharp	   and	  
Hahn,	   2011).	   It	   consists	   of	   at	   least	   nine	   genetically	   distinct	  subtypes	  (or	   clades),	  
denoted	   subtype	  A,	   B,	   C,	  D,	   F,	  G,	  H,	   J	   and	   K	   (Perrin	   et	   al.,	   2003,	   Robertson	   et	   al.,	  
2000).	   	   Subtype	   B	   is	   the	   dominant	   form	   in	   Europe,	   the	   Americas,	   Japan,	   and	  
Australia,	  whilst	  subtype	  C	  is	  dominant	  in	  southern	  Africa,	  eastern	  Africa,	  India,	  and	  
parts	  of	  China	  (Taylor	  and	  Hammer,	  2008).	  	  Group	  O	  is	  less	  prevalent	  than	  group	  M	  
and	   represents	   less	   than	   1%	   of	   global	   HIV-­‐1	   infections	   restricted	   mainly	   to	  
Cameroon,	  Gabon,	  and	  neighbouring	  countries	  (Mauclere	  et	  al.,	  1997,	  De	  Leys	  et	  al.,	  
1990).	   Group	   N	   infections	   have	   been	   documented	   in	   13	   individuals,	   all	   from	  
Cameroon	   (Simon	  et	  al.,	  1998,	  Vallari	  et	  al.,	  2010,	  Sharp	  and	  Hahn,	  2011)	  and	  two	  
cases	  of	  group	  P	  have	  been	  reported	  also	  in	  individuals	  from	  Cameroon	  (Plantier	  et	  
al.,	  2009).	  	  
	  
3.2. Structure	  of	  HIV-­‐1	  
The	   genome	  of	  HIV,	   similar	   to	   retroviruses	   in	   general,	   contains	   three	  major	   genes	  
gag,	  pol,	   and	  env	   (Figure	  1.3).	   	   The	  gag	   gene	   (group-­‐specific-­‐antigen)	   encodes	   the	  
core	  structural	  proteins	  (p24,	  p7,	  p6)	  and	  matrix	  (p17)	  and	  the	  env	  gene	  encodes	  the	  
viral	   envelope	   glycoproteins	   gp120	   and	   gp41,	   which	   are	   used	   for	   cell	   surface	  
receptor	  recognition.	  The	  pol	  gene	  encodes	  for	  enzymes	  crucial	  for	  viral	  replication,	  
namely	  reverse	  transcriptase	  which	  converts	  viral	  RNA	  into	  DNA,	  the	  integrase	  which	  
incorporates	   the	   viral	   DNA	   into	   host	   chromosomal	   DNA	   (the	   provirus)	   and	   the	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protease	  which	  is	  responsible	  for	  cleaving	  large	  Gag	  and	  Pol	  protein	  precursors	  into	  









Figure	   1.3.	   The	   viral	   genome	   for	   HIV-­‐1	   consists	   of	   nine	   open	   reading	   frames:	   gag,	  pol	  
and	  env.	  Gag	  encodes	  the	  proteins	  that	  form	  the	  viral	  capsid.	   	  Env	  encodes	  the	  envelope	  
surface	   proteins.	  Pol	  encodes	   the	   three	   catalytic	   enzymes:	  Reverse	   Transcriptase	  
(RT),	  Integrase	  (IN),	  and	  the	  Protease	  (PR).	  	  The	  remaining	  six	  open	  reading	  frames	  encode	  
accessory	  proteins:	  Vif,	  Vpr,	  Nef,	  Tat,	  Rev,	  and	  Vpu.	  	  
	  
A	  defining	   feature	  of	   retroviruses	   is	   their	  ability	   to	  assemble	   into	  particles	   that	  are	  
able	   to	   leave	   producer	   cells	   and	   spread	   infection	   to	   susceptible	   cells.	   Virion	  
morphogenesis	   can	  be	  divided	   into	   three	   stages,	   1)	  assembly:	   the	  virion	   is	   created	  
and	   vital	   components	   are	   packaged;	  2)	   budding:	   wherein	   the	   virion	   crosses	   the	  
plasma	   membrane	   and	   acquires	   its	   lipid	   envelope;	   and	   3)	   maturation:	   the	   virion	  
changes	  structure	  and	  becomes	  infectious	  (Figure	  1.4).	  The	  Gag	  polyprotein	  and	  its	  
proteolytic	  maturation	  products,	  which	  function	  as	  the	  major	  structural	  proteins	  of	  
the	  virus,	  coordinate	  these	  stages	  (Sundquist	  and	  Krausslich,	  2012).	  	  
	  
Six	  virally	  regulatory/accessory	  genes	  carried	  by	  HIV-­‐1	  in	  its	  9,2	  kB	  RNA	  include	  tat,	  
rev,	  nef,	  vif,	  vpr,	  and	  vpu	  and	  these	  contribute	  to	  the	  genetic	  complexity	  of	  the	  virus.	  
Tat	  and	  rev	  stimulate	  the	  transcription	  of	  proviral	  HIV-­‐1	  DNA	  into	  RNA,	  enhance	  the	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transportation	  of	  HIV	  RNA	  from	  the	  nucleus	  to	  the	  cytoplasm	  and	  are	  important	  for	  
translation	  (Fanales-­‐Belasio	  et	  al.,	  2010,	  Emerman	  and	  Malim,	  1998).	  	  	  
	  
	  	  	  
Figure	  1.4.	  Representation	  of	  HIV’s	  lifecycle:	  The	  HIV	  lifecycle	  begins	  with	  the	  interaction	  
of	  a	  virus	  particle	  with	  a	  receptor	  on	  the	  cell’s	  surface,	  resulting	  in	  the	  fusion	  of	  the	  viral	  
and	   cellular	  membranes	   and	   transfer	   of	   the	   viral	   contents	   into	   the	   cell.	   	   The	   viral	   RNA	  
genome	   is	   reverse	   transcribed	   and	   produces	   a	   DNA	   copy	   which	   is	   imported	   into	   the	  
nucleus.	  	  Within	  the	  nucleus,	  the	  viral	  DNA	  is	  integrated	  into	  the	  hosT-­‐cell	  genome	  and	  is	  
transcribed	  from	  within	  the	  host	  genome,	  then	  exported	  from	  the	  nucleus.	  The	  translation	  
of	  the	  viral	  proteins	  by	  hosT-­‐cell	  machinery	  begins	  and	  the	  major	  structural	  protein,	  Gag,	  is	  
transported	   to	   the	   plasma	   membrane	   where	   it	   directs	   assembly	   of	   the	   viral	   coat	   and	  
incorporates	   other	   viral	   proteins	   and	   the	   viral	   genome.	   The	   virus	   buds	   through	   the	   cell	  
membrane,	  and	  Gag	  is	  cleaved	  by	  the	  viral	  protease	  leading	  to	  a	  structural	  change	  of	  the	  
virion	   into	   its	  mature	   infectious	   form,	  which	   is	   capable	  of	   fusing	  with	  a	  new	  susceptible	  
cell	  (figure	  adapted	  from	  Monini	  et	  al.	  (2004),	  with	  permission	  from	  the	  Nature	  Publishing	  
Group).	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Nef	  has	   been	   shown	   to	   have	   a	   number	   of	   functions	   such	   as	   CD4	   and	   HLA	   class	   I	  
downregulation	   (Schwartz	   et	   al.,	   1996,	   Greenberg	   et	   al.,	   1998),	   activation	   of	   p21-­‐
activated	  protein	   kinase	   (Pak2)	   (Foster	   and	  Garcia,	   2007,	   Foster	   and	  Garcia,	   2008)	  
and	   enhancement	   of	   virion	   infectivity	   (Miller	   et	   al.,	   1994).	   The	   downregulation	   of	  
CD4	  and	  MHC	  class	   I	  molecules	   from	  the	  surface	  of	  HIV-­‐1-­‐infected	  cells	   represents	  
an	   important	   escape	   mechanism	   for	   the	   virus	   in	   evading	   recognition	   and	   attack	  
mediated	   by	   cytotoxic	   CD8+	   T-­‐cells	   and	   to	   also	   avoid	   recognition	   by	   CD4+	   T-­‐cells	  
(Foster	  and	  Garcia,	  2007,	  Foster	  and	  Garcia,	  2008).	  Downregulation	  of	  CD4+	  T-­‐cells	  is	  
thought	   to	  be	  primarily	   for	   enhancing	   virion	   release,	   virus	   infectivity	   and	   this	  may	  
also	  be	  a	  mechanism	  to	  avoid	  antibody	  mediated	  cytotoxicity	  (Veillette	  et	  al.,	  2014).	  	  
The	   virion	   infectivity	   factor	   (Vif)	   suppresses	   the	   antiretroviral	   cellular	   enzyme	  
APOBEC3G	  and	  other	  cytidine	  deaminases	  in	  the	  cytoplasm	  (Marin	  et	  al.,	  2003)	  and	  
is	  essential	  for	  efficient	  viral	  replication	  in	  primary	  cells	  (Desrosiers	  et	  al.,	  1998).	  	  The	  
virion-­‐associated	  protein	  (Vpr)	  has	  the	  ability	  to	  delay	  or	  arrest	  infected	  cells	  in	  the	  
G2	  phase	  of	  the	  cell	  cycle	  (Fletcher	  et	  al.,	  1996),	  facilitates	  infection	  of	  macrophages	  
(Eckstein	   et	   al.,	   2001)	   and	   activates	   HIV	   transcription	   (Felzien	   et	   al.,	   1998).	   By	  
counteracting	  host	   restriction	   factors	   (particularly	  Tetherin)	   (Neil	  et	  al.,	  2008),	  Vpu	  
enhances	  efficient	  release	  of	  virions	  from	  infected	  cells	  (Varthakavi	  et	  al.,	  2003)	  and	  
downregulates	  the	  CD4	  molecules	  during	  the	  late	  stages	  of	  HIV-­‐1	  infection	  (Levesque	  
et	  al.,	  2003).	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3.3. Transmission	  of	  HIV-­‐1	  
The	  most	   common	  mode	   of	   HIV-­‐1	   infection	   is	   sexual	   transmission	   via	   the	   genital	  
mucosa	   or	   rectal	   mucosa	   (Cohen	   et	   al.,	   1997,	   Royce	   et	   al.,	   1997).	   	   Upon	   sexual	  
transmission,	   HIV-­‐1	   infects	   Langerhans	   cells	   and	   dendritic	   cells	   that	   reside	   in	   the	  
submucosal	   tissues	   (Spira	   et	   al.,	   1996)	   as	   these	   cells	   express	   CD4	   and	   CCR5	  
molecules	   on	   their	   surfaces,	   which	   serve	   to	   facilitate	   viral	   entry	   (Elsaesser	   et	   al.,	  
2009).	   	   The	   lamina	   propria	   of	   the	   human	   vagina	   also	   contains	  many	   CD4+	   T-­‐cells,	  
which	   express	   relatively	   high	   levels	   of	   CCR5	   compared	   with	   T-­‐cells	   found	   in	  
peripheral	  blood	   (Hladik	  and	  Hope,	  2009,	  Elsaesser	  et	  al.,	  2009,	  Spira	  et	  al.,	  1996).	  	  
Entry	   of	   HIV-­‐1	  into	   host	   T-­‐cells	   depends	   largely	   upon	   the	   interaction	   of	   the	   viral	  
glycoprotein	  envelope	  gp120	   subunit	  with	   cell	   surface	  CD4	   (Dalgleish	  et	  al.,	   1984).	  
Upon	  CD4	  binding,	  subsequent	  conformational	  changes	  of	  gp120	  trigger	  interactions	  
of	  the	  Env	  with	  HIV-­‐1	  co-­‐receptors	  CCR5	  or	  CXCR4	  (Moore,	  1997).	   	  As	  a	  result,	  this	  
binding	  to	  co-­‐receptors	  exposes	  the	  Env	  gp41	  transmembrane	  subunit	  and	  promotes	  
fusion	  of	  viral	  and	  cellular	  membranes	  (Furuta	  et	  al.,	  1998).	  	  	  
	  
Findings	   from	  studies	  of	  macaques	   infected	   intravaginally	  with	  SIV	   show	   that	  virus	  
replication	   is	   initially	   confined	   to	   the	   mucosal	   infection	   site	   where	   small	   foci	   of	  
infection	  are	  established	  locally,	  some	  of	  which	  expand	  and	  disseminate	  virus	  to	  the	  
draining	   lymph	   node	   and	   blood	   (Haase,	   2010).	   Single-­‐genome	   amplification	   and	  
sequencing	   of	   the	   first	   detectable	   virus	   has	   shown	   that	   approximately	   80%	   of	  
mucosally	  transmitted	  HIV-­‐1	  subtype	  B	  and	  C	  infections	  originate	  from	  single	  viruses	  
(Keele	   et	   al.,	   2008)	   and	   these	   primary	   founder	   viruses	   have	   been	   shown	   to	   infect	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CD4+	   T-­‐cells	   with	   greater	   efficiency	   than	   they	   can	   infect	   monocytes	   and	  
macrophages	   (Salazar-­‐Gonzalez	   et	   al.,	   2009).	   Productive	   infection	   has	   also	   been	  
shown	   to	   arise	   from	   a	   single	   infecting	   virus	   in	   rhesus	  macaques	   inoculated	   intra-­‐	  
rectally	   with	   a	   complex	   SIV	   quasispecies	   thus	   further	   supporting	   the	   use	   of	   SIV	  
infection	  of	  rhesus	  macaques	  as	  a	  model	  for	  HIV-­‐1	  transmission	  and	  vaccine	  studies	  
(Keele	  et	  al.,	  2009,	  McMichael	  et	  al.,	  2010).	  	  
	  
4. The	  acute	  phase	  of	  HIV-­‐1	  infection	  
4.1. Viral	  dynamics	  
Acute	  HIV-­‐1	  infection	  is	  the	  phase	  of	  HIV	  disease	  immediately	  after	  infection	  during	  
which	   the	   initial	   burst	   of	   viremia	   in	   newly	   infected	   patients	   occurs	  whilst	   anti-­‐HIV	  
antibodies	   are	   undetectable.	  	   After	   transmission	   of	   the	   virus,	   there	   is	   an	   interval,	  
known	  as	  the	  eclipse	  phase,	  which	  is	  the	  time	  before	  viral	  RNA	  becomes	  detectable	  
in	  the	  plasma	  (Keele	  et	  al.,	  2008,	  Lee	  et	  al.,	  2009).	  The	   length	  of	   the	  eclipse	  phase	  
before	  virus	  dissemination	   takes	  place	  may	   range	   from	  5–6	  days	   to	  several	  weeks,	  
with	   exposure	   to	   lower	   doses	   of	   the	   virus	   being	   associated	   with	   longer	   eclipse	  
periods	  (Keele	  et	  al.,	  2008,	  Lee	  et	  al.,	  2009,	  Liu	  et	  al.,	  2010,	  Stone	  et	  al.,	  2010).	  
	  
Following	  infection	  and	  the	  replication	  of	  the	  virus	  in	  the	  mucosa,	  virus	  and/or	  virus	  
infected	   cells	   are	   transported	   to	   draining	   lymph	   nodes,	   where	   they	   encounter	  
activated	  CD4+CCR5+	  T-­‐cells	  and	  thus	  facilitating	  further	  viral	  amplification	  in	  these	  
cells	   (Haase,	   2010).	   	   Subsequently,	   the	   virus	   spreads	   via	   the	   blood	   to	   the	   other	  
lymphoid	   tissues	   reaching	   peak	   plasma	   levels,	   usually	   more	   than	   a	   million	   RNA	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copies	  per	  ml	  of	  blood	  at	  21–28	  days	  after	  HIV-­‐1	  infection	  in	  humans	  (McMichael	  et	  
al.,	  2010).	  	  
	  
4.2. The	  acute	  retroviral	  syndrome	  
The	   clinical	   effects	   of	   HIV-­‐1	   infection	   are	   diverse,	   ranging	   from	   an	   asymptomatic	  
seroconversion	   to	   a	   severe	   illness	   that	  may	   require	   hospitalization	   of	   the	   patient.	  
Acute	   HIV	   infection	   often	   remains	   undiagnosed	   partly	   because	   the	   symptoms	   are	  
protean	  and	  are	  also	  typical	  of	  other	  viral	  infections	  like	  influenza	  or	  mononucleosis	  
(Tindall	  et	  al.,	  1988,	  Niu	  et	  al.,	  1993).	  The	  onset	  of	  illness	  is	  usually	  between	  2	  and	  6	  
weeks	   after	   viral	   transmission	   and	   most	   patients	   experience	   fever,	   disseminated	  
lymphadenopathy,	  often	  associated	  with	  headache,	  myalgias,	  anorexia,	  rash,	  and/or	  
diarrhoea	  (Busch,	  1994).	  A	  more	  severe	  clinical	  syndrome	  during	  acute	  HIV	  infection	  
has	  been	  associated	  with	  rapid	  HIV	  disease	  progression	  (Pedersen	  et	  al.,	  1989).	  
	  
4.3. Staging	  of	  acute	  HIV-­‐1	  infection	  	  
Analysis	   of	   samples	   obtained	   from	   individuals	   during	   early	   HIV-­‐1	   infection	   has	  
revealed	   that	   the	   first	   few	  weeks	  after	   infection	  can	  be	  divided	   into	  clinical	   stages	  
that	  are	  defined	  by	  a	  sequential	  gain	  in	  positive	  HIV-­‐1	  clinical	  diagnostic	  assays	  (viral	  
RNA	   measured	   by	   PCR,	   p24	   and	   p31	   viral	   antigens	   and	   HIV-­‐1-­‐specific	   antibodies	  
measured	   by	   enzyme-­‐linked	   immunosorbent	   assay	   (ELISA)	   and	   HIV-­‐1-­‐specific	  
antibodies	  detected	  by	  Western	  blot)	  (Fiebig	  et	  al.,	  2003).	  	  Based	  on	  this	  sequential	  
gain	  in	  positivity	  of	  these	  HIV-­‐1	  clinical	  diagnostic	  assays,	  patients	  can	  be	  categorized	  
into	  Fiebig	  stages	  I–VI	  (Table	  1.2).	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Table	   1.2.	   Laboratory	   stages	   of	   primary	   HIV	   infection	   based	   on	   the	   emergence	   of	   viral	  
markers	  in	  seroconverting	  plasma	  donors	  (adapted	  from	  Fiebig	  et	  al.,	  2003).	  
	  
	  
Infected	  individuals	  progress	  from	  acute	  infection	  through	  to	  the	  early	  chronic	  stage	  
of	  infection	  at	  the	  end	  of	  Fiebig	  stage	  V,	  approximately	  100	  days	  following	  infection,	  
(Fiebig	  et	  al.,	  2003,	  McMichael	  et	  al.,	  2010)	  (Figure	  1.5).	  	  At	  this	  time	  the	  plasma	  viral	  
load	  begins	   to	   plateau	   and	  decreases	   to	   a	   steady	   level	   referred	   to	   as	   the	   viral	   set	  
point.	  	  The	  mechanisms	  underlying	  the	  establishment	  of	  the	  viral	  set	  point	  are	  poorly	  
understood,	   but	   may	   involve	   the	   interplay	   between	   host	   immune	   responses	   and	  
viral	  replication.	  	  The	  viral	  load	  set	  point	  is	  an	  established	  predictor	  of	  HIV-­‐1	  disease	  
progression	   and	  mortality	  where	   a	  high	  viral	  set	   point	   is	   a	  marker	   of	   rapid	   disease	  
progression;	   the	  higher	  the	  set	  point,	   the	  more	  rapid	  the	   immunologic	  progression	  
to	  disease	  (Mellors	  et	  al.,	  1997)	  	  


















Figure	  1.5.	   Schematic	   representation	  of	   the	   course	  of	  HIV-­‐1	  infection	  showing	   changes	   in	  
viral	   load,	   antibodies,	   CD4	   and	   CD8	   T-­‐cell	   counts	   in	   peripheral	   blood	  in	   untreated	  
individuals.	  	  
	  
Although	  several	  mechanisms	  such	  as	  the	  innate	  immune	  system,	  host	  factors,	  age,	  
virulence	   of	   the	   infecting	   strain	   and	   other	   immunological	   factors	   are	   known	   to	  
influence	   the	   rate	   of	   HIV	   disease	   progression,	   the	   adaptive	   immune	   response	   is	  
thought	  to	  be	  the	  most	  critical	  component	  of	  the	   immune	  system	  in	  the	  control	  of	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5. The	  innate	  immune	  response	  to	  HIV-­‐1	  	  
5.1. Dendritic	  cells	  
The	   immune	   response	   to	   HIV-­‐1	   requires	   the	   successful	   activation	   of	   innate	  
immunity,	  which	   stimulates	   the	   development	   of	   the	   subsequent	   adaptive	   immune	  
response.	  The	   innate	   response	   triggered	  during	  acute	  HIV-­‐1	   infection	   is	   thought	   to	  
be	  one	  of	  the	  key	  aspects	  of	  the	  immune	  system,	  which	  determines	  establishment	  of	  
infection	   and	   the	   rate	   of	   subsequent	   disease	   progression	   (McMichael	   et	   al.,	   2010,	  
Borrow	  and	  Bhardwaj,	  2008,	  Borrow	  et	  al.,	  2010).	  	  	  	  
	  
Dendritic	  cells	  (DCs)	  known	  as	  the	  sentinels	  of	  the	  immune	  system,	  are	  strategically	  
located	   in	   skin,	   mucosal	   tissues	   (including	   oral	   and	   vaginal	   mucosal	   surfaces)	   and	  
lymphoid	  tissues,	  and	  are	  proposed	  to	  be	  among	  the	  first	  cells	  that	  encounter	  HIV-­‐1	  
during	  sexual	  transmission	  (Haase,	  2005,	  Coleman	  et	  al.,	  2013).	  	  Through	  expression	  
of	  a	  diverse	  array	  of	  receptors	  and	  signalling	  molecules,	   these	  professional	  antigen	  
presenting	  cells	  play	  a	  critical	  role	  in	  the	  early	  host	  response	  to	  infection	  by	  acting	  as	  
potent	   antigen-­‐presenting	   cells	   and	   by	   producing	   cytokines	   that	   mediate	   direct	  
effector	   and	   immunoregulatory	   functions	   which	   can	   stimulate	   adaptive	   immune	  
responses	  and	  also	  mediate	  rapid	  antimicrobial	  effector	  functions	  (Banchereau	  et	  al.,	  
2000,	  Borrow	  and	  Bhardwaj,	  2008).	  	  Dendritic	  cells	  are	  highly	  efficient	  at	  stimulating	  
HIV-­‐specific	   T-­‐cell	   responses	  as	   well	   as	   priming	   polyfunctional	   HIV-­‐specific	   T-­‐cell	  
responses	   (Zarling	   et	   al.,	   1999,	   Colleton	   et	   al.,	   2009,	   Lubong	   Sabado	   et	   al.,	   2009,	  
McMichael	   et	   al.,	   2010).	   	   However,	   during	   acute	   HIV-­‐1	   infection	   there	   is	   a	   rapid	  
decline	   in	  the	  number	  of	  circulating	  DCs,	  mainly	  plasmacytoid	  DCs	  and	  this	  may	  be	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the	   result	   of	   activation-­‐induced	   cell	   death	   or	   the	   migration	   of	   activated	   DCs	   into	  
lymph	  nodes	  (Malleret	  et	  al.,	  2008,	  Lore	  et	  al.,	  2002).	  	  In	  chronic	  HIV-­‐1	  infection,	  the	  
depletion	   of	   pDCs	   has	   been	   associated	   with	   HIV	   disease	   progression	   and	  
development	  of	  opportunistic	  infections	  (Soumelis	  et	  al.,	  2001).	  	  
	  
5.2. Natural	  killer	  cells	  
Other	   key	  players	   in	   the	   innate	   immune	   system	  are	  natural	   killer	   (NK)	   cells,	  which	  
contribute	  to	   innate	  defence	  against	  viral	   infections	  as	  they	  respond	  rapidly	  during	  
the	  early	  events	  of	  HIV-­‐1	  infection.	  	  The	  classical	  NK	  cells	  are	  non-­‐T-­‐cell	  lymphocytes,	  
lacking	  expression	  of	  T-­‐cell	  receptors	  (Biron	  et	  al.,	  1999)	  as	  well	  as	  a	  small	  subset	  of	  
T-­‐lymphocytes	  expressing	  surface	  markers	  characteristic	  of	  both	  T-­‐cells	  and	  NK	  (NKT)	  
cells	   are	   now	   appreciated	   to	   form	   an	   important	   link	   between	   the	   innate	   and	  
adaptive	   immune	   responses	   (Alter	   et	   al.,	   2007,	   Borrow	   and	   Bhardwaj,	   2008).	   	   An	  
increased	  percentage	  of	  NK	  cells	  has	  been	  observed	  in	  the	  blood	  during	  acute	  HIV-­‐1	  
infection	   and	   longitudinal	   data	   also	   show	   that	   NK	   cell	   populations	   are	   expanded	  
around	  the	  time	  of	  peak	  plasma	  viremia	  prior	  to	  seroconversion	  and	  the	  appearance	  
of	  HIV-­‐specific	  CD8+	  T-­‐cell	  responses	  (Alter	  et	  al.,	  2005,	  Alter	  et	  al.,	  2007).	  	  Because	  
of	  their	  activation	  during	  acute	  HIV-­‐1	  infection	  and	  their	  heightened	  activity	  in	  HIV-­‐
exposed,	   seronegative	   individuals,	   it	   has	   been	   suggested	   that	   these	   cells	   may	  
contribute	  directly	  or	   indirectly	   to	  control	  of	  primary	  viraemia	  and	  may	  also	  play	  a	  
role	  in	  preventing	  the	  establishment	  of	  infection	  (Alter	  et	  al.,	  2005,	  Alter	  et	  al.,	  2007,	  
Borrow	  and	  Bhardwaj,	  2008,	  Titanji	  et	  al.,	  2008,	  Scott-­‐Algara	  et	  al.,	  2003).	  	  	  NK	  cells	  
may	   also	   inhibit	   HIV-­‐1	   replication	   and	   spread	   via	   lysis	   of	   virally	   infected	   cells	   or	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production	  of	  antiviral	  cytokines	  (e.g.	  IFN-­‐γ)	  and	  chemokines	  (Borrow	  and	  Bhardwaj,	  
2008).	  Although	  the	  significance	  of	  innate	  responses	  as	  determinants	  of	  the	  outcome	  
of	  HIV-­‐1	  infection	  has	  been	  demonstrated,	  more	  work	  is	  still	  needed	  to	  understand	  
how	   innate	   immune	   responses	   can	   be	   harnessed	   to	   combat	   HIV-­‐1	   (Borrow	   and	  
Bhardwaj,	  2008,	  McMichael	  et	  al.,	  2010).	  	  
	  
5.3. Host	  restriction	  factors	  
As	  part	  of	  the	  innate	  immune	  response	  to	  HIV-­‐1,	  cell-­‐intrinsic	  factors	  also	  contribute	  
in	   suppressing	   viral	   replication.	   	   These	   are	   known	   as	   restriction	   factors	   and/or	  
intrinsic	   resistance	   factors,	   and	   they	   provide	   an	   early	   line	   of	   defence	   against	  
infection	  as	  a	  part	  of,	  or	  even	  occurring	  before	  innate	  antiviral	  responses	  (Monajemi	  
et	   al.,	   2012).	   	   The	  most	  widely	   recognized	   restriction	   factors,	  which	   restrict	   HIV-­‐1	  
replication	   in	   target	   T-­‐cells	   and	   provide	   the	   host	   with	   a	   pre-­‐mobilized	   defence	  
against	  retroviral	  infection	  are	  APOBEC3G	  (Sheehy	  et	  al.,	  2002),	  TRIM5α	  (Stremlau	  et	  
al.,	  2004)	  and	  tetherin	  (Neil	  et	  al.,	  2008).	  	  
	  
APOBEC3G	   (apolipoprotein	  B	  mRNA-­‐editing,	   enzyme-­‐catalytic,	   polypeptide-­‐like	  3G)	  
is	  a	  human	  enzyme	  encoded	  by	  the	  APOBEC3G	  gene	  belonging	  to	  the	  APOBEC	  super-­‐
family	  of	  proteins	  and	  has	  the	  ability	  to	  interfere	  with	  HIV	  replication	  (Monajemi	  et	  
al.,	  2012).	   	  This	   family	  of	  proteins	  has	  been	  suggested	  to	  play	  an	   important	   role	   in	  
innate	  anti-­‐viral	  immunity	  by	  converting	  deoxycytidine	   (dC)	   to	  deoxyuridine	   (dU)	   in	  
single	  stranded	  DNA	  (ssDNA)	  or	  RNA	  of	  human	  and	  viral	  genomes,	  most	  notable	  HIV,	  
thereby	   affecting	   a	   variety	   of	   inhibiting	   proper	   viral	   replication	   (Conticello,	   2008,	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Monajemi	   et	   al.,	   2012).	   This	   protein	   is	   mainly	   expressed	   in	   CD4+	  T-­‐cells,	  
macrophages,	   as	   wells	   as	   dendritic	   cells,	   however,	   expression	  may	   be	   induced	   by	  
interferons	   in	  other	  tissues	  (Tanaka	  et	  al.,	  2006,	  Pion	  et	  al.,	  2006,	  Monajemi	  et	  al.,	  
2012).	   	   APOBEC3G	   can	   interrupt	   dissemination	   of	   HIV	   by	   binding	   viral	   RNA,	  
interfering	   with	  reverse	   transcription	  (cDNA),	   physically	   blocking	   reverse	  
transcriptase	   and	   obstructing	   integration	   into	   the	   hosT-­‐cell	   genome	  (Mbisa	   et	   al.,	  
2007,	   Anderson	   and	   Hope,	   2008).	   After	   the	   reverse	   transcription	   stage,	  
incorporation	  of	  dU	  into	  the	  neo-­‐synthesized	  minus	  strand	  DNA	  of	  the	  HIV	  genome	  
has	   been	   shown	   to	   interfere	   with	   synthesis	   of	   the	   complementary	   plus	   strand	  
(Klarmann	   et	   al.,	   2003,	  Monajemi	   et	   al.,	   2012).	   However,	   lentiviruses	   such	   as	   HIV	  
have	   evolved	   several	   strategies,	   primarily	   in	   the	   form	  of	   auxiliary	   proteins	   such	   as	  
Vif,	   which	   interacts	  with	   APOBEC3G	   and	   triggers	   its	  degradation	   via	   the	   ubiquitin-­‐
dependent	  proteosomal	  pathway	  (Yu	  et	  al.,	  2003,	  Goncalves	  and	  Santa-­‐Marta,	  2004,	  
Sheehy	  et	  al.,	  2003).	  
	  
TRIM5-­‐alpha:	  Mammalian	  cells	  express	  several	  factors	  that	  inhibit	  lentiviral	  infection	  
and	   one	   of	   these	   factors,	   tripartite	   motif-­‐containing	   motif	   5	   alpha	  (TRIM5α),	  
mediates	   species-­‐specific	   and	   early	   block	   of	   retrovirus	   infection	   (Reymond	   et	   al.,	  
2001).	  	  In	  Old	  World	  monkeys,	  rhesus	  TRIM5α may	  restrict	  HIV-­‐1	  infection	  by	  binding	  
to	   the	   viral	   capsid,	   leading	   to	   its	   premature	   disassembly	   or	   by	   blocking	   virus	  
production	   (Stremlau	  et	  al.,	  2004,	  Uchil	  et	  al.,	  2008,	  Zhang	  et	  al.,	  2008).	   	  Although	  
human	   TRIM5	   has	   also	   been	   shown	   to	   possess	   some	   anti-­‐HIV	   activity,	   its	   effect	  
however,	  has	  been	  shown	  to	  be	  significantly	  less	  potent	  than	  that	  of	  rhesus	  TRIM5α 
(Stremlau	   et	   al.,	   2004,	   Zhang	   et	   al.,	   2008,	   Kaumanns	   et	   al.,	   2006).	   	   Studies	   have	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suggested	  that	  genetic	  variants	  of	  human	  TRIM5	  may	  influence	  relative	  susceptibility	  
to	   HIV-­‐1	   infection,	   antiretroviral	   function	   and	   the	   rate	   of	   disease	   progression	  
(Javanbakht	  et	  al.,	  2006,	  Speelmon	  et	  al.,	  2006).	   	  Recently	  Richardson	  et	  al.	   (2014)	  
investigated	   the	   role	   of	   protein	   stability	   in	   conferring	   TRIM5α-­‐mediated	   HIV-­‐1	  
restriction	  and	  they	  demonstrated	  that	  human	  TRIM5α	  protein	  was	  less	  stable	  than	  
rhesus	   TRIM5α,	   and	   this	   difference	   correlated	   with	   higher	   self-­‐ubiquitination	  
activity.	   Using	   a	   stabilized	   form	   of	   human	   TRIM5α	   in	   which	   the	   steady-­‐state	  
expression	  level	  was	  more	  similar	  to	  rhesus	  TRIM5α,	  the	  authors	  were	  able	  to	  show	  
comparable	  HIV-­‐1	  restriction	  activity	  in	  HIV-­‐1	  challenge	  assays.	  Interestingly,	  primary	  
human	  CD4+	  T-­‐cells	  expressing	  a	  stabilized	  human	  TRIM5α	  were	  protected	  from	  HIV-­‐
1	  mediated	  destruction	  in	  vivo	  (Richardson	  et	  al.,	  2014).	  	  
Tetherin:	  Human	  cells	  also	  possess	  an	  antiviral	  activity	  that	  inhibits	  the	  release	  of	  a	  
broad-­‐spectrum	   of	   enveloped	   viruses,	   including	   retroviruses	   and	   this	   antiviral	  
activity	   can	  be	   constitutively	   expressed	  or	   induced	  by	   interferon-­‐alpha	   (Neil	   et	   al.,	  
2008,	  Pardieu	  et	  al.,	  2010,	  Xu	  et	  al.,	  2011).	  	  This	  antiviral	  activity	  consists	  of	  protein-­‐
based	   tether,	   termed	   'tetherin'	   because	   it	   directly	   tethers	   virions	   to	   infected	   cells	  
through	   the	   partition	   of	   its	   membrane	   anchors	   into	   both	   virion	   and	   cell	  
membranes	  thus	   causing	   the	   retention	   of	   fully	   formed	   virions	   on	   infected	   cell	  
surfaces	  (Perez-­‐Caballero	  et	  al.,	  2009).	  However,	  HIV-­‐1	  can	  overcome	  the	  restriction	  
imposed	   by	   tetherin	   through	   the	   activity	   of	   viral	   protein	   U	   (Vpu),	  which	  mediates	  
surface	  downregulation	  and	  degradation	  of	  tetherin	  (Neil	  et	  al.,	  2008,	  Van	  Damme	  et	  
al.,	  2008,	  Schindler	  et	  al.,	  2010,	  Douglas	  et	  al.,	  2009).	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6. 	  The	  adaptive	  immune	  response	  to	  HIV-­‐1	  
6.1. The	  antibody	  response	  	  
The	   last	   few	   years	   have	   seen	   a	   rapid	   acceleration	   in	   our	   understanding	   of	   human	  
antibodies	  that	  neutralize	  HIV-­‐1	  and	  much	  of	  this	  has	  been	  enabled	  by	  technologies	  
which	   allow	   for	   the	   identification	   of	   effective	   neutralizers	   from	   HIV-­‐1-­‐infected	  
donors	  capable	  of	  neutralizing	  a	  broad	  spectrum	  of	  HIV-­‐1	  isolates	  (Doria-­‐Rose	  et	  al.,	  
2014,	  Scheid	  et	  al.,	  2011,	  Walker	  et	  al.,	  2009b,	  Wu	  et	  al.,	  2010).	  	  	  Infection	  by	  HIV-­‐1	  
elicits	   a	   strong	   antibody	   response	   to	   both	   the	   surface	   unit	   (gp120)	   and	   the	  
transmembrane	   unit	   (gp41)	   envelope	   glycoprotein	   as	   well	   as	   to	   conformationally	  
dependent	  epitopes	  formed	  by	  the	  trimeric	  Env	  spike	  (Pantophlet	  and	  Burton,	  2006,	  
Mascola	   and	   Montefiori,	   2010).	   However,	   these	   Env-­‐directed	   responses	   consist	  
predominantly	  of	  non-­‐neutralizing	  and	  neutralizing	  antibodies	  are	  usually	  detected	  
several	   months	   later	   (Wei	   et	   al.,	   2003,	   Gray	   et	   al.,	   2007,	   Pantophlet	   and	   Burton,	  
2006,	  Shen	  et	  al.,	  2009,	  Stamatatos	  et	  al.,	  2009).	  Although	  the	  detection	  of	  cytotoxic	  
T-­‐cell	   activity	   coincides	   with	   the	   initial	   decrease	   in	   plasma	   viral	   RNA	   levels,	  
neutralizing	  antibodies	  against	  autologous	  virus	  are	  detected	  in	  the	  majority	  of	  HIV-­‐
infected	  individuals	  from	  approximately	  12	  weeks	  or	  later	  after	  HIV-­‐1	  infection	  (Wei	  
et	  al.,	  2003,	  Gray	  et	  al.,	  2007).	  	  Screening	  of	  thousands	  of	  HIV-­‐1	  infected	  individuals	  
in	  different	  cohorts	  has	  revealed	  that	  some	  degree	  of	  neutralization	  of	  heterologous	  
viruses	  eventually	  arises	  in	  20-­‐25%	  of	  patients	  and	  antibodies	  appear	  after	  1-­‐4	  years	  
of	   infection,	   however,	   evidence	   of	   their	   efficacy	   in	   the	   control	   of	   viremia	   is	   still	  
lacking	   (Gray	  et	  al.,	  2007,	  Shen	  et	  al.,	  2009,	  Stamatatos	  et	  al.,	  2009).	   Interestingly,	  
approximately	  1%	  of	  infected	  individuals,	  referred	  to	  as	  elite	  neutralizers,	  develop	  an	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exceptionally	  broad	  and	  potent	  neutralizing	  antibody	   response	   (Simek	  et	  al.,	  2009,	  
Bello	   et	   al.,	   2009,	   Lambotte	  et	   al.,	   2009).	   	   In	  HIV-­‐1	   clade	  B	   infection,	   the	   range	  of	  
epitopes	   bound	   by	   the	   earliest	   autologous-­‐virus	   neutralizing	   antibodies	   is	   narrow	  
and	  epitopes	  are	  mostly	  restricted	  to	  certain	  virus	  isolates	  (Wei	  et	  al.,	  2003,	  Richman	  
et	   al.,	   2003).	   	   Similarly,	   in	   HIV-­‐1	   clade	   C,	   the	   initial	   autologous-­‐virus	   neutralizing	  
antibodies	   are	   induced	  with	   similar	   kinetics	   and	   are	   typically	   specific	   only	   for	   the	  
initially	  transmitted	  Env	  variant	  (Moore	  et	  al.,	  2008).	  	  Moreover,	  antibodies	  specific	  
for	  the	  more	  conserved	  regions	  of	  HIV-­‐1	  Env	  are	  rarely	  generated	  during	  the	  course	  
of	   HIV-­‐1	   infection;	  when	   they	   do	   occur,	   they	   develop	   only	   after	   20–30	  months	   of	  
infection	  (Calarese	  et	  al.,	  2003,	  Kwong	  et	  al.,	  2002,	  Shen	  et	  al.,	  2009).	  	  	  
	  
During	  acute	  HIV-­‐1	  and	  SIV	  infection	  the	  virus	  replicates	  profusely	  in	  mucosal	  B	  cell	  
inductive	  microenvironments	  such	  as	  Peyer’s	  patches,	  high	  levels	  of	  HIV	  and	  SIV	  can	  
induce	  lysis	  of	  uninfected	  bystander	  follicular	  B	  cells,	  apoptosis	  of	  B	  cells	  and	  loss	  of	  
nearly	   50%	   of	   germinal	   centers	   within	   the	   first	   80	   days	   of	   infection	   (Alam	   et	   al.,	  
2008,	  Fox	  et	  al.,	  1991,	  Pantaleo	  et	  al.,	  1993,	  McMichael	  et	  al.,	  2010).	  	  The	  early	  loss	  
of	   germinal	   centers	   may	   result	   in	   defects	   in	   the	   ability	   to	   rapidly	   generate	   high-­‐
affinity	   HIV-­‐1	   antibodies	   and	   result	   in	   the	   delayed	   induction	   of	   autologous-­‐virus-­‐
neutralizing	  antibodies	  (McMichael	  et	  al.,	  2010,	  Pantaleo	  et	  al.,	  1991,	  Muro-­‐Cacho	  et	  
al.,	   1995).	   	   The	   finding	   that	   the	   generation	   of	   potentially	   protective	   antibodies	   is	  
delayed	   until	   after	   initial	   control	   of	   viraemia	   and	   the	   narrowness	   of	   the	   breath	   of	  
these	   neutralizing	   antibodies	   implies	   that	   key	   vaccine	   strategies	  which	  will	   enable	  
effective	  control	  of	  early	  viral	  expansion	  have	  to	  focus	  on	  priming	  an	  early	  and	  broad	  
antibody	   response	   targeting	  multiple	  neutralizing	  epitopes	  and	  also	   induce	  a	   rapid	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secondary	   response	   (McMichael	   et	   al.,	   2010).	   	   However,	   vaccine	   protocols	   with	   a	  
number	   of	   envelope	   presentations,	   including	   live	   and	   inactivated	   virus	   and	  
recombinant	  envelope	  proteins	  lack	  the	  ability	  to	  elicit	  strong	  neutralizing	  responses	  
to	   primary	   isolates	   of	   HIV-­‐1	   or	   SIV	   capable	   of	   protection	   against	   challenge	   with	  
primary	   viruses	   (Mascola	   and	   Montefiori,	   2010,	   Pantophlet	   and	   Burton,	   2006,	  
Burton,	  1997).	  	  	  
	  
6.2. The	  CD8+	  T-­‐cell	  response	  
There	   is	  compelling	  evidence	  that	  acute-­‐phase	  HIV-­‐1-­‐specific	  CD8+	  T-­‐cell	  responses	  
play	   an	   important	   role	   in	   determining	   the	   subsequent	   clinical	   course	   of	   disease.	  	  
CD8+	   T-­‐cell	   depletion	   studies	   have	   demonstrated	   that	   in	   non-­‐human	   primates	  
infected	  with	   pathogenic	   SIV,	   the	   absence	   of	   CD8+	   T-­‐cells	   during	   acute	   or	   chronic	  
infection	   resulted	   in	   a	   significant	   increase	   in	   virus	   replication	   and	   acceleration	   in	  
disease	  progression	  (Schmitz	  et	  al.,	  1999,	   Jin	  et	  al.,	  1999).	   	  Numerous	  studies	  have	  
also	   demonstrated	   that	   vaccine-­‐induced	   CD8+	   T-­‐cells	   can	   protect	   against	   the	  
development	   of	   AIDS	   when	   macaques	   were	   challenged	   with	   an	   SIV-­‐HIV	   chimera	  
(Amara	  et	  al.,	  2001,	  Barouch	  et	  al.,	  2001,	  Barouch	  et	  al.,	  2000,	  Barouch	  et	  al.,	  2012,	  
Liu	  et	  al.,	  2009a,	  Barouch	  et	  al.,	  2013,	  Hansen	  et	  al.,	  2013).	  	  
	  
In	  both	  HIV-­‐1	  and	  SIV	  infection	  the	  first	  wave	  of	  virus-­‐specific	  CD8+	  T-­‐cell	  responses	  
occurs	   as	   viremia	   approaches	   its	   peak,	   and	   the	   CD8+	   T-­‐cell	   response	   peaks	   1–2	  
weeks	  later,	  coinciding	  with	  the	  decline	  in	  viraemia	  (Koup	  et	  al.,	  1994,	  Borrow	  et	  al.,	  
1994,	   Goonetilleke	   et	   al.,	   2009,	   Pantaleo	   et	   al.,	   1994,	   Huber	   and	   Trkola,	   2007,	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Radebe	  et	  al.,	  2011,	  Liu	  et	  al.,	  2013).	  	  The	  range	  of	  epitopes	  recognized	  by	  the	  CD8+	  
T-­‐cell	  response	  during	  acute	  HIV-­‐1	  infection	  is	  narrow,	  even	  at	  the	  time	  of	  maximal	  
decline	   in	  peak	  viremia	  when	  only	  a	   very	   few	  epitopes	  are	   targeted	   (Altfeld	  et	  al.,	  
2001,	   Turnbull	   et	   al.,	   2009,	   Radebe	   et	   al.,	   2011,	   Goonetilleke	   et	   al.,	   2009).	   	   The	  
earliest	   CD8+	   T-­‐cell	   responses	   are	   often	   specific	   for	   Env	   and	   Nef	   with	   responses	  
against	   Gag	   p24	   and	   Pol	   proteins	   arising	   during	   later	   waves	   of	   T-­‐cell	   responses	  
(Turnbull	  et	  al.,	  2009,	  Goonetilleke	  et	  al.,	  2009,	  Radebe	  et	  al.,	  2011).	   	   	  Despite	   the	  
narrowness	  of	  the	  acute	  phase	  CD8+	  T-­‐cell	  response,	  both	  human	  and	  animal	  studies	  
have	  demonstrated	  that	  the	  emergence	  of	  a	  CD8+	  T-­‐cell	  response	  is	  important	  in	  the	  
control	   of	   virus	   replication	   in	   early	   infection,	   before	   the	   appearance	   of	   anti-­‐HIV	  
binding	   and/or	   neutralising	   antibodies	   (Hansen	   et	   al.,	   2009,	   Bimber	   et	   al.,	   2009,	  
Wilson	   et	   al.,	   2009,	   Streeck	   et	   al.,	   2009b,	   Borrow	   et	   al.,	   1994,	   Koup	   et	   al.,	   1994,	  
Goonetilleke	   et	   al.,	   2009,	   Schmitz	   et	   al.,	   1999,	   Burton	   et	   al.,	   2004,	  Walker	   et	   al.,	  
2009a,	  Hubner	  et	  al.,	  2009,	  Buchbinder	  et	  al.,	  2008,	  McElrath	  et	  al.,	  2008,	  Virgin	  and	  
Walker,	  2010).	  
	  
6.3. Role	  of	  HLA	  class	  I	  in	  mediating	  CD8+	  T-­‐cell	  responses	  	  
CD8+	   T-­‐cells	   detect	   HIV-­‐1	   peptides	   through	   T-­‐cell	   receptor	   (TCR)-­‐mediated	  
recognition	   of	   peptides	  which	   are	   selected	   and	   transported	   to	   the	   cell	   surface	   by	  
HLA	  class	  I	  proteins	  inducing	  T-­‐cell	  activation	  and	  clonal	  expansion,	  which	  is	  followed	  
by	  lysis	  of	  infected	  target	  T-­‐cells	  (Koup	  et	  al.,	  1989,	  Kaslow	  et	  al.,	  1996,	  Neefjes	  et	  al.,	  
2011).	  	  	  Although	  many	  thousands	  of	  different	  peptides	  can	  be	  potentially	  generated	  
for	  CD8+	  T-­‐cell	  recognition,	  the	   intricate	  system	  of	   intracellular	  peptide	  processing,	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transport	   and	  binding	   to	  available	  HLA-­‐I	   allomorphs,	   and	  TCR	   repertoire	  matching,	  
constrain	   these	   candidates	   to	   a	   relatively	   small	   number	   of	   peptide	   epitopes	   that	  
serve	   as	   targets	   for	   the	   effector	   CD8+	   T-­‐cells	   (Yewdell,	   2006,	   Irvine	   and	   Bennink,	  
2006).	  	  The	  control	  of	  HIV	  replication	  has	  also	  been	  linked	  with	  the	  ability	  to	  mount	  a	  
diverse	   class	   I	   restricted	   response,	   where	   HIV-­‐infected	   individuals	   who	   are	  
heterozygous	   at	   the	   HLA	   class	   I	   loci	   have	   been	   shown	   to	   have	   a	   slower	   disease	  
progression	  (Carrington	  et	  al.,	  1999).	  	  	  
	  
6.4. CD8+	  T-­‐cell	  immunodominance	  
Depending	  on	  the	  relative	  contribution	  of	  epitope-­‐specific	  CD8+	  T-­‐cell	  responses	  to	  
the	  overall	  magnitude	  of	  HIV-­‐1-­‐specific	  CD8+	  T-­‐cell	   responses	   in	  a	  given	   individual,	  
these	   CD8+	   T-­‐cells	   responses	   can	   be	   classified	   as	   immunodominant,	   co-­‐dominant	  
and	  subdominant	  (Streeck	  and	  Nixon,	  2010,	  Loffredo	  et	  al.,	  2008,	  Tenzer	  et	  al.,	  2009,	  
Goulder	  et	  al.,	  1997b).	  	  Specific	  immunodominant	  patterns	  of	  CD8+	  T-­‐cell	  responses	  
have	  been	  identified	  during	  acute	  HIV-­‐1	  infection	  that	  are	  linked	  to	  a	  low	  ensuing	  set	  
point	  suggesting	  that	  the	  hierarchy	  of	  HIV-­‐1-­‐specific	  CD8+	  T-­‐cell	  responses	   in	  acute	  
infection	  may	   be	   crucial	   for	   the	   effectiveness	   of	   the	   immune	   response	   (Liu	   et	   al.,	  
2013,	   Streeck	   et	   al.,	   2009b).	   	   Indeed,	   individuals	   able	   to	   mount	   certain	  
immunodominant	   responses	   in	   acute	   HIV-­‐1	   infection	   have	   been	   shown	   to	   on	  
average	  have	  a	  lower	  viral	  set	  point	  than	  those	  who	  do	  not	  target	  those	  epitopes	  in	  
acute	   HIV-­‐1	   infection	   (Streeck	   et	   al.,	   2009b,	   Allen	   et	   al.,	   2000,	   Liu	   et	   al.,	   2013).	  	  	  
These	  data	  show	  that	  the	  generation	  of	   immunodominant	  CD8+	  T-­‐cell	  responses	   in	  
the	  acute	  phase	  of	  infection	  may	  impact	  viral	  load	  set	  point	  and	  subsequent	  disease	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progression.	  Owing	   to	   their	   early	  presentation,	  high	   immunogenicity	   and	  apparent	  
involvement	   in	   the	   initial	   control	   of	   viremia,	   these	   early-­‐recognized	   CD8+	   T-­‐cell	  
epitopes	  represent	  key	  targets	  in	  vaccine	  development	  (Yu	  et	  al.,	  2002).	  
	  
6.5. CD8+	  T-­‐cells	  exert	  selective	  pressure	  
An	  indicator	  of	  CD8+	  T-­‐cell	   immune	  pressure	  on	  the	  virus	   is	  the	  emergence	  of	  viral	  
escape	   within	   targeted	   epitopes	   (Fischer	   et	   al.,	   2010,	   Goonetilleke	   et	   al.,	   2009,	  
Brumme	  et	  al.,	  2008,	  Liu	  et	  al.,	  2013,	  Ferrari	  et	  al.,	  2011).	  	  	  CD8+	  T-­‐cells	  are	  able	  to	  
exert	   significant	   selective	   pressure	   on	   HIV-­‐1	   and	   SIV	   during	   acute	   and	   chronic	  
infection	  and	  thus	  lower	  viral	  replication	  (Cao	  et	  al.,	  2003b,	  Borrow	  et	  al.,	  1997,	  Allen	  
et	  al.,	  2000,	  Moore	  et	  al.,	  2002,	  Allen	  et	  al.,	  2005,	  Kawashima	  et	  al.,	  2009,	  Pereyra	  et	  
al.,	  2008).	  	  In	  fact,	  after	  the	  initial	  CD8+	  T-­‐cell	  response	  wave,	  significant	  changes	  in	  
the	   sequence	   of	   the	   virus	   have	   been	   observed	   with	   rapid	   selection	   of	   mutations	  
occurring	   at	   discrete	   sites	   in	   the	   virus	   genome	   (Salazar-­‐Gonzalez	   et	   al.,	   2009,	  
Bernardin	  et	  al.,	  2005,	  Goonetilleke	  et	  al.,	  2009,	  Liu	  et	  al.,	  2013).	  	  More	  rapid	  escape	  
has	  been	  associated	  with	  the	  most	  immunodominant	  CD8+	  T-­‐cell	  response	  within	  an	  
individual	  (Liu	  et	  al.,	  2013,	  Turk	  et	  al.,	  2013),	  and	  escape	  from	  such	  responses	  may	  
be	  linked	  to	  establishment	  of	  viral	  set	  point	  (Henn	  et	  al.,	  2012).	  	  	  
	  
Detailed	   analysis	   of	   four	   patients	   by	  Goonetilleke	   et	   al.,	   2009	   showed	   that	   during	  
acute	   infection	   HIV-­‐1–specific	   T-­‐cells	   rapidly	   select	   escape	   mutations	   concurrent	  
with	  falling	  virus	  load	  and	  that	  CD8+	  T-­‐cell–mediated	  killing	  significantly	  contributed	  
to	  the	  killing	  of	  productively	  infected	  cells	  in	  acute	  HIV-­‐1	  infection	  thus	  contributing	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to	   the	   initial	   decline	   of	   plasma	   virus	   in	   acute	   infection.	   	   By	   single	   genome	  
amplification	  they	  were	  able	  to	  detect	  viral	  evolution	  at	  sites	  of	  CD8+	  T-­‐cell	  pressure	  
during	   peak	   viremia,	   thus	   clearly	   demonstrating	   that	   there	   is	   effective	   pressure	  
being	  applied	  as	  it	  leads	  to	  a	  significant	  turnover	  in	  the	  replicating	  virus	  population.	  	  
A	  mathematical	  model	  of	  these	  data	  postulates	  that	  15%–	  35%	  of	  infected	  cells	  can	  
be	  killed	  by	  CD8+	  T-­‐cells	  of	  a	  single	  specificity	  per	  day	  in	  vivo	  during	  acute	  infection	  
(Ganusov	  et	  al.,	  2011,	  Liu	  et	  al.,	  2013,	  Goonetilleke	  et	  al.,	  2009).	  
	  	  	  
6.6. The	  fitness	  of	  the	  infecting	  virus	  
Current	  data	  convincingly	  demonstrate	  the	  role	  of	  CD8+	  T-­‐cells	   in	  combating	  HIV-­‐1	  
infection	   and	   have	   been	   a	   driving	   force	   in	   strategies	   aimed	   at	   eliciting	   these	  
responses	  with	  HIV-­‐1	  vaccines	  (Burton	  et	  al.,	  2004,	  Walker	  et	  al.,	  2009a,	  Hubner	  et	  
al.,	   2009,	   Buchbinder	   et	   al.,	   2008,	  McElrath	   et	   al.,	   2008,	   Virgin	   and	  Walker,	   2010,	  
Hansen	   et	   al.,	   2011,	   Korber	   et	   al.,	   2009,	   Barouch	   et	   al.,	   2010,	   Stephenson	   et	   al.,	  
2012).	  A	  major	  obstacle	  however,	  is	  CTL-­‐mediated	  selection	  leading	  to	  viral	  escape,	  
which	  occurs	  frequently	  in	  both	  acute/early	  and	  chronic	  HIV-­‐1	  infection	  (Boutwell	  et	  
al.,	  2010,	  Wang	  et	  al.,	  2009,	  Brumme	  et	  al.,	  2009,	  Ganusov	  et	  al.,	  2011).	   	  Although	  
the	  evasion	  of	  intrinsic	  immune	  responses	  through	  escape	  mutations	  may	  represent	  
a	  survival	  benefit	  to	  the	  virus,	  the	  same	  mutations	  can	  carry	  associated	  fitness	  costs	  
as	   evidenced	   by	   the	   reversion	   of	   transmitted	   escape	  mutations	   during	   acute	   and	  
early	  HIV-­‐1	   infection	   (Leslie	   et	   al.,	   2004,	  Goonetilleke	   et	   al.,	   2009,	   Li	   et	   al.,	   2007).	  	  
Many	   of	   the	   critical	   escape	  mutations	  which	   carry	   an	   associated	   fitness	   cost	   have	  
been	  identified	  in	  the	  relatively	  conserved	  Gag	  protein	  (Wright	  et	  al.,	  2010,	  Boutwell	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et	   al.,	   2009,	   Brockman	   et	   al.,	   2007,	   Schneidewind	   et	   al.,	   2008),	  whilst	   CTL	   escape	  
mutations	  in	  Env	  protein	  have	  been	  shown	  to	  have	  a	  neutral	  effect	  on	  virus	  fitness,	  
suggesting	   a	   balance	   between	   immunologic	   escape	   and	   replicative	   fitness	   costs	  
(Troyer	   et	   al.,	   2009).	   	   A	   number	   of	   studies	   have	   reported	   that	   in	   chronic	   HIV-­‐1	  
infection,	   there	   is	   a	   correlation	   between	   in	   vitro	   HIV-­‐1	   replication	   capacity	   and	  
plasma	   viremia	   or	   disease	   progression	   (Blaak	   et	   al.,	   1998,	   Brumme	   et	   al.,	   2007,	  
Wright	   et	   al.,	   2010).	   	   Studies	   of	   HIV-­‐1	   elite	   controllers	   who	   are	   able	   to	   maintain	  
viremia	   to	   limits	   below	   detection,	   have	   revealed	   the	   presence	   of	   replication-­‐
competent	   viruses	   in	   these	   individuals,	   however,	   these	   viruses	  were	   shown	   to	   be	  
less	  fit	  (Blankson	  et	  al.,	  2007,	  Lassen	  et	  al.,	  2009,	  Miura	  et	  al.,	  2009).	   	  There	  is	  also	  
data	   demonstrating	   that	   acute/early	   stage	   viruses	   from	   individuals	   with	   a	   slower	  
rate	  of	  disease	  progression	  also	  display	  reduced	  replication	  capacity	  during	  the	  early	  
stages	  of	  infection,	  suggesting	  that	  viral	  dynamics	  during	  acute	  infection	  may	  have	  a	  
major	  impact	  on	  HIV	  disease	  progression	  and	  outcome	  (Miura	  et	  al.,	  2010,	  Prince	  et	  
al.,	  2012,	  Brockman	  et	  al.,	  2010,	  Wright	  et	  al.,	  2011).	  	  
	  
6.7. CD4+	  T-­‐cells	  in	  HIV-­‐1	  infection	  
The	  hallmark	  of	  HIV-­‐1	  infection	  is	  the	  depletion	  of	  CD4+	  T-­‐cells	  in	  peripheral	  blood,	  
lymphoid	  organs	  and	  mucosal	  sites	  (Haase,	  2005).	  Since	  CD4+	  T-­‐cells	  play	  a	  vital	  role	  
in	   immune	   defences	   against	   almost	   all	   pathogens,	   HIV-­‐1-­‐infected	   individuals	   are	  
subject	   to	   a	   variety	   of	   opportunistic	   infections	   (Okoye	   et	   al.,	   2007,	   Andrews	   and	  
Koup,	   1996,	   Rosenberg	   et	   al.,	   1997).	   Activated	   CD4+	   T	   helper	   cells	   are	   the	   main	  
target	  of	  HIV-­‐1	  and	  are	  killed	  by	  infection	  and	  HIV-­‐1	  induced	  apoptosis	  (Groux	  et	  al.,	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1992,	  Musey	  et	  al.,	  1999).	  	  	  Activated	  CD4+	  T-­‐helper	  cells	  mediate	  a	  Th1	  response	  by	  
producing	  IL-­‐2	  and	  IFN-­‐γ,	  cytokines	  essential	  for	  maintaining	  an	  effective	  CD8+	  T-­‐cell	  
response	  (Altfeld	  et	  al.,	  2001,	  Kalams	  et	  al.,	  1999,	  Rosenberg	  et	  al.,	  1997,	  Ramduth	  
et	   al.,	   2005).	   However,	   as	   a	   result	   of	   continuous	   viral	   replication,	   the	   CD4+	   T-­‐cell	  
population	  lose	  the	  ability	  to	  produce	  IL-­‐2	  or	  to	  proliferate	  and	  may	  result	  in	  lack	  of	  
viral	  control	  (Iyasere	  et	  al.,	  2003,	  Younes	  et	  al.,	  2003,	  Palmer	  et	  al.,	  2005).	  	  	  
	  
6.8. Immune	  activation	  and	  HIV	  pathogenesis	  
Data	   from	   animal	   models	   and	   human	   studies	   show	   that	   acute	   HIV-­‐1	   infection	   is	  
characterized	  by	  a	   rapid	  and	  massive	  depletion	  of	  CCR5+CD4+	  memory	  T-­‐cells	  and	  
these	  cells	  account	  for	  most	  of	  the	  CD4+	  T-­‐cells	  found	  in	  the	  mucosal	  surface	  of	  the	  
intestinal	  tract	  (Veazey	  et	  al.,	  2000,	  Brenchley	  et	  al.,	  2004a).	  	  The	  depletion	  of	  CD4+	  
T-­‐cells	   in	   mucosal	   lymphoid	   tissues	   results	   in	   the	   absence	   of	   key	   regulatory	   and	  
effector	   functions	   that	   CD4+	   T-­‐cells	   perform	   in	   controlling	   immune	   response,	   thus	  
the	  extent	  of	  the	  initial	  damage	  at	  the	  mucosal	  surface	  may	  subsequently	  determine	  
the	   course	   of	   infection	   (Brenchley	   et	   al.,	   2006a,	   Hel	   et	   al.,	   2006,	   Gupta,	   1993,	  
Pedersen	   et	   al.,	   1990).	   	   	   Loss	   of	   mucosal	   CD4+	   T-­‐cells	   may	   also	   disrupt	   various	  
immune	   components	   that	   constitute	   the	   mucosal	   barrier	   in	   the	   gut	   thus	   causing	  
microbial	  translocation	  into	  circulation	  and	  the	  systemic	  immune	  system	  resulting	  in	  
enhanced	  T-­‐cell	   activation	   (Catalfamo	  et	   al.,	   2008,	   Equils	   et	   al.,	   2001,	   Faure	  et	   al.,	  
2000,	  Brenchley	  et	  al.,	  2006b,	  Nowroozalizadeh	  et	  al.,	  2010,	  Deeks	  et	  al.,	  2004).	  	  The	  
increased	  levels	  of	  activation	  result	  in	  increased	  CD4+	  and	  CD8+	  T-­‐cell	  turnover	  and	  
death	  of	  these	  activated	  cells	  (Alter	  et	  al.,	  2004,	  Brenchley	  et	  al.,	  2006b,	  Douek	  et	  al.,	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2003,	   Hellerstein	   et	   al.,	   2003).	   	   In	   addition,	   T-­‐cell	   immune	   activation	   during	   acute	  
HIV-­‐1	   infection	   is	   characterized	   by	   an	   increased	   expression	   of	   pro-­‐inflammatory	  
cytokines	  (Godfried	  et	  al.,	  1993,	  Fahey	  et	  al.,	  1990,	  Miedema	  et	  al.,	  2013,	  Stacey	  et	  
al.,	  2009,	  Roberts	  et	  al.,	  2010)	  which	  enhance	  HIV-­‐1	  replication	  and	  CD4+	  T-­‐cell	  loss	  
by	  directly	  promoting	  proviral	  transcription,	  by	  recruiting	  and	  activating	  CD4+	  T-­‐cell	  
targets	  for	  HIV-­‐1	  infection,	  and	  by	  inducing	  apoptosis	  of	  bystander	  T-­‐cells	  (Osborn	  et	  
al.,	  1989,	  Swingler	  et	  al.,	  1999,	  Katsikis	  et	  al.,	  2011).	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7. Rationale	  for	  the	  study:	  
	  
Evidence	  suggests	  that	  CD8+	  T-­‐cells	  play	  a	  major	  role	  in	  the	  control	  of	  HIV-­‐1	  viremia	  
and	   apply	   significant	   immune	   pressure	   on	   HIV-­‐1	   replication.	   	   However,	   significant	  
numbers	  of	  HIV-­‐specific	  CD8+	  T-­‐cells	  responses	  are	  seen	  in	  both	  chronically	  infected	  
rapid	   progressors	   and	   controllers.	   	   The	   presence	   of	   virus-­‐specific	   CD8+	   T-­‐cells	   in	  
individuals	  with	  varying	  levels	  of	  viral	  control	  suggests	  that	  CD8+	  T-­‐cells	  may	  differ	  in	  
their	   antiviral	   function	   or	   efficacy.	   	   The	  mechanisms	   underlying	   differences	   in	   the	  
control	   of	   viremia,	   particularly	   the	   reasons	   why	   particular	   individuals	   experience	  
more	   effective	   primary	   viremia	   resolution	   are	   still	   not	   well	   understood.	   	   It	   is	  
important	   to	   identify	   the	   specificity	   and	   patterns	   of	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	  
responses	   and	   how	   they	   mediate	   viral	   control	   in	   order	   to	   accurately	   define	   the	  
immune	  correlates	  for	  protection.	  In	  order	  to	  uncover	  some	  of	  the	  features	  of	  CD8+	  
T-­‐cell	   subsets	   responsible	   for	   the	   control	   of	   HIV	   replication,	   we	   investigated	   the	  
patterns	   and	   features	   of	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	   responses	   during	   acute	   and	  
primary	  HIV-­‐1	   infection	  and	  their	  association	  with	  viral	  control.	   	  We	  also	  sought	  to	  
determine	  the	  impact	  of	  acute	  phase	  immune	  activation	  on	  the	  acute	  HIV-­‐1-­‐specific	  
CD8+	   T-­‐cell	   response	   and	   on	   disease	   progression.	   	  We	   hypothesized	   that	   protein-­‐
specific	  and	  epitope-­‐specific	   immunodominance	  patterns	  during	   the	   first	  12	  weeks	  
of	  HIV-­‐1	  infection	  are	  associated	  with	  disease	  progression.	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8. Objectives	  of	  the	  Study:	  
1. To	   characterize	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	   responses	   and	   their	  
immunodominance	  patterns	  during	  primary	  HIV-­‐1	  infection.	  	  
	  
2. To	   assess	   the	   impact	   of	   early	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	   responses	   on	   viral	  
control	  and	  viral	  evolution	  
	  
3. To	  assess	  the	  impact	  of	  memory	  CD8+	  T-­‐cell	  responses	  during	  primary	  HIV-­‐1	  
clade	  C	  infection	  on	  long-­‐term	  disease	  progression.	  
	  
4. To	  characterize	   fluctuations	  of	  early	  cytokine	  expression	  and	   levels	  of	  T-­‐cell	  
immune	  activation	   in	  acute	  HIV-­‐1	   infection	  and	   the	   impact	  of	   these	   factors	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Chapter	  2 :	  Limited	  immunogenicity	  of	  HIV	  CD8+	  T-­‐
cell	  epitopes	  in	  acute	  clade	  C	  virus	  infection	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1. Abstract	  
	  
Background:	   HIV-­‐1-­‐specific	   CD8+	   responses	   contribute	   to	   the	   decline	   in	   acute	  
peak	  viremia	  following	  infection.	  	  However,	  data	  on	  the	  relative	  immunogenicity	  
of	  CD8+	  T-­‐cell	  epitopes	  during	  and	  after	  acute	  viremia	  are	  lacking.	  	  	  
	  
Methods:	  We	  characterized	  CD8+	  T-­‐cell	  responses	  in	  20	  HIV-­‐1C	  acutely	  infected,	  
antiretroviral-­‐naive	  subjects	  using	  the	   IFN-­‐γ	  ELISPOT	  assay.	  Eleven	  of	   these	  had	  
not	  fully	  seroconverted	  at	  analysis.	  Viruses	  from	  plasma	  were	  sequenced	  within	  
defined	  CTL	  epitopes	  for	  selected	  subjects.	  	  
	  
Results:	   At	   approximately	   28	   days	   after	   estimated	   initial	   infection,	   CD8+	   T-­‐cell	  
responses	   were	   directed	   against	   an	   average	   of	   3	   of	   the	   410	   peptides	   tested	  
(range	   0-­‐6);	   two	   individuals	   had	   no	   detectable	   responses	   at	   this	   time.	   At	   18	  
weeks,	  the	  average	  number	  of	  peptides	  targeted	  had	  increased	  to	  5	  (range	  0-­‐11).	  	  
Of	   56	   optimal	   Gag	   CTL	   epitopes	   sequenced,	   31	  were	  wildtype	   in	   the	   infecting	  
viruses,	  but	  only	  11	  of	  31	  elicited	  measurable	  CD8+	  T-­‐cell	  responses.	  	  
	  
Conclusion:	   These	   data	   demonstrate	   that	   the	  majority	   of	   CD8+	   responses	   that	  
subsequently	   arise	   are	   not	   elicited	   during	   acute	   HIV	   infection	   despite	   the	  
presence	  of	  the	  cognate	  epitope	  in	  the	  infecting	  strain.	  	  	  There	  is	  a	  need	  to	  define	  
factors	   that	   influence	   lack	  of	   induction	  of	   effective	   immune	   responses	   and	   the	  
parameters	  that	  dictate	  immunodominance	  in	  acute	  infection.	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2. Introduction	  
HIV-­‐1-­‐specific	   CD8+	   T-­‐lymphocytes	   have	   been	   a	   key	   focus	   for	   HIV	   vaccine	  
development	  efforts,	  in	  part	  because	  approaches	  based	  on	  the	  development	  of	  a	  
neutralizing	  antibody	  based	  vaccine	  have	  thus	  far	  failed	  to	  induce	  broadly	  cross	  
reactive	   neutralizing	   antibodies	   (Walker	   et	   al.,	   2009a,	   Hubner	   et	   al.,	   2009,	  
Buchbinder	  et	  al.,	   2008,	  McElrath	  et	  al.,	   2008,	  Virgin	  and	  Walker,	  2010)	  and	   in	  
part	   because	   induction	   of	   T-­‐cell	   responses	   in	   animal	   models	   of	   AIDS	   virus	  
infection	   impact	   viral	   set	   point	   and	   disease	   progression	   (Hansen	   et	   al.,	   2009,	  
Bimber	  et	  al.,	  2009,	  Wilson	  et	  al.,	  2009).	  	  	  
	  
Numerous	   studies	   in	   clade	   B	   infection	   have	   shown	   that	   early	   CD8+	   T-­‐cell	  
responses	  are	  narrowly	  directed,	  and	  specific	  immunodominant	  T-­‐cell	  responses	  
detected	  during	   acute	  HIV-­‐1	   infection	   are	   associated	  with	   the	   subsequent	   viral	  
set	  point	  (Yu	  et	  al.,	  2002,	  Lichterfeld	  et	  al.,	  2005,	  Altfeld	  et	  al.,	  2006,	  Streeck	  et	  
al.,	  2009b).	  However,	   these	  studies	  have	  had	  a	  number	  of	   limitations.	   	   In	  most	  
studies	  to	  date,	  although	  subjects	  have	  been	  identified	  prior	  to	  seroconversion,	  
the	   initial	   assays	   of	   T-­‐cell	   function	   have	   been	   performed	   following	  
seroconversion.	  	  Studies	  that	  link	  CD8+	  T-­‐cell	  responses	  to	  seroconversion	  status	  
and	  contemporaneous	  viral	  load	  are	  lacking,	  and	  overall	  there	  is	  a	  paucity	  of	  data	  
on	  HIV-­‐1-­‐specific	  CD8+	  T-­‐cell	   responses	   for	   the	  ethnicities	  most	   ravaged	  by	   the	  
HIV-­‐1	  pandemic	  and	  for	  the	  clades	  responsible	  in	  these	  regions.	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Moreover,	  most	  studies	  on	  immune	  responses	  in	  acute	  infection	  have	  relied	  on	  
identification	  of	   subjects	  based	  on	   symptoms	  of	  acute	   infection	   staged	  as	  days	  
following	  onset	  of	  symptoms	  (Koup	  et	  al.,	  1994,	  Streeck	  et	  al.,	  2009b,	  Turnbull	  et	  
al.,	  2009),	  whereas	  the	  evolution	  of	  antibody	  responses	  used	  in	  the	  Fiebig	  staging	  
of	  acute	   infection	  were	  obtained	   from	  a	   cohort	  of	  asymptomatic	  blood	  donors	  
(Fiebig	  et	  al.,	  2003)	  who	  would	  not	  have	  qualified	   for	  donation	   if	   they	  had	  had	  
typical	  acute	  infection	  symptoms	  such	  as	  fever	  and	  malaise.	  	  	  
	  
To	   address	   these	   limitations	   and	   to	   define	   the	   characteristics	   of	   HIV-­‐1-­‐specific	  
immunity	  in	  acute	  HIV-­‐1C	  infection,	  we	  screened	  persons	  at	  voluntary	  counseling	  
and	   testing	   (VCT)	   centers	   testing	   negative	   by	   standard	   antibody	   assays	   for	  
evidence	  of	  HIV	  RNA	   (Bassett	  et	  al.,	   2011).	   	   Subjects	  were	  enrolled	  after	   initial	  
screening,	  allowing	  us	  to	  document	  the	  decline	  in	  viral	  load	  concurrent	  with	  the	  
measurement	  of	  immune	  responses.	  	  Using	  the	  ELISPOT	  assay,	  we	  evaluated	  the	  
breadth	  and	  magnitude	  of	  HIV-­‐specific	  CD8+	  T-­‐cell	   responses	  over	   the	   first	   few	  
weeks	  of	  infection	  using	  synthetic	  overlapping	  peptides	  and	  defined	  HLA	  class	  I-­‐
restricted	   epitopes.	   	  Our	   data	   indicate	   that	   limited	   T-­‐cell	   breadth	   is	   associated	  
with	  the	  initial	  decline	  in	  viremia	  in	  acute	  HIV-­‐1C	  infection,	  and	  that	  the	  majority	  
of	  epitopes	  known	  to	  be	  targeted	   in	  the	  context	  of	  expressed	  class	   I	  molecules	  
are	  not	  immunogenic	  in	  the	  earliest	  stages	  of	  infection.	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3. Materials	  and	  methods	  
3.1. Study	  Participants	  
The	   HIV	   Pathogenesis	   Programme	   (HPP)	   Acute	   Infection	   Study	   is	   an	   ongoing	  
effort	  to	  characterize	  acute	  HIV-­‐1	  subtype	  C	  infection	  in	  Durban,	  KwaZulu-­‐Natal.	  
Recruitment	  of	  subjects	  with	  acute	  and	  early	  HIV	  infection	  was	  achieved	  through	  
the	   recruitment	   of	   subjects	   at	   3	   different	   sites:	   St.	   Mary’s	   Hospital,	   McCord	  
Hospital	  and	  Prince	  Mshiyeni.	   Individuals	  testing	  negative	  or	  discordant	  by	  dual	  
commercial	   rapid	   HIV-­‐1	   tests	   (Bioline,	   Standard	   Diagnostics,	   Inc.,	   Kyonggi-­‐do,	  
Korea);	  and	  Sensa	   (Hitech	  Healthcare	  LTC,	  China)	  were	  recruited	   for	  HIV-­‐1	  RNA	  
testing.	  	  Acute	  HIV-­‐1	  infection	  was	  defined	  by	  a	  positive	  HIV-­‐1	  RNA	  test,	  negative	  
HIV-­‐1	  enzyme	  immunoassay	  test	  (SD	  HIV1/2	  ELISA	  3.0	  (Standard	  Diagnostics,	  Inc.,	  
Kyonggi,	  Korea))	  and	  a	  negative	  or	  indeterminate	  Western	  blot	  (Genetic	  Systems,	  
Bio-­‐Rad,	   Redmond,	  USA).	   Centers	   for	  Disease	   Control	   (CDC)	   criteria	  were	   used	  
for	  the	  interpretation	  of	  Western	  blot	  results	  such	  that	  a	  positive	  sample	  had	  at	  
least	  two	  of	  the	  major	  bands	  (gp160,	  gp120,	  gp41	  and	  p24),	  with	  either	  gp160	  or	  
gp120	  present	  as	  well	  as	  gp41	  or	  p24	  (Centers	   for	  Disease,	  1985).	   	   If	   the	  result	  
did	  not	  meet	  these	  requirements	  but	  one	  or	  more	  bands	  were	  present;	  or	  where	  
the	   band	   intensity	   was	   less	   than	   the	   weak	   positive	   control	   this	   result	   was	  
classified	  as	   indeterminate.	   	   	  Negative	  results	  exhibited	  no	  reactive	  bands.	   	  We	  
estimated	  the	   infection	  date	  as	  occurring	  14	  days	  prior	   to	  the	   first	  positive	  HIV	  
RNA	  and	  negative	  HIV	  antibody	  test	  as	  previously	  described	  (van	  Loggerenberg	  et	  
al.,	  2008).	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A	  total	  of	  42	  subjects	  were	  identified,	  of	  whom	  20	  were	  enrolled.	  The	  study	  was	  
approved	  by	  the	  Biomedical	  Research	  Ethics	  Committee	  (BREC)	  of	  the	  University	  
of	   KwaZulu-­‐Natal.	   All	   study	  participants	   provided	  written	   informed	   consent	   for	  
participation	  in	  the	  study.	  
	  
3.2. Isolation	  of	  PBMCs	  
Blood	   was	   collected	   in	   EDTA	   tubes	   and	   processed	   within	   6	   hrs	   of	   collection.	  
Peripheral	   blood	   mononuclear	   cells	   (PBMCs)	   were	   isolated	   from	   whole	   blood	  
using	  the	  Ficoll-­‐Histopaque	  (Sigma,	  St	  Louis,	  Mo)	  density	  gradient	  centrifugation	  
and	  used	  fresh	  in	  ELISPOT	  assays.	  	  	  
	  
3.3. Viral	  load	  quantification,	  and	  CD4+	  T-­‐cell	  enumeration	  
HIV-­‐1	   RNA	   in	   plasma	   was	   measured	   using	   the	   Roche	   Amplicor	   version	   1.5	   or	  
Cobas	  Taqman	  HIV-­‐1	  Test	  according	  to	  the	  manufacturer's	  instructions.	   	  CD4+	  T-­‐
cells	  were	  enumerated	  using	  Tru-­‐Count	  technology	  and	  analyzed	  on	  a	  four-­‐color	  
flow	  cytometer	  (Becton	  Dickinson)	  according	  to	  the	  manufacturer's	  instructions.	  	  	  
	  
3.4. HLA	  typing	  	  
DNA	   for	   HLA	   typing	  was	   extracted	   using	   Puregene	   DNA	   isolation	   kit	   for	   blood	  
(Gentra	   Systems,	   Minneapolis,	   Minn.)	   according	   to	   the	   manufacturer’s	  
instructions.	   	  HLA	   class	   I	   typing	  was	  done	  by	  DNA	  PCR	  using	   sequence	   specific	  
primers	   as	   previously	   described	   (Kiepiela	   et	   al.,	   2004).	   	   Briefly,	   genomic	   DNA	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samples	  were	   initially	   typed	  to	  an	  oligo-­‐allelic	   level	  using	  Dynal	  RELITM	  reverse	  
Sequence	  Specific	  Oligonucleotide	  (SSO)	  kits	  for	  the	  HLA-­‐A,	  -­‐B	  and	  -­‐C	  loci	  (Dynal	  
Biotech).	  Refining	  the	  genotype	  to	  the	  allele	  level	  was	  performed	  using	  the	  Dynal	  
Biotech	  sequence-­‐specific	  priming	  kits	  in	  conjunction	  with	  the	  previous	  SSO	  type.	  	  
	  
3.5. Synthetic	  HIV-­‐1	  peptides	  	  
A	   panel	   of	   410	   peptides	   (18-­‐mers	   overlapping	   by	   10	   amino	   acid	   residues),	  
spanning	   the	   entire	   HIV-­‐1	   clade	   C	   consensus	   sequence	   together	   with	   optimal	  
peptides	   with	   known	   HLA	   class	   I	   restriction	   patterns,	   were	   synthesized	   on	   an	  
automated	  peptide	  synthesizer	  (MBS	  396;	  Advanced	  ChemTech)	  and	  used	  in	  the	  
ELISPOT	  assay	  (Chessman	  et	  al.,	  2008).	  	  
	  
3.6. IFN-­‐gamma	  ELISPOT	  Assay	  	  
Assessment	  of	  HIV-­‐1-­‐specific	  CD8+	  responses	  was	  performed	  on	  peripheral	  blood	  
mononuclear	   cell	   (PBMC)	   samples	   collected	   at	   2-­‐4,	   4-­‐6,	   6-­‐8,	   8-­‐12	   and	   12-­‐18	  
weeks	   (14-­‐28,	   29-­‐56,	   57-­‐84,	   85-­‐126	   days)	   following	   initial	   viral	   load	   screening.	  	  
PBMCs	   (50,000-­‐100,000	  cells/well)	  were	   plated	   in	   96-­‐well	   polyvinylidene	   plates	  
(MAIP	  S45;	  Millipore),	  precoated	  with	  anti-­‐human	  IFN-­‐γ	  monoclonal	  antibody	  1-­‐
D1k	   (0.5	   µg/ml;	   Mabtech).	   	   Peptides	   were	   added	   at	   2	  µg/ml	   in	   a	   matrix	  
(Thobakgale	   et	   al.,	   2007).	   	   Phytohemagglutinin	   (1	   µg/ml)	   stimulation	   was	  
included	   as	   a	   positive	   control,	   and	  medium	  alone	   as	   a	   negative	   control.	   Plates	  
were	   incubated	   overnight	   at	   37°C	   and	   5%	   CO2,	   then	   washed	  with	   phosphate-­‐
buffered	  saline	  before	  addition	  of	   the	  biotinylated	  anti-­‐IFN-­‐	  MAb,	  7-­‐B6-­‐1	  biotin	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(Mabtech),	   at	   0.5	  µg/ml	  and	   incubation	   for	   90	  minutes.	   	   Following	  
washing,	  streptavidin-­‐conjugated	  alkaline	  phosphatase	  (Mabtech)	  was	  added	  for	  
45	  minutes.	   	   IFN-­‐γ-­‐producing	   cells	   were	   noted	   by	   direct	   visualization	   following	  
development	  with	   alkaline	   phosphatase	   colour	   reagents	   (Bio-­‐Rad).	   	   A	   response	  
was	   defined	   as	   positive	   when	   there	   were	   at	   least	   100	   spot	   forming	   cells	  
(SFCs)/million	   PBMC	   and	   the	   total	   number	   of	   spots	   was	   3	   standard	   deviations	  
above	  the	  negative	  control	  value.	  	  In	  addition	  to	  overlapping	  peptides,	  peptides	  
corresponding	   to	  optimal	  HIV-­‐1	  CTL	  epitopes	  described	   for	   the	   individual’s	  HLA	  
class	  I	  type	  were	  tested	  at	  a	  peptide	  concentration	  of	  2	  µg/ml.	  	  
	  
To	  verify	  peptides	  identified	  as	  positive	  in	  the	  peptide	  pool	  matrix,	  PBMCs	  from	  
the	  same	  time	  point	  were	  stimulated	  with	  individual	  peptides	  that	  were	  common	  
to	   two	   peptide	   pools	   in	   the	   initial	   ELISPOT	   screen.	  	   The	   criteria	   used	   to	   define	  
positive	  responses	  in	  the	  peptide	  pool	  matrix	  were	  also	  used	  for	  the	  verification	  
assay.	   	   In	   98%	   of	   the	   matrix	   positive	   responses,	   at	   least	   one	   single	   peptide	  
positive	   reaction	  was	   confirmed.	   The	   sensitivity	   of	   the	  matrix	   approach	  for	   the	  
detection	  of	  peptide-­‐specific	  T-­‐cell	   responses	  was	   found	   to	  be	  82%	   for	  Nef	  and	  
Gag.	   	   The	   sensitivity	   was	   calculated	   by	   dividing	   the	   number	   of	   responses	  
detected	  in	   the	   peptide	   matrix	   by	   the	   number	   of	   responses	   detected	   using	  
individual	  peptides	  (Addo	  et	  al.,	  2003).	  	  
	  
All	  responses	  at	  the	  first	  sampling	  time	  point	  were	  evaluated	  using	  fresh	  PBMC,	  
which	  provide	  greater	  sensitivity	  in	  ELISPOT	  assays	  in	  comparison	  to	  viably	  frozen	  
cells	   (Mooij	   et	   al.,	   2009).	   	   Fresh	   cells	   were	   also	   used	   in	   all	   but	   10%	   of	   assays	  
	   44	  
performed	   at	   later	   time	   points.	   PBMC	   were	   frozen	   (90%	   calf	   serum	   and	   10%	  
DMSO)	   at	   -­‐160°C	   until	   use.	   Cell	   viability	   was	   determined	   using	   a	   Guava	  
automated	   counter	   (Guava	   Technologies,	   Hayward,	   CA)	   and	   the	   ELISPOT	   assay	  
was	  performed	  only	  when	  PBMC	  viability	  was	  greater	  than	  80%.	  
	  
3.7. Gag	  amplification	  and	  sequencing	  
Viral	   RNA	  was	   isolated	   from	   140µl	   of	   plasma	   samples	   using	   the	   QIAamp	   Viral	  
RNA	  Extraction	  Mini	  Kit	   (Qiagen,	  Hilden,	  Germany).	  Viral	  RNA	  was	  then	  reverse	  
transcribed	   using	   ThermoScript™	   RT-­‐PCR	   System	   kit	   (Invitrogen,	   Carlsbad,	   CA,	  
USA)	   and	   the	   gene-­‐specific	   primer,	   GagD	   reverse	   as	   previously	   described	  
(Chopera	   et	   al.,	   2008).	   To	   amplify	   the	   HIV-­‐1	   gag	   region,	   a	   nested	   PCR	   was	  
performed	  with	   two	   sets	   of	   primers,	  GagD	   forward	   (5′-­‐TCT	   CTA	  GCA	  GTG	  GCG	  
CCC	  G-­‐3′)	   and	  GagD	   reverse	   for	   the	   first	   round	   and	  GagA	   forward	   (5′-­‐CTC	   TCG	  
ACG	  CAG	  GAC	  TCG	  GCT	  T-­‐3′)	  and	  GagC	  reverse	  (5′-­‐TCT	  TCT	  AAT	  ACT	  GTA	  TCA	  TCT	  
GC-­‐3′)	   for	  the	  second	  round	  as	  previoulsy	  described	  (Chopera	  et	  al.,	  2008).	  The	  
resulting	  PCR	  product	  was	  then	  purified	  using	  purification	  columns	  from	  Illustra™	  
GFX™	   PCR	   DNA	   Gel	   Band	   Purification	   Kit,	   (GE	   Healthcare,	   Little	   Chalfont,	  
Buckinghamshire,	   UK)	   and	   cloned	   into	   a	   PCR	   2.1-­‐TOPO	   vector	   (Invitrogen,	  
Carlsbad,	  CA,	  USA).	  Plasmid	  DNA	  was	   isolated	   from	   individual	   randomly	  picked	  
white	   bacterial	   colonies	   (GeneJet	   Plasmid	   Mini	   Prep	   Kit;	   Fermentas,	   Vilnius,	  
Lithuania)	   and	   were	   screened	   for	   the	   presence	   of	   the	   insert	   with	   the	   EcoRI	  
restriction	   enzyme	   (New	   England	   BioLabs,	   Ipswich,	  MA,	   USA).	   Sequencing	   was	  
done	  using	  the	  ABI	  PRISM	  Big	  Dye	  Terminator	  Cycle	  Sequencing	  Ready	  Reaction	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kit	   version	   3.4	   (Applied	   Biosystems,	   Foster	   City,	   CA,	   USA).	   A	   modified	   NAP	  
algorithm	   (Huang	  et	   al.,	   1996)	  was	  used	   to	   align	   sequences	   to	  HXB2	   (Genbank	  
Acc.	   No.	   K03455)	   and	   insertions	   with	   respect	   to	   HXB2	   were	   stripped	   before	  
further	  analysis.	  	  
	  
3.8. Statistical	  analysis	  
The	   Mann-­‐Whitney	   nonparametric	   analysis	   was	   used	   to	   test	   for	   significant	  
differences	  between	  HLA	  groups.	   	  For	  assessments	  of	   the	  relationship	  between	  
immune	   responses	   and	   viral	   load,	   Spearman	   rank	   correlations	   were	   used.	  	  
Statistical	   analyses	   were	   performed	   using	   GraphPad	   Prism	   version	   5.0	   for	  
Windows	  (GraphPad	  Software,	  San	  Diego	  California	  USA).	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4. Results	  
4.1. Viral	  load	  and	  CD4	  counts	  in	  HIV-­‐1	  clade	  C	  acute	  infection	  
HIV-­‐specific	   CD8+	   T-­‐cell	   responses	   have	   been	   documented	   in	   primary	   HIV	  
infection;	   however,	   very	   little	   is	   known	   about	   the	   breadth	   and	   magnitude	   of	  
these	   responses	   in	   the	   earliest	   phase	   of	   infection,	   prior	   to	   seroconversion.	  	  
Moreover,	   most	   studies	   have	   evaluated	   responses	   well	   after	   the	   documented	  
decline	   in	   viremia,	   such	   that	   very	   little	   data	   are	   available	   during	   documented	  
periods	   of	   viral	   load	   decline.	   	   To	   begin	   to	   address	   these	   issues,	   we	   recruited	  
persons	  with	  acute	  clade	  C	  HIV	  infection	  who	  had	  not	  yet	  seroconverted.	  	  Twenty	  
such	  persons	  were	  identified,	  all	  of	  whom	  initially	  tested	  negative	  or	  discordant	  
by	  two	  rapid	  HIV	  tests	  currently	  in	  use	  at	  Voluntary	  Counseling	  and	  Testing	  (VCT)	  
sites	  in	  KwaZulu-­‐Natal,	  and	  were	  then	  screened	  for	  HIV	  RNA	  in	  plasma.	  	  	  In	  each	  
case,	   RNA+Ab−	   status	   was	   confirmed	   by	   positive	   quantitative	   HIV-­‐1	   reverse	  
transcription–polymerase	   chain	   reaction	   (PCR),	   negative	   ELISA	   test	   and	   a	  
negative	  Western	  blot,	  and	  all	  were	  subsequently	  documented	  to	  seroconvert	  to	  
HIV.	  	  The	  representative	  serological	  and	  viral	  profile	  of	  subjects	  recruited	  into	  the	  
study	  is	  given	  in	  Table	  2.1.	  
The	   characteristics	   of	   each	   of	   the	   recruited	   subjects	   are	   listed	   in	   Table	   2.2.	  
Median	  age	  at	  enrolment	  was	  29	  years	  (range	  21-­‐66)	  and	  60%	  of	  the	  participants	  
were	  female.	   	  Subjects	  were	  heterogeneous	  with	  respect	  to	  viral	   load	  obtained	  
at	   the	   time	   of	   diagnosis,	   ranging	   from	   28,720	   to	   33,200,000	   RNA	   copies/ml	  
plasma	   (median	   5,572,000	   RNA	   copies/ml).	   	   The	  majority	   of	   individuals	   in	   the	  
cohort	  exhibited	  a	  dramatic	  elevation	  in	  plasma	  viral	  load	  before	  seroconversion	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indicative	  of	  acute	  HIV	  and	  this	  was	  followed	  by	  a	  steady	  decline	  in	  viremia	  over	  
the	   first	   year	   of	   infection,	   as	   well	   as	   a	   decline	   in	   absolute	   CD4+	   T-­‐cell	   counts	  


















Figure	  2.1.	  Plasma	  HIV-­‐1	  RNA	  titres	  and	  CD4+	  T-­‐cell	  counts	  in	  primary	  infection.	  Scatter	  
plot	  of	  (A)	  plasma	  HIV-­‐1	  RNA	  levels	  and	  median	  plasma	  HIV-­‐1	  RNA	  levels	  in	  the	  cohort	  
(solid	   black	   line)	   from	   the	   time	  of	   seroconversion	   up	   to	   one	   year	   post	   infection;	   (B)	  
individual	  absolute	  CD4+	  T-­‐cell	  counts	  and	  median	  CD4+	  count	  (solid	  black	  line)	  in	  the	  
cohort	  during	  acute	  HIV-­‐1	  infection	  up	  to	  one	  year	  post	  infection.	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Table	  2.1.	  Typical	  evolution	  of	  key	  viral	  and	  serological	  markers	  during	  the	  first	  weeks	  
following	  infection	  with	  HIV-­‐1.	  	  
!"#$"%&'
!"#$%&'$(%)*+,-)'* ./ 01 /2 3/ ..2 .45
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The	   initial	   screening	   was	   limited	   to	   obtaining	   a	   plasma	   sample,	   thus	   no	   T-­‐cell	  
assays	  were	  performed	  at	  this	  time.	  The	  viral	   load	  at	  enrolment,	  when	  the	  first	  
ELISPOT	   assays	  were	   performed	   (on	   average	   14	   days	   following	   the	   initial	   RNA	  
assay)	  was	  371,000	  RNA/ml	   (range	  1,090-­‐2,840,000)	  and	   the	  average	  CD4+	  cell	  
counts	  obtained	  at	  this	  time	  were	  389	  cells/mm3,	  again	  with	  a	  wide	  range	  from	  
151-­‐691	  cells/mm3.	  	  Of	  note,	  four	  of	  the	  20	  subjects	  expressed	  the	  HLA-­‐B*58:02	  
allele	   which	   is	   associated	   with	   rapid	   disease	   progression	   and	   poor	   prognosis	  
(Ngumbela	   et	   al.,	   2008).	   	   Surprisingly,	   these	   four	   subjects	   had	   a	   lower	  median	  
plasma	   viral	   load	   and	   a	   higher	   CD4+	   count	  when	   compared	   to	   the	   rest	   of	   the	  
cohort	  not	  expressing	  this	  allele,	  with	  a	  median	  viral	  load	  approximately	  10	  fold	  
less	   than	   the	   cohort	   as	   a	   whole	   (506,000	   RNA	   copies/ml,	   range	   112,500-­‐
4,560,000	   vs	   7,425,000	   RNA	   copies/ml	   range	   28,700-­‐33,200,000	   and	   median	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CD4+	  cell	  count	  519	  cells/mm3,	  range	  238-­‐691	  vs.	  385	  cells/mm3,	  range	  151-­‐652	  
cells/mm3,	   respectively),	   however	   these	   differences	   did	   not	   reach	   statistical	  
significance	   (p=0.199	  and	  p=0.163,	   respectively).	   	  The	  two	  subjects	  with	  known	  
protective	   alleles	   HLA-­‐B*57:03	   and	  HLA-­‐B*58:01	   had	   initial	   viral	   loads	   of	   1.1M	  
and	   7.3M	   respectively,	   indicating	   even	   with	   these	   few	   numbers	   that	   pre-­‐
seroconversion	  viral	  loads	  in	  persons	  with	  protective	  HLA	  class	  I	  alleles	  can	  be	  in	  
the	  range	  of	  the	  median	  for	  clade	  C	  virus	  infection.	  
	  
Together	   these	  results	   indicate	  that	  a	  strategy	  based	  on	  nucleic	  acid	   testing	  on	  
persons	  who	   test	   negative	   at	  VCT	   sites	   can	   identify	   acute	  HIV-­‐1	   virus	   infection	  
during	   times	   of	   peak	   viremia	   following	   acute	  HIV	   infection,	   and	   these	   subjects	  
can	  be	  successfully	  recruited	  for	  follow	  up	  studies.	  These	  data	  also	  indicate	  that	  
acute	  HIV	  clade	  C	  virus	  infection	  is	  somewhat	  heterogeneous	  with	  respect	  to	  pre-­‐
seroconversion	   viral	   load,	   early	   CD4+	   cell	   counts	   and	   expressed	   HLA	   class	   I	  
alleles.	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Table	  2.2:	  Demographic	  and	  clinical	  characteristics	  of	  enrolled	  subjects.	  
	  
4.2. HIV-­‐1	  -­‐specific	  CD8+	  T-­‐cell	  responses	  prior	  to	  and	  following	  seroconversion	  
Although	  studies	  of	  acute	  HIV	   infection	  have	  assessed	  CD8+	  T-­‐cell	   responses	   in	  
persons	   identified	   prior	   to	   seroconversion,	   there	   are	   some	   important	   caveats:	  
most	   of	   initial	   assays	   were	   performed	   post-­‐seroconversion,	   and/or	   with	  
cryopreserved	  samples	  (Altfeld	  et	  al.,	  2001,	  Alter	  et	  al.,	  2002,	  Koup	  et	  al.,	  1994).	  	  
Moreover,	  few	  have	  assessed	  responses	  to	  all	  expressed	  viral	  proteins	  (Altfeld	  et	  
al.,	   2001,	  Streeck	  et	  al.,	  2009b,	  Alter	  et	  al.,	   2002,	  Blankson,	  2009).	   	   To	  address	  
these	   gaps	   in	   knowledge,	   we	   performed	   a	   detailed	   analysis	   of	   CD8+	   T-­‐cell	  
responses	   to	   all	   expressed	   HIV	   proteins	   using	   fresh	   PBMCs	   obtained	   prior	   to	  
antibody	   seroconversion.	   	   Since	   only	   plasma	   was	   obtained	   during	   initial	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screening,	   these	   assays	  were	   limited	   to	   the	   11	   subjects	   for	  whom	   subsequent	  
samples	  were	  available	  prior	  to	  seroconversion	  (Table	  2.3).	  	  All	  11	  subjects	  were	  
Fiebig	  stage	  IV	  or	  earlier.	  	  	  
	  
Table	  2.3.	  Viral	  load	  characteristics	  and	  antibody	  pattern	  against	  HIV-­‐1	  western	  blot	  in	  
11	   individuals	   who	   had	   not	   fully	   seroconverted	   when	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	  
responses	  to	  peptides	  spanning	  the	  entire	  HIV	  proteome	  were	  evaluated	  at	  ~28	  days	  




Screening VL                  
(RNA copies/ml)
Enrollment VL          
(days after 
screening)
WB bands at 
enrollment
AS1-703 4 560 000 119,000 (14) p24, p40, p55/51
AS1-919 6 280 000 484,000 (15) p24, p40
AS2-174 7 390 000 330,000 (21) p18, p24
AS2-802 732 260 138,300 (15) p18, p24, p40
AS2-945 1 100 000 1,872 (32) p24, p40, p55/51
AS2-973 10 000 000 66,530 (15) p24
AS2-1037 12 100 000 708,000 (23) p24, p40, p55/51
AS3-017 22 000 000 2,840,000 (14) 0
AS3-458 280 000 1,650,000 (14) p24, p55/51
AS3-513 112 448 1,967,000 (14) p24
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HIV-­‐1-­‐specific	   CD8+	  T-­‐cell	   responses	  were	  detected	   in	   9	  of	   the	  11	   subjects	  but	  
were	   narrowly	   directed	   in	   each	   case	   (Table	   2.4).	   The	   overlapping	   peptides	  
targeted	  as	  well	  as	  their	  sequences	  are	  listed	  in	  Table	  2.5.	  Two	  subjects	  with	  no	  
detectable	  responses	  had	  each	  experienced	  an	  approximate	  50-­‐100	  fold	  drop	  in	  
viremia	   at	   the	   time	   of	   testing;	   both	   made	   detectable	   responses	   at	   later	   time	  
points.	   	   Although	   the	   two	  most	   frequently	   recognized	   proteins	   at	   the	   earliest	  
time	  point	  were	  Nef	  (peptides	  #69	  to	  #84)	  and	  Gag	  (peptides	  #4	  to	  #65),	  targeted	  
by	   50%	   and	   36%	   of	   the	   subjects	   respectively,	   there	   was	   great	   heterogeneity	  
among	  subjects	  with	  respect	  to	  the	  specificity	  of	  the	  initial	  responses.	  	  Moreover,	  
among	   those	   with	   detectable	   responses,	   there	   were	   dramatic	   differences	   in	  
magnitude,	  with	  total	  detectable	  epitope-­‐specific	  responses	  ranging	  from	  as	  high	  
as	  4,000	  SFC/million	  PBMC	  detected	  to	  as	  low	  as	  100	  SFC/million	  PBMC.	  
	  	  
HIV-­‐1-­‐specific	   responses	   were	   subsequently	   tested	   longitudinally	   in	   these	  
individuals	  up	  to	  18	  weeks	  (Table	  2.4).	   	  At	  this	  time,	  responses	  were	  detectable	  
in	  10	  of	   the	  11	  subjects,	  albeit	  at	  different	  magnitudes,	  and	  both	  subjects	  who	  
initially	  tested	  negative	  (AS2-­‐0945	  and	  AS2-­‐0973)	  now	  had	  detectable	  responses.	  	  
Of	  the	  nine	  with	  initially	  positive	  responses,	  at	  least	  one	  of	  these	  responses	  was	  
still	   detected	   in	   eight	   subjects	   at	   the	   later	   time	   point.	   	   There	   were	   only	   two	  
subjects	  in	  whom	  the	  initial	  breadth	  of	  responses	  declined	  at	  the	  follow-­‐up	  time	  
point.	   	  Of	   the	  nine	  subjects	   in	  whom	  an	   initial	   immunodominant	   response	  was	  
detected,	   this	   response	   was	   still	   present	   at	   follow-­‐up	   weeks	   later	   in	   seven.	  	  
However,	   there	  was	  no	  consistent	  pattern	   in	   terms	  of	  specificity,	  magnitude	  or	  
evolution	  of	  responses	  in	  these	  individuals.	  	  These	  results	  indicate	  that	  the	  initial	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responses	   largely	  persist,	  and	   that	   those	  with	  no	   initial	   responses	  were	  able	   to	  
mount	  immune	  responses	  subsequently.	  
	  













at 12-18 weeks 
AS1-703 Nef-81, Nef-83 Nef-83 (490) 850 #81
AS1-919
Nef-83,  Nef-202, 
Nef-203
Nef-83 (280) 740 None
AS2-174 gp41-366 gp41-366 (700) 700
#25, #35, #36, #41, 







#11, #35, #36, #44, 
#64, #65, #82, #83, 
#294
AS2-945 None None 0
#20, #22, #33, #84, 
#181
AS2-973 None None 0 #275, #294, #407
AS2-1037 Gag-41, Rev-100 Rev-100 (580) 720
#40, #41, #46, #76, 





Gag-16 (1020) 2700 #40
AS3-458 gp120-316 gp120-316 (420) 420
#42, #157, #194, 
#225, #252, #316




Nef-78 (700) 2280 #41, #78, #81, #83














and	   viral	   load	   kinetics	   in	   individuals	   not	   fully	   seroconverted	   at	   ~28	   days	   post	   the	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4.3. Evolution	  of	  CD8+	  T-­‐cell	  responses	  following	  acute	  HIV	  infection	  
To	   further	   characterize	   the	   evolution	   of	   CD8+	   T-­‐cell	   responses	   following	   acute	  
HIV-­‐1	   infection,	   we	   performed	   a	   longitudinal	   analysis	   in	   all	   20	   subjects.	   	   The	  
magnitude	   of	   responses	   at	   approximately	   4	  weeks	   after	   the	   estimated	   date	   of	  
infection	  ranged	  from	  150-­‐8,770	  SFC/million	  PBMC.	  There	  was	  a	  15-­‐fold	  decline	  
in	   viral	   loads	   from	   the	   initial	   screening	   value,	   CD8+	   T-­‐cell	   responses	   were	  
directed	   against	   an	   average	   of	   3	   peptides	   (range	   0–6)	   and	   the	   most	   targeted	  
protein	  was	  Nef	   followed	   by	   Pol	   and	  Gag	   (Figure	   2.2).	   	   At	   18	  weeks,	   the	   total	  
magnitude	  of	  responses	  ranged	  from	  500-­‐11,240	  SFC/mil	  PBMC	  and	  the	  average	  
number	   of	   peptides	   targeted	   was	   5	   (range	   0-­‐11).	   	   The	   overlapping	   peptides	  
targeted	  as	  well	  as	  their	  sequences	  are	  listed	  in	  Table	  2.5.	  
	  
At	  6-­‐8	  weeks	  post	  the	  estimated	  date	  of	  infection,	  our	  analyses	  for	  all	  20	  subjects	  
revealed	  that	  there	  was	  a	  significant	  positive	  correlation	  between	  the	  magnitude	  
of	   Nef	   CD8+	   T-­‐cell	   responses	   and	   plasma	   viremia	   (P=0.003).	   	   Plotting	   the	  
magnitude	   of	   virus-­‐specific	   T-­‐cell	   responses	   targeting	   other	   HIV-­‐1	   proteins	  
against	  plasma	  viral	   load	  over	   time	  revealed	  that	   the	  kinetics	  of	  expansion	  and	  
contraction	  of	  T-­‐cell	   responses	   in	   the	  subjects	  did	  not	  correlate	  with	   their	  viral	  
load	   dynamics.	   	   In	   subjects	   sampled	   prior	   to	   the	   documented	   peak	   in	   plasma	  
viremia	  (AS3-­‐458	  and	  AS3-­‐513),	  the	  magnitude	  of	  T-­‐cell	  responses	  were	  found	  to	  
be	   lower	  during	  peak	  viremia	  with	  an	   increase	  thereafter.	  Likewise,	   in	  all	  other	  
subjects,	  the	  higher	  enrolment	  plasma	  viremia	  was	  not	  accompanied	  by	  a	  higher	  
T-­‐cell	   response;	   instead,	   the	   breadth	   and	   magnitude	   of	   responses	   increased	  
following	  the	  decline	  in	  viremia.	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Table	   2.5.	   Overlapping	   peptides	   targeted	   in	   the	   cohort	   between	   4-­‐18	   weeks	   post	  
infection.	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!<D >HI 5'#:5=*755*'&'##* !?DE %@/?F .)4.#(6)>36699)9
!DF >HI #*&#*(-7'')6&(*=*9 !?E8 %@/?F 14--#4+49'&:'11*5
!D/ >HI '')6&(*=*94-,16#-5 !"/; %@/?F '475=+(+(,-3:+:#-:
!D? >HI *94-,16#-5+=96>- !"?0 %@/?F ()7&>*1>>:'1((4,*
!D" >HI 6#-5+=96>-1+#+#4)- !"8< %@/?F :#>(13'7>(1#***1)
!D8 >HI >-1+#+#4)-+*15#935 !"8D %@/?F 7>(1#***1)=#=111>1
!D0 >HI )-+*15#935'*4+4 !";; %@8/ )4*:(&)-*'=66**#(9
!E0 )HJ =&:**6:4)(('(*- !8F0 4KI 4',,.-47)):>#95-),
!E; )HJ 6:4)(('(*-67>+- !8FD 4KI ,+'477&4,(+*#&:)*4
!/FF )HJ )9):)6)6(,7(7&)(* !8FE 4KI ,(+*#&:)*4('1-9#*
!/F/ )HJ 6(,7(7&)(*713*#)+: !8// 4KI *61#&)=9,*#,#47(&9
!/F? )HJ (*713*#)+:&+4+*6* !8/" 4KI 47(&9)*))-7164=+#*








aPeptides	   are	   numbered	   sequentially,	   as	   follows:	   Gag	   peptides	   1	   to	   66;	   Nef	  
peptides	  67-­‐93;	  	  Rev	  peptides	  94-­‐107;	  	  Tat	  peptides	  111-­‐122;	  Vpu	  peptides	  123-­‐
131;	  Protease	  peptides	  145-­‐164;	  RT	  peptides	  165-­‐240;	   Intergrase	  peptides	  241-­‐
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Figure	   2.2.	   	   Average	   magnitude	   of	   HIV-­‐1	   specific	   CD8+	   T-­‐cell	   responses	   in	   early	  
infection	  for	  all	  participants.	  The	  magnitude	  of	  HIV-­‐1-­‐specific	  CD8+	  T-­‐cell	  responses	  to	  
overlapping	  HIV	  peptides	  spanning	  each	  of	  the	  designated	  proteins	  are	  shown	  on	  the	  y	  
axis	  as	  SFC/million	  PBMCs	  and	  the	  x	  axis	  denotes	  when	  the	  assays	  were	  done	  (number	  
of	   days	   post	   the	   estimated	   time	  of	   infection).	   	   Solid	   lines	   represent	   IFN-­‐γ	   release	   in	  




4.4. Limited	  breadth	  of	  HIV-­‐1-­‐specific	  T-­‐cell	  epitopes	  in	  primary	  infection	  	  
The	   above	   analyses	   determined	   HIV-­‐1–specific	   CD8+	   T-­‐cell	   responses	   using	  
overlapping	   peptides,	   thus	   did	   not	   define	   the	   actual	   targeted	   epitopes	   within	  
those	   peptides.	   	   To	   delineate	   the	   precise	   regions	   being	   targeted,	   a	   subset	   of	  
peptides	   corresponding	   to	   previously	   described	   epitopes	   for	   each	   person’s	  
respective	   HLA	   class	   I	   allotypes	   were	   used	   (Table	   2.6)	   (Brander	   and	   Goulder,	  
2000).	  	  The	  analyses	  were	  restricted	  to	  HLA	  class	  I	  alleles	  that	  were	  expressed	  in	  
at	   least	   three	   participants,	   and	   for	   which	   at	   least	   three	   optimal	   CD8+	   T-­‐cell	  
epitopes	   had	   been	   described	   and	   could	   be	   tested	   against	   the	   subjects’	   PBMC.	  
The	   frequencies	   of	   these	   qualifying	   HLA	   class	   I	   alleles	   expressed	   in	   the	   study	  
	   57	  
cohort,	   as	   well	   as	   the	   number	   of	   epitopes	   tested	   for	   each	   HLA	   allele	   and	   the	  
percentage	   of	   individuals	   with	   detectable	   CD8+	   T-­‐cell	   responses	   to	   the	   tested	  
epitopic	  peptides	  restricted	  by	  the	  designated	  allele,	  are	  listed	  in	  Table	  2.7.	  	  The	  
majority	   of	   HIV-­‐1	   clade	   C	   epitopes	   that	   have	   been	   described	   in	   chronic	   HIV	  
infection	   were	   not	   targeted	   in	   these	   early	   stages	   of	   infection,	   indicating	   that	  
there	   are	   marked	   differences	   in	   the	   inductive	   phase	   of	   the	   immune	   response	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Table	  2.6.	  Optimal	  CD8+	  T-­‐cell	  peptides	  corresponding	  to	  defined	  epitopes	  for	  the	  HLA	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aPeptide	  identification	  provides	  the	  restricting	  HLA	  Class	  I	  allele,	  the	  first	  and	  last	  amino	  
acid	   of	   the	   respective	   epitope,	   the	   length	   of	   the	   epitope,	   and	   the	   HIV-­‐1	   protein	  
containing	  the	  epitope.	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Table	   2.7.	   	   HLA	   frequencies	   in	   study	   cohort	   and	   the	   percentage	   of	   subjects	   with	  
responses	  against	  peptides	  associated	  with	  individual	  HLA	  expression.	  
	  
To	   further	   define	   these	   relationships,	   we	   assessed	   the	   persistence	   of	   early	  
epitope-­‐specific	   immune	   responses	   for	   the	   most	   frequently	   targeted	   early	  
epitopes	  (Figure	  2.3).	  	  For	  five	  of	  the	  seven	  epitopes	  tested,	  there	  was	  a	  decrease	  
over	  time	  in	  the	  targeting	  of	  these	  epitopes	  in	  persons	  expressing	  the	  restricting	  
HLA	   allele,	   but	   the	   immunodominance	   patterns	   of	   CD8+	   T-­‐cells	   remained	  
unchanged	   in	   the	   individuals	  with	  detectable	   responses.	   	   There	  was	  no	   shift	   in	  
the	  immunodominance	  hierarchy	  in	  HLA-­‐B*1503	  restricted	  responses	  measured	  
at	  6-­‐8	  and	  8-­‐12	  weeks	  against	   the	  HLA-­‐B*1503-­‐restricted	  epitopes	  RT(Int)-­‐FY10	  
and	   p24-­‐IY9,	   and	   the	   epitopes	   were	   found	   to	   be	   immunodominant	   and	  
subdominant,	  respectively.	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Figure	   2.3.	   Immunodominance	   patterns	   of	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	   responses	  
restricted	   by	   individual	   HLA	   class	   I	   alleles	   at	   4-­‐6	   weeks	   and	   12-­‐18	   weeks	   post	   the	  
estimated	  time	  of	  infection.	  	  The	  percentage	  of	  participants	  expressing	  the	  respective	  
allele	   that	   had	   detectable	   peptide-­‐specific	   CD8+	   T-­‐cell	   responses	   is	   shown	   on	   the	   y	  
axis.	   	   HLA-­‐restricted	   HIV-­‐specific	   CD8+	   T-­‐cell	   epitopes	   are	   aligned	   on	   the	   x	   axis	   and	  
their	   location	  on	  the	  major	  HIV-­‐1	  proteins	  is	  also	  indicated.	   	  Data	  are	  shown	  only	  for	  
HLA	  class	   I	  alleles	   that	  were	  expressed	   in	  at	   least	   three	   individuals,	  and	   for	  which	  at	  
least	  three	  HIV-­‐1-­‐specific	  optimal	  CD8+	  T-­‐cell	  epitopes	  had	  been	  defined.	  
	  
	  Similarly,	   CD8+	   T-­‐cell	   responses	   against	   the	   HLA-­‐B*44-­‐restricted	   epitope	   p24-­‐
AW11	   and	   the	   HLA-­‐B*1510	   restricted	   epitope	   Rev-­‐IL9	   remained	  
immunodominant	  during	  the	  earliest	  and	  latest	  tested	  time	  points	  in	  individuals	  
expressing	  these	  respective	  alleles.	   	  However,	  there	  was	  a	  shift	  in	  the	  hierarchy	  
of	   responses	   in	   individuals	   expressing	   the	   HLA-­‐A*30	   where	   the	   initially	  
immunodominant	  RT-­‐AY11	  epitope	   later	   became	   subdominant	   and	  CD8+	  T-­‐cell	  
responses	   against	   the	   initially	   subdominant	   Int-­‐KIY9	   epitope	   became	  
immunodominant	   (Figure	   2.3).	   	   Overall,	   these	   data	   demonstrate	   the	  
immunodominance	   patterns	   of	   specific	   epitopes	   during	   acute	   infection	   are	  
persistent	  for	  the	  majority	  of	  HLA	  class	  I	  alleles	  which	  could	  be	  assessed,	  but	  that	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many	   class	   I	   alleles	   are	   infrequently	   utilized	   in	   early	   infection,	   and	   many	  
potentially	  immunogenic	  epitopes	  are	  not	  targeted.	  
	  
4.5. Effect	  of	  sequence	  variation	  on	  recognition	  by	  specific	  CTL	  
Others	  (Turnbull	  et	  al.,	  2009)	  and	  we	  (Altfeld	  et	  al.,	  2003)	  have	  shown	  that	  up	  to	  
30%	   of	   early	   responses	   may	   be	   missed	   when	   using	   peptides	   representing	   a	  
reference	  strain	  of	  virus.	   	  We	  therefore	  sequenced	  plasma	  virus	  to	  determine	  if	  
lack	   of	   CD8+	   recognition	   related	   to	   lack	   of	   expression	   of	   the	   cognate	   epitope.	  	  
We	   focused	   these	   efforts	   on	   the	   gag	   region,	   as	   targeting	   of	   Gag	   has	   been	  
associated	  with	  lower	  viral	  loads	  (Kiepiela	  et	  al.,	  2007).	  	  Plasma	  virus	  sequencing	  
revealed	   that	   of	   the	   56	   epitope	   sequences	   evaluated,	   31	  were	  wild-­‐type	   virus	  
sequences;	  however,	  these	  did	  not	  elicit	  detectable	  CD8+	  T-­‐cell	  responses	  in	  20	  
of	  31	  (65%)	  of	  cases	  (Table	  2.8).	  	  In	  the	  two	  subjects	  in	  whom	  we	  failed	  to	  detect	  
any	  CD8+	  T-­‐cell	  responses	  prior	  to	  seroconversion	  (Table	  2.4;	  AS2-­‐945	  and	  AS2-­‐
973),	   both	   were	   infected	   with	   viruses	   that	   contained	   epitopes	   present	   in	   the	  
reference	   set	  of	  peptides	  used	   in	   the	  assays.	   	   These	  data	   indicate	   that	  despite	  
expression	  of	  the	  restricting	  HLA	  class	  I	  allele	  and	  the	  presence	  of	  cognate	  viral	  
sequence,	  CD8+	  responses	  to	  the	  virus	  were	  often	  not	  mounted,	  suggesting	  that	  
the	  immunogenicity	  of	  these	  epitopes	  is	  suboptimal,	  and	  that	  factors	  other	  than	  
IFN-­‐gamma	   expressing	   CD8+	   T-­‐cells	   may	   be	   involved	   in	   the	   initial	   decline	   in	  
viremia.	  	  
	   63	  




	   64	  





CD8+ T cell  
Response
VHQAISPRTL




























	   65	  
5. Discussion	  
Despite	  the	  dominance	  of	  HIV-­‐1	  subtype	  C	  worldwide,	  the	  evolution	  of	  virologic	  
and	   immunologic	   parameters	   in	   acute	   HIV-­‐1C	   infection	   have	   not	   been	  
extensively	   characterized.	   	   By	   RNA	   screening	   of	   persons	   testing	   negative	   by	  
standard	   antibody	   assays,	   we	   were	   able	   to	   recruit	   20	   subjects	   before	  
seroconversion,	  and	  characterize	  viral	  kinetics	  and	  evolving	  HIV-­‐specific	  CD8+	  T-­‐
cell	   responses	   during	   acute	   infection.	   	   Despite	   high	   viremia,	   responses	   were	  
narrowly	   directed,	   and	   the	   majority	   of	   epitopes	   targeted	   in	   chronic	   infection	  
(Kiepiela	   et	   al.,	   2007)	   did	   not	   induce	   detectable	   responses	   during	   the	   rapid	  
decline	   of	   viremia.	   	   Although	   the	   ELISPOT	   assay	   can	   underestimate	   the	   true	  
magnitude	   of	   T-­‐cell	   responses	   (Sun	   et	   al.,	   2003,	   Turnbull	   et	   al.,	   2009,	  
Goonetilleke	   et	   al.,	   2009)	   and	   autologous	   virus	   sequences	   can	   differ	   from	   the	  
reference	   strains	  used,	  HIV-­‐1-­‐specific	  CD8+	   responses	  ultimately	  arose	   in	   these	  
persons,	   indicating	   that	   many	   immunogenic	   epitopes	   are	   not	   targeted	   in	   the	  
earliest	  stages	  of	  infection,	  at	  a	  time	  when	  viral	  load	  is	  rapidly	  declining.	  	  	  	  	  
	  
Longitudinal	  assays	  for	  responses	  during	  and	  following	  acute	  infection	  allowed	  us	  
to	  address	  not	  only	  the	  specificity	  of	  responses	  but	  also	  their	  persistence.	  	  In	  the	  
entire	  cohort,	   responses	   to	  Nef-­‐derived	  peptides	  were	  dominant	   in	   the	  earliest	  
stages	   of	   infection,	   consistent	   with	   other	   data	   (Blankson,	   2009,	   Celum	   et	   al.,	  
2010,	  Harari	   et	  al.,	   2009).	   	  However,	  only	  approximately	  half	  of	   the	   individuals	  
tested	   targeted	  Nef	   in	   the	   early	   stages,	   although	   82%	   targeted	   this	   protein	   at	  
some	   time	   during	   the	   average	   5	  months	   of	   follow	   up	   (data	   not	   shown),	   again	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suggesting	   impaired	   induction	   of	   responses	   in	   acute	   infection.	   	   A	   trend	   was	  
observed	   where	   high	   T-­‐cell	   responses	   against	   the	   Nef	   proteins	   correlated	  
positively	  with	  high	  viral	  loads,	  as	  has	  been	  reported	  in	  other	  studies	  (Lichterfeld	  
et	   al.,	   2004b,	   Blankson,	   2009,	   Novitsky	   et	   al.,	   2003,	   Masemola	   et	   al.,	   2004a,	  
Masemola	  et	  al.,	  2004b),	  suggesting	  that	  these	  responses	  are	  driven	  by	   level	  of	  
antigenemia,	   rather	   than	   they	   being	   causal	   in	   lowering	   viral	   load,	   again	  
suggesting	   impaired	   functional	   CD8+	   T-­‐cell	   responses	   in	   the	   earliest	   stages	   of	  
acute	  infection.	  	  However,	  there	  was	  no	  correlation	  between	  the	  magnitude	  and	  
breadth	   of	   CD8+	   T-­‐cell	   responses	   for	   other	   viral	   proteins	   and	   the	   concurrent	  
plasma	  viral	   load,	  consistent	  with	  other	   reports	   (Addo	  et	  al.,	  2003,	  Betts	  et	  al.,	  
2001,	  Cao	  et	  al.,	  2003a).	  	  	  
	  
By	   assessing	   responses	   using	  peptides	   representing	  optimal	   epitopes,	  we	  were	  
able	   to	  assess	   the	  hierarchy	   in	   the	  development	  of	  epitope-­‐specific	  CD8+	  T-­‐cell	  
responses	   restricted	   by	   specific	   HLA	   alleles,	   their	   immunodominance	   patterns,	  
and	  the	  timing	  of	  induction	  of	  these	  responses.	  	  Within	  a	  month	  of	  the	  estimated	  
time	  of	   infection,	  CD8+	  T-­‐cell	   responses	  were	  detected	  against	   44%	  of	  peptide	  
epitopes	   matched	   for	   each	   subjects’	   HLA	   and	   against	   56%	   of	   the	   epitopes	  
presented	  by	  their	  expressed	  alleles	  at	  3	  months.	  These	  data	  confirmed	  that	  the	  
detectable	   responses	   in	   early	   infection	   are	   largely	   maintained,	   although	  
immunodominance	  often	  shifts.	   	   	  Further	  investigation	  is	  required	  to	  determine	  
whether	  the	  changes	  in	  the	  magnitude	  of	  responses	  and	  immunodominance	  are	  
the	   result	   of	   sequence	   evolution	   within	   targeted	   epitopes	   or	   their	   flanking	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regions	  (Altfeld	  et	  al.,	  2006),	   immunoregulation	  (Day	  et	  al.,	  2006,	  Trautmann	  et	  
al.,	  2006,	  Petrovas	  et	  al.,	  2006,	  Kaufmann	  et	  al.,	  2007),	  or	  other	  mechanisms.	  	  	  
	  
6. 	  Conclusion	  
We	   demonstrate	   that	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	   responses	   can	   be	   detected	  
before	  complete	  seroconversion,	  but	  many	  of	  the	  epitopes	  that	  elicit	  responses	  
in	   chronic	   infection	   are	   not	   immunogenic	   during	   acute	   infection.	   	   We	   also	  
confirm	   previous	   studies	   showing	   that	   the	   initial	   HIV-­‐1	   specific	   immune	  
responses	   are	   narrowly	   directed,	   and	   extend	   these	   by	   showing	   the	   paucity	   of	  
responses	   even	   when	   dramatic	   drops	   in	   viremia	   have	   occurred.	   	   Moreover,	  
although	  response	  breadth	  and	  magnitude	  expands	  with	  duration	  of	  infection,	  a	  
significant	   proportion	   of	   individuals	   are	   still	   unable	   to	  make	   responses	   despite	  
the	   presence	   of	   cognate	   peptides	   restricted	   by	   the	   corresponding	   HLA	   allele.	  	  
Further	  studies	  are	  needed	  to	  address	  why	  recognition	  of	  HIV-­‐1	  peptides	  appears	  
to	  be	  selective	  during	  acute	  infection	  as	  the	  lack	  of	  recognition	  may	  contribute	  to	  
the	   failure	   to	   control	   viremia	   to	   a	   low	   set	   point.	   	   Moreover	   the	   paucity	   of	  
responses	  during	  the	  dramatic	  reduction	  in	  viremia	  suggests	  that	  tissue	  specific	  
responses	   as	   well	   as	  measures	   of	   CD8+	   T-­‐cell	   function	   other	   than	   IFN-­‐gamma	  
should	  be	  examined	  to	  better	  define	  the	  role	  of	  HIV-­‐specific	  CD8+	  T-­‐cells	   in	  the	  
initial	   decline	   in	   viremia.	   	   Further	   studies	   are	   needed	   to	   understand	   the	  
determinants	   and	   role	   of	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	   responses	   in	   high	   burden	  
settings	  where	  an	  effective	  HIV-­‐1	  vaccine	  is	  urgently	  needed.	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Chapter	  3 :	  Progressive	  broadening	  of	  HIV-­‐1	  Gag-­‐
specific	  CD8+	  T-­‐cell	  responses	  is	  associated	  with	  
viral	  control	  despite	  limited	  immunogenicity	  and	  
infrequent	  immune	  escape	  in	  early	  HIV-­‐1	  infection	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1. Abstract	  
Background:	   	  We	  characterized	  protein-­‐specific	  CD8+	  T-­‐cell	   immunodominance	  
patterns	   during	   the	   first	   year	   of	   HIV-­‐1	   infection,	   and	   their	   impact	   on	   viral	  
evolution	  and	  immune	  control.	  
Methods:	  We	  analyzed	  CD8+	  T-­‐cell	  responses	  to	  the	  full	  HIV-­‐1	  proteome	  during	  
the	   first	  year	  of	   infection	   in	  eighteen	  antiretroviral-­‐naïve	   individuals	  with	  acute	  
HIV-­‐1	   subtype	   C	   infection,	   all	   identified	   prior	   to	   seroconversion.	   	   	   Ex	   vivo	   and	  
cultured	   IFN-­‐γ	   ELISPOT	   assays	   were	   performed	   and	   viruses	   from	   plasma	   were	  
sequenced	  within	  defined	  CTL	  Gag	  epitopes.	  	  	  
Results:	   Nef-­‐specific	   CD8+	   T-­‐cell	   responses	   were	   dominant	   during	   the	   first	   4	  
weeks	  post	  infection	  and	  made	  up	  40%	  of	  total	  responses	  at	  this	  time,	  yet	  by	  1	  
year	  responses	  against	  this	  region	  had	  declined	  and	  Gag	  responses	  made	  up	  47%	  
of	  all	  T-­‐cell	  responses	  measured.	  	  An	  inverse	  correlation	  between	  the	  breadth	  of	  
Gag-­‐specific	   responses	   and	   viral	   load	   set	   point	   was	   evident	   at	   26	   weeks	  
(p=0.0081;	  r=	  -­‐0.60)	  and	  beyond.	  	  An	  inverse	  correlation	  between	  the	  number	  of	  
persistent	  responses	  targeting	  Gag	  and	  viral	  set	  point	  was	  also	  identified	  (p=0.01;	  
r=-­‐0.58).	   Gag-­‐specific	   responses	   detectable	   by	   cultured	   ELISPOT	   correlated	  
negatively	   with	   viral	   load	   set	   point	   (p=0.0013;	   r=-­‐0.91).	   Sequence	   evolution	   in	  
targeted	  and	  non-­‐targeted	  Gag	  epitopes	  in	  this	  cohort	  was	  infrequent.	  	  	  
Conclusions:	  These	  data	  underscore	   the	   importance	  of	  HIV-­‐specific	  CD8+	  T-­‐cell	  
responses,	  particularly	   to	  the	  Gag	  protein,	   in	  the	  maintenance	  of	   low	  viral	   load	  
levels	  during	  primary	  infection	  and	  show	  that	  these	  responses	  are	  initially	  poorly	  
elicited	   by	   natural	   infection.	   	   These	   data	   have	   implications	   for	   vaccine	   design	  
strategies.	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2. Introduction:	  
There	  is	  compelling	  evidence	  that	  acute-­‐phase	  HIV-­‐specific	  CD8+	  T-­‐cell	  responses	  
play	  an	  important	  role	  in	  determining	  the	  subsequent	  clinical	  course	  of	  disease.	  	  
Experimental	  data	  and	  mathematical	  models	  show	  that	  the	  appearance	  of	  HIV-­‐1-­‐
specific	   CD8+	   T-­‐cells	   coincides	   with	   and	   contributes	   to	   the	   decline	   in	   peak	  
viremia	  in	  acute	  infection	  (Borrow	  et	  al.,	  1994,	  Koup	  et	  al.,	  1994,	  Goonetilleke	  et	  
al.,	  2009,	  Pantaleo	  et	  al.,	  1994,	  Liu	  et	  al.,	  2013),	  and	  CD8+	  T-­‐cell	  responses	  have	  
been	  detected	   in	   some	   cases	  when	  antibodies	   are	  not	   yet	  detectable	  by	   ELISA	  
and	  Western	  blot	  assays	  (Huber	  and	  Trkola,	  2007,	  Radebe	  et	  al.,	  2011,	  Liu	  et	  al.,	  
2013,	  Goonetilleke	  et	  al.,	  2009).	  	  An	  indicator	  of	  CD8+	  T-­‐cell	  immune	  pressure	  on	  
the	  virus	   is	   the	  emergence	  of	  viral	  escape	  within	  CTL	  epitopes,	  which	  has	  been	  
demonstrated	  to	  occur	  as	  early	  as	  10	  days	  after	  the	  first	  detection	  of	  a	  CD8+	  T-­‐
cell	  response	  during	  acute	  HIV-­‐1	  infections	  (Fischer	  et	  al.,	  2010,	  Goonetilleke	  et	  
al.,	  2009),	  but	  the	  kinetics	  of	  escape	  is	  quite	  variable	  (Brumme	  et	  al.,	  2008,	  Liu	  et	  
al.,	  2013).	  	  Together	  these	  data	  indicate	  that	  early	  immune	  responses	  are	  critical	  
for	  immune	  containment	  of	  HIV	  infection.	  	  
	  
Despite	   strong	   data	   that	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cells	   play	   a	   critical	   role	   in	   viral	  
control,	   there	   is	   also	   evidence	   of	   marked	   heterogeneity	   in	   the	   antiviral	  
effectiveness	   of	   these	   cells.	   	   First,	   is	   the	   observation	   that	   almost	   all	   HIV-­‐1-­‐
infected	   individuals	  have	  detectable	  CD8+	  T-­‐cell	   responses,	   irrespective	  of	   viral	  
control	   or	   disease	   progression	   status	   (Betts	   et	   al.,	   2001,	   Addo	   et	   al.,	   2003),	  
suggesting	  that	  some	  CD8+	  T-­‐cells	  are	  inefficient	  at	  suppressing	  virus	  replication	  
(Gray	   et	   al.,	   2009,	   Chen	  et	   al.,	   2009,	   Ferrari	   et	   al.,	   2011,	   Perreau	  et	   al.,	   2013).	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Indeed,	  even	  in	  late	  stage	  infection	  the	  majority	  of	  detectable	  HIV-­‐specific	  CD8+	  
T-­‐cell	   responses	   are	   able	   to	   target	   the	   circulating	   virus	   (Draenert	   et	   al.,	   2004,	  
Koibuchi	   et	   al.,	   2005).	   	   Secondly,	   it	   has	   been	   demonstrated	   that	   CD8+	   T-­‐cells	  
targeting	  different	  viral	  proteins	  differ	  in	  their	  antiviral	  effectiveness	  (Chen	  et	  al.,	  
2009),	   consistent	   with	   clinical	   data	   that	   Gag	   but	   not	   Env-­‐	   or	   Nef-­‐specific	  
responses	  are	  associated	  with	  lower	  viremia	  (Saez-­‐Cirion	  et	  al.,	  2009,	  Julg	  et	  al.,	  
2010,	  Chen	  et	  al.,	  2009,	  Perez	  et	  al.,	  2013,	  Kiepiela	  et	  al.,	  2007,	  Turk	  et	  al.,	  2013).	  	  
Third,	  there	  is	  variability	  in	  the	  hierarchy	  of	  responses	  following	  infection	  and	  the	  
ability	   of	   HLA-­‐restricted	   CD8+	   T-­‐cell	   responses	   to	   drive	   viral	   immune	   escape	   is	  
not	   consistent	   and	   remains	   incompletely	   characterized	   (Brumme	   et	   al.,	   2008,	  
Streeck	  et	  al.,	  2009b,	  Liu	  et	  al.,	  2013).	  	  	  	  	  	  
	  
Studies	   conducted	   during	   acute	   and	   early	   HIV-­‐1	   infection	   offer	   an	   important	  
opportunity	  to	  characterize	  and	  understand	  better	  the	  quality	  and	  phenotype	  of	  
CD8+	   T-­‐cells	   that	  mediate	   control	   of	   viral	   replication	   and	   disease	   progression.	  	  	  
Numerous	   studies	   have	   examined	   these	   responses	   in	   early	   stages	   of	   infection	  
(Turk	  et	  al.,	  2013,	  Mlotshwa	  et	  al.,	  2010,	  Gray	  et	  al.,	  2009,	  Streeck	  et	  al.,	  2009b,	  
Henn	   et	   al.,	   2012,	   Freel	   et	   al.,	   2011,	   Borrow	   et	   al.,	   1994,	   Koup	   et	   al.,	   1994,	  
McMichael	  et	  al.,	  2010,	  Fischer	  et	  al.,	  2010,	  Lichterfeld	  et	  al.,	  2004b)	  but	  less	   is	  
known	  about	   the	   impact	   and	   fate	  of	  CD8+	  T-­‐cell	   immune	   responses	   in	   cohorts	  
limited	  to	  persons	  with	  clearly	  defined	  dates	  of	  acute	  infection	  in	  whom	  studies	  
have	  been	  initiated	  within	  a	  month	  of	  exposure	  to	  the	  virus	  (Goonetilleke	  et	  al.,	  
2009,	  Ferrari	  et	  al.,	  2011,	  Turk	  et	  al.,	  2013,	  Mlotshwa	  et	  al.,	  2010,	  Radebe	  et	  al.,	  
2011,	  Jones	  et	  al.,	  2004,	  Gray	  et	  al.,	  2009).	  A	  number	  of	  studies	  have	  reported	  on	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the	  longitudinal	  analysis	  of	  CD8+	  T-­‐cell	  responses	  in	  relation	  to	  time	  from	  initial	  
acute	  or	  primary	  infection	  and	  viral	  load,	  in	  order	  to	  determine	  the	  kinetics	  and	  
fate	  of	   these	   responses	   and	   their	   impact	   on	   the	   virus	  over	   time	   (Ferrari	   et	   al.,	  
2011,	  Mlotshwa	  et	  al.,	  2010,	  Streeck	  et	  al.,	  2009b,	  Perez	  et	  al.,	  2013,	  Liu	  et	  al.,	  
2013,	  Goonetilleke	  et	  al.,	  2009,	  Allen	  et	  al.,	  2005,	  Brumme	  et	  al.,	  2008,	  Turk	  et	  
al.,	   2013).	   	   	   However,	   very	   few	   studies	   have	   assessed	   CD8+	   T-­‐cell	   immune	  
responses	  to	  the	  entire	  viral	  proteome	  during	  acute	  infection	  and	  at	  one	  year	  in	  
antiretroviral	   therapy	   naïve	   persons	   with	   clearly	   defined	   dates	   of	   infection,	   in	  
high	  prevalence	  and	   incidence	  settings	  (Mlotshwa	  et	  al.,	  2010,	  Liu	  et	  al.,	  2013).	  	  
This	   is	   an	   important	   consideration	   in	   view	   of	   evidence	   of	   viral	   adaptation	   to	  
endemic	   population	   HLA	   and	   loss	   of	   CTL	   epitopes	   over	   the	   course	   of	   the	  
epidemic	   (Kawashima	   et	   al.,	   2009,	   Schellens	   et	   al.,	   2011)	   and	   the	   emerging	  
evidence	  of	  high	  transmission	  of	  escape	  variants	  (Goepfert	  et	  al.,	  2008,	  Wright	  et	  
al.,	  2011).	  
	  
Here,	  using	  a	  cohort	  of	  acutely	   infected,	  antiretroviral	  therapy	  naive	   individuals	  
with	   a	   reliable	   estimated	   time	   of	   infection	   in	   a	   high	   HIV-­‐1	   prevalence	   and	  
incidence	   setting,	   we	   have	   conducted	   a	   longitudinal	   analysis	   of	   immune	  
responses	  in	  persons	  with	  acute	  HIV-­‐1	  subtype	  C	  infection	  identified	  prior	  to	  full	  
seroconversion	   in	   order	   to	   define	   the	   specificity	   of	   the	   earliest	   CD8+	   T-­‐cell	  
responses,	   the	   fate	   of	   these	   responses	   over	   time,	   the	   evolving	  
immunodominance	  patterns	  and	   impact	  on	  viral	  control	  within	  the	  first	  year	  of	  
infection.	  	  Our	  data	  provide	  evidence	  of	  marked	  differences	  in	  immunogenicity	  of	  
individual	  viral	  proteins	  for	  induction	  of	  HIV-­‐specific	  CD8+	  T-­‐cell	  responses	  during	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acute	  HIV	  infection,	  and	  lack	  of	  a	  clear	  relationship	  of	  early	  CD8+	  T-­‐cell	  responses	  
to	  viral	   load.	   	   	  However,	  over	   the	  one	  year	  period	  of	   follow	  up,	   the	  number	  of	  
targeted	   Gag	   CD8+	   T-­‐cell	   epitopes	   increased	   resulting	   in	   a	   significant	   negative	  
association	   between	   these	   responses	   and	   viral	   load	   set	   point.	   	   CD8+	   T-­‐cell	  
immune	   responses	   generated	   during	   the	   acute	   phase	   of	   infection	   persisted	   or	  
waned	   irrespective	   of	   cognate	   epitope	   sequence,	   with	   persistence	   of	   initial	  
responses	   correlating	  with	   lower	   viral	   set	   point.	   	  Moreover,	   some	  Gag-­‐specific	  
immune	   responses	   that	   were	   no	   longer	   detected	   by	   standard	   IFN-­‐gamma	  
ELISPOT	   assay	   persisted	   as	   memory	   responses	   and	   appeared	   to	   contribute	   to	  
lower	   viremia.	   	   This	   information	   sheds	   light	  on	   the	   characteristics	   and	  antiviral	  
efficacy	   of	   evolving	   CD8+	   T-­‐cell	   immune	   responses	   responsible	   for	   long-­‐term	  
control	   of	   HIV-­‐1	   infection	   in	   a	   high	   incidence	   setting	   and	   has	   important	  
implications	   for	   both	   prophylactic	   and	   therapeutic	   vaccine	   design	   for	   this	  
population.	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3. Materials	  and	  methods	  
3.1. Study	  participants	  
	  The	  cohort	  consisted	  of	  18	  antiretroviral	  treatment-­‐naïve	  individuals	  with	  acute	  
HIV-­‐1	   subtype	  C	   infection	  enrolled	  as	  part	  of	   the	  HIV	  Pathogenesis	  Programme	  
(HPP)	  Acute	   Infection	  Study	   in	  Durban,	  KwaZulu-­‐Natal,	   South	  Africa	   (Radebe	  et	  
al.,	   2011).	   Briefly,	   study	   participants	   were	   recruited	   from	   HIV	   Counseling	   and	  
Testing	   (HCT)	   centers	   in	   the	   greater	   Durban	   area	   based	   on	   negative	   HIV	   rapid	  
testing,	  and	  those	  testing	  positive	  by	  plasma	  HIV	  RNA	  were	  offered	  enrollment	  
into	  the	  study.	  	  Blood	  samples	  were	  obtained	  from	  study	  participants	  at	  2-­‐4,	  4-­‐6,	  
6–8,	  8–12,	  12–18,	  24-­‐26,	  and	  50-­‐52	  weeks	  post-­‐infection.	  	  The	  date	  of	  infection	  
was	  estimated	  to	  be	  14	  days	  prior	  to	  screening,	  as	  previously	  described	  (Radebe	  
et	  al.,	  2011).	   	   	  The	  median	  age	  at	  recruitment	  was	  28	  years	  (interquartile	  range	  
[IQR]	   26	   to	   40	   years),	   and	   60%	   of	   the	   participants	   were	   female.	   	   The	  median	  
plasma	  viral	   load	  at	  enrollment	  was	  5,572,160	  RNA	  copies/ml,	   (IQR,	  921,090	  to	  
9,320,000	  RNA	  copies/ml)	   and	   the	  median	  CD4	   count	  was	  389	   cells/mm3	   (IQR,	  
275	   to	  496	  cells/mm3).	   	   The	  average	  viral	   load	  between	  3	  and	  12	  months	  post	  
infection	  was	  the	  measure	  of	  viral	  load	  set	  point	  used	  in	  this	  study	  and	  could	  be	  
calculated	   for	   all	   study	   subjects.	   	   The	   Biomedical	   Research	   Ethics	   Committee	  
(BREC)	  of	   the	  University	  of	  KwaZulu-­‐Natal	  and	  the	   institutional	   review	  board	  of	  
Massachusetts	   General	   Hospital	   approved	   this	   study,	   and	   all	   the	   participants	  
provided	  written	  informed	  consent	  for	  participation	  in	  this	  study.	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3.2. Synthetic	  HIV-­‐1	  subtype	  C	  peptides	  	  
A	  panel	  of	  410	  consensus	  subtype	  C	  peptides	  (18-­‐mers	  overlapping	  by	  10	  amino	  
acid	   residues),	   spanning	   the	   entire	  HIV-­‐1	  proteome	   corresponding	   to	   the	   gene	  
products	  Gag,	  Pol,	  Nef,	  Env,	  Vif,	  Vpr,	  Vpu,	  Tat,	  and	  Rev	  were	  synthesized	  on	  an	  
automated	   peptide	   synthesizer	   (MBS	   396;	   Advanced	   ChemTech,	   Louisville,	  
Kentucky)	  and	  used	  in	  the	  ELISPOT	  assay	  as	  previously	  described	  (Thobakgale	  et	  
al.,	  2007).	  	  HLA	  class	  I-­‐restricted	  epitopes	  predicted	  from	  the	  published	  epitopes	  
on	  the	  HIV	  immunology	  database	  were	  also	  tested	  based	  on	  the	  HLA	  type	  (Llano	  
et	  al.,	  2013)	  of	  the	  individual.	  
	  
3.3. Viral	  load	  determination,	  CD4	  T-­‐cell	  counts,	  and	  HLA	  typing	  	  
Plasma	  HIV-­‐1	  RNA	  levels	  were	  quantified	  using	  the	  Roche	  Amplicor	  version	  1.5	  or	  
Cobas	   Taqman	  HIV-­‐1	   Test	   according	   to	   the	  manufacturer’s	   instructions	   (Roche	  
Diagnostics,	  Branchburg,	  NJ).	  Absolute	  blood	  CD4	  T-­‐cell	  counts	  were	  enumerated	  
using	   Tru-­‐Count	   technology	   and	   analysed	   on	   a	   FACSCalibur	   flow	   cytometer	  
(Becton	  Dickinson)	  and	  were	  expressed	  as	  cells/mm3.	  High-­‐resolution	  HLA	  typing	  
was	  performed	  as	  previously	  described	  (Radebe	  et	  al.,	  2011).	  
	  
3.4. Interferon-­‐γ 	  ELISPOT	  Assay	  	  	  
IFN-­‐γ	   enzyme-­‐linked	   immunosorbent	   spot	   assays	   (ELISPOT)	  were	   performed	   as	  
described	  previously	  (Streeck	  et	  al.,	  2009a,	  Radebe	  et	  al.,	  2011,	  Thobakgale	  et	  al.,	  
2007).	   	   Briefly,	   peripheral	   blood	   mononuclear	   cell	   (PBMC)	   samples	   were	  
stimulated	  with	  HIV-­‐1	  peptide	  pools	   (2	  µg/ml)	  and	   incubated	  overnight	  at	  37°C	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with	  5%	  CO2.	  Phytohemagglutinin	  (PHA)	  was	  used	  as	  a	  positive	  control	  (duplicate	  
wells)	  at	  a	  final	  concentration	  of	  4	  µg/ml	  and	  negative	  controls	  consisted	  of	  cells	  
without	  stimuli	  (quadruplicate	  wells).	  	  Confirmation	  of	  positive	  responses	  at	  the	  
single-­‐peptide	   level	   within	   peptide	   pools	   was	   undertaken	   in	   a	   second	   ELISPOT	  
assay.	   	  A	   response	  was	  defined	  as	  positive	  when	   there	  were	  at	   least	  100	   spot-­‐
forming	  cells	  (SFCs)/million	  PBMCs	  and	  the	  total	  number	  of	  spots	  was	  3	  standard	  
deviations	  above	  the	  negative	  control	  value	  (Novitsky	  et	  al.,	  2001,	  Ngumbela	  et	  
al.,	  2008).	  	  To	  be	  conservative	  in	  estimating	  the	  breadth	  of	  a	  response,	  responses	  
to	   2	   overlapping	   peptides	   were	   classified	   as	   one	   response;	   to	   3	   overlapping	  
peptides	  were	  classified	  as	  2	  responses.	  In	  addition	  to	  overlapping	  peptides,	  HLA	  
class	   I-­‐restricted	   epitopes	   predicted	   from	   the	   published	   epitopes	   on	   the	   HIV	  
immunology	  database	  (Llano	  et	  al.,	  2013),	  based	  on	  the	  expressed	  HLA	  alleles	  of	  
the	  participants	  were	  also	  tested	  at	  a	  peptide	  concentration	  of	  2	  µg/mL.	  
	  
3.5. Cultured	  IFN-­‐γ 	  ELISPOT	  Assay	  
The	   cultured	   IFN-­‐γ	   enzyme-­‐linked	   immunosorbent	   spot	   assays	  were	  performed	  
as	  described	  previously	  (Ndhlovu	  et	  al.,	  2012,	  Calarota	  et	  al.,	  2008).	  	  Briefly,	  5-­‐10	  
×	  106	  peptide-­‐stimulated	  were	  cultured	  at	  37°C	  and	  5%	  CO2	  for	  12	  days	  in	  5-­‐10	  ml	  
of	  RPMI	  medium	  containing	  10%	  heat-­‐inactivated	  fetal	  calf	  serum	  (R10	  medium)	  
and	   supplemented	   with	   50	   units/ml	   of	   recombinant	   human	   interleukin	   2	   (IL-­‐
2)(R10/50	   medium).	   Unstimulated	   cells	   cultured	   with	   IL-­‐2	   (R10/50	   medium)	  
alone	   were	   used	   as	   controls.	   A	   peptide	   concentration	   of	   100	   ng/ml	   (the	   final	  
concentration	   of	   each	   peptide	   within	   the	   pool)	   was	   selected	   for	   these	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experiments.	   	  Fresh	  R10/50	  medium	  was	  added	  to	  the	  cultures	  at	  day	  3,	  day	  7,	  
and	  day	  10	  as	  needed.	  	  On	  day	  12,	  cells	  were	  harvested,	  washed	  three	  times	  with	  
fresh	   R10	   medium	   and	   rested	   at	   37°C	   and	   5%	   CO2	   overnight	   in	   fresh	   R10	  
medium.	   Cells	  were	   then	  plated	   for	   a	   standard	   ELISPOT	   assay	   as	   described	   for	  
the	  ex	  vivo	  ELISPOT.	  	  
	  
3.6. Virus	  sequencing	  	  
Viral	   RNA	  was	   isolated	   from	   140µl	   of	   plasma	   samples	   using	   the	   QIAamp	   Viral	  
RNA	  Extraction	  Mini	  Kit	   (Qiagen,	  Hilden,	  Germany).	  Viral	  RNA	  was	  then	  reverse	  
transcribed	   using	   ThermoScript™	   RT-­‐PCR	   System	   kit	   (Invitrogen,	   Carlsbad,	   CA,	  
USA)	   and	   the	   gene-­‐specific	   primer,	   GagD	   reverse	   as	   previously	   described	  
(Chopera	   et	   al.,	   2008).	   	   To	   amplify	   the	   HIV-­‐1	   Gag	   region,	   a	   nested	   PCR	   was	  
performed	  with	  two	  sets	  of	  primers,	  Gag	  forward	  (5′-­‐TCT	  CTA	  GCA	  GTG	  GCG	  CCC	  
G-­‐3′)	   and	  GagD	   reverse	   for	   the	   first	   round	  and	  GagA	   forward	   (5′-­‐CTC	  TCG	  ACG	  
CAG	  GAC	  TCG	  GCT	  T-­‐3′)	  and	  GagC	  reverse	  (5′-­‐TCT	  TCT	  AAT	  ACT	  GTA	  TCA	  TCT	  GC-­‐
3′)	  for	  the	  second	  round	  as	  previoulsy	  described	  (Chopera	  et	  al.,	  2008).	  Resulting	  
PCR	  products	  were	  purified	  using	  purification	  columns	  from	  Illustra™	  GFX™	  PCR	  
DNA	  Gel	  Band	  Purification	  Kit,	  (GE	  Healthcare,	  Little	  Chalfont,	  Buckinghamshire,	  
UK)	   and	   cloned	   into	   a	   PCR	   2.1-­‐TOPO	   vector	   (Invitrogen,	   Carlsbad,	   CA,	   USA).	  
Plasmid	   DNA	   was	   isolated	   from	   individual	   randomly	   picked	   white	   bacterial	  
colonies	  (GeneJet	  Plasmid	  Mini	  Prep	  Kit;	  Fermentas,	  Vilnius,	  Lithuania)	  and	  were	  
screened	  for	  the	  presence	  of	  the	  insert	  with	  the	  EcoRI	  restriction	  enzyme	  (New	  
England	  BioLabs,	   Ipswich,	  Massachusetts,	  USA).	  Sequencing	  was	  done	  using	  the	  
ABI	  PRISM	  Big	  Dye	  Terminator	  Cycle	  Sequencing	  Ready	  Reaction	  kit	  version	  3.4	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(Applied	   Biosystems,	   Foster	   City,	   CA,	   USA).	   Sequences	   were	   assembled	   and	  
edited	  using	  the	  Sequencher	  Program	  v5.0	  (Gene	  Codes	  Corporation,	  Ann	  Arbor,	  
MI,	  USA).	  	  
	  
3.7. Statistical	  analysis	  
Statistical	   analysis	   and	   graphical	   presentation	  were	   performed	   using	  GraphPad	  
Prism	   software	   version	   5.0	   for	  Windows.	   	   For	   assessments	   of	   the	   relationship	  
between	  immune	  responses	  and	  viral	  load,	  statistical	  analysis	  of	  significance	  was	  
based	  on	  two-­‐tailed	  t	  tests	  using	  Spearman	  rank	  correlations.	   	  A	  value	  of	  <0.05	  
was	  considered	  statistically	  significant.	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4. Results	  
4.1. Association	  of	  CD8+	  T-­‐cell	  responses	  with	  viral	  load	  	  
In	   earlier	   studies,	   we	   examined	   the	   breadth	   and	   specificity	   of	   CD8+	   T-­‐cell	  
responses	   to	  HIV	  during	   the	   first	  18	  weeks	  of	   infection	   in	   twenty	  subjects	  with	  
acute	  HIV	   infection	   (Radebe	   et	   al.,	   2011).	   	   Here	  we	   extended	   these	   studies	   by	  
examining	   changes	   in	   the	   frequency	   of	   recognition,	  magnitude	   and	   breadth	   of	  
HIV-­‐1-­‐specific	  CD8+	  T-­‐cell	  responses	  during	  the	  entire	  first	  year	  of	  infection.	  Viral	  
load	  measurements	  and	  CD4+	  T-­‐cell	  counts	  from	  the	  18	  individuals	  from	  whom	  
blood	   samples	   were	   available	   at	   sequential	   time	   points	   over	   the	   first	   year	   of	  
infection	   are	   shown	   in	   Figure	   3.1.	   We	   screened	   18	   subjects	   using	   the	   IFN-­‐γ	  
ELISPOT	   assay	   with	   synthetic	   peptides	   spanning	   HIV-­‐1	   Gag,	   Pol,	   Env,	   Nef,	   Tat,	  
Vpr,	  Rev,	  Vif,	  and	  Vpu.	  	  PBMCs	  were	  stimulated	  with	  pools	  of	  overlapping	  15-­‐	  to	  
20-­‐mer	  peptides,	  in	  addition,	  each	  subject's	  PBMCs	  were	  evaluated	  according	  to	  
their	  class	  I	  HLA	  type	  for	  selective	  recognition	  of	  8-­‐	  to	  11-­‐mers	  corresponding	  to	  
previously	  defined	  class	  I	  MHC-­‐restricted	  HIV-­‐1-­‐specific	  CTL	  epitopes	  (Llano	  et	  al.,	  
2013).	  	  A	  summary	  of	  the	  defined	  class	  I	  MHC-­‐restricted	  HIV-­‐1	  epitopes	  targeted	  
per	  subject	  is	  given	  in	  Table	  3.1	  and	  depicted	  in	  Figures	  3.2	  and	  3.3.	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Figure	   3.1.	   Alignment	   of	   viral	   load	   data	   from	   18	   subjects	   during	   acute	  HIV	   infection	  
and	   over	   the	   first	   year	   of	   infection.	   For	   each	   patient,	   the	   viral	   load	   (log10copies/ml	  
plasma)	  and	  CD4+	  T-­‐cell	  counts	  determined	  at	  sequential	  time	  points	  throughout	  the	  
course	   of	   acute	   and	   early	   infection	   are	   plotted	   against	   time,	   measured	   weeks	   post	  
infection.	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  Table	  3.1.	  HIV-­‐1-­‐specific	  CD8+-­‐T-­‐cell	   responses:	  breadth,	  HLA	   class	   I	   usage,	   and	   total	  
frequency	  during	  the	  first	  year	  of	  HIV-­‐1C	  infection.	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Figure	  3.2.	  Kinetics	  of	  HIV-­‐1-­‐specific	  CD8+	  T-­‐cell	  responses	  during	  the	  1	  year	  follow-­‐up	  
period.	   (A)	   Frequency	   of	   T-­‐cell	   recognition	   across	   the	   entire	   HIV-­‐1	   subtype	   C	  
proteome.	  The	  bars	  represent	  response	  frequencies	  to	  Nef,	  Pol,	  Gag,	  Env,	  Regulatory	  
(Rev,	   Tat)	   and	   Accessory	   (Vpr,	   Vpu,	   and	   Vif)	   proteins	   from	   4	   to	   52	   weeks	   post	  
infection;	  (B)	  Bar	  graphs	  depicting	  the	  relative	  contributions	  of	  Nef,	  Gag,	  Pol,	  Env,	  and	  
Regulatory	   (Rev,	  Tat)	  and	  Accessory	   (Vpr,	  Vpu,	  and	  Vif)	  proteins	  the	  total	  magnitude	  
and	  (C)	  breadth	  of	  HIV-­‐1-­‐specific	  T-­‐cell	  responses	  at	  the	  specified	  time	  points.	  	  
	  
	  
At	  4	  weeks	  post	  infection,	  the	  earliest	  time	  point	  of	  measurement	  of	  HIV-­‐specific	  
CD8+	   T-­‐cell	   responses,	   55%	  of	   the	   subjects	  made	  Nef-­‐specific	   T-­‐cell	   responses,	  
followed	   by	  Gag	   (33%)	   and	   Pol	   (27%),	   and	   VVTRV	   (Vif,	   Vpr,	   Vpu,	   Rev	   and	   Tat)	  
(16%)	  and	  Env	  (10%)	  (Figure	  4.2A).	  Responses	  against	  Nef	  increased	  in	  frequency	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and	   at	   18	   and	   26	   weeks,	   77%	   of	   the	   subjects	   had	   detectable	   Nef	   responses,	  
subsequently,	   these	   responses	   underwent	   a	   marked	   decline	   and	   at	   52	   weeks	  
only	   50%	   of	   the	   subjects	   had	   detectable	   anti-­‐Nef	   responses.	   	   In	   contrast,	  
epitopes	  in	  the	  Gag	  region	  were	  targeted	  by	  only	  33%	  of	  the	  subjects	  at	  4	  weeks	  
and	  this	  number	  increased	  to	  94%	  at	  52	  weeks.	  	  The	  number	  of	  individuals	  with	  
detectable	  responses	  against	  Pol	  peaked	  at	  12	  weeks	  when	  88%	  of	  subjects	  had	  
detectable	   anti-­‐Pol	   responses.	   	   The	   sequences	   of	   the	   defined	   class	   I	   MHC-­‐
restricted	  HIV-­‐1-­‐specific	  CD8+	  epitopes	   that	  were	   targeted,	   the	   restricting	  MHC	  
class	  I	  allele,	  and	  position	  of	  these	  epitopes	  in	  the	  HIV-­‐1	  genome	  as	  well	  as	  OLPs	  
that	  were	  targeted	  but	  have	  not	  been	  previously	  defined	  are	  listed	  in	  Tables	  3.2	  
and	  3.3.	  	  	  
	  
Evolution	   of	   immune	   responses	   was	   also	   apparent	   in	   terms	   of	   the	   breadth	   of	  
responses	   to	   individual	   viral	   proteins.	   	   	   For	   this	   analysis	  we	  examined	   the	   sum	  
total	  responses	  detected	  in	  the	  18	  study	  subjects.	  	  A	  total	  of	  41	  T-­‐cell	  responses	  
against	  epitopes	  in	  Gag,	  Pol,	  Nef,	  Env,	  Vif,	  Vpr,	  Vpu,	  Tat,	  and	  Rev	  were	  measured	  
at	   4	   weeks.	   As	   expected,	   Nef	   responses	   were	   dominant	   in	   breadth	   and	  made	  
42%	  of	  the	  total	  detectable	  HIV-­‐specific	  CD8+	  T-­‐cell	  response	  at	  this	  time,	  whilst	  
Pol	   and	   Gag-­‐specific	   responses	   contributed	   24%	   and	   17%,	   respectively	   (Figure	  
3.3).	   	   In	   those	   in	   whom	   HIV-­‐1-­‐specific	   T-­‐cell	   responses	   were	   detected,	   the	  
median	  magnitude	  of	   responses	  was	  quite	   variable	   over	   time,	   and	   the	  median	  
values	  for	  Nef-­‐specific	  responses	  were	  generally	  higher	  in	  magnitude	  than	  those	  
directed	  against	  other	  regions.	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Figure	  3.3.	  	  Evolution	  of	  IFN-­‐γ 	  ELISPOT	  CD8+	  T-­‐cell	  responses	  targeting	  epitopes	  in	  (A)	  
Nef,	  (B)	  Pol,	  (C)	  Gag,	  (D)	  Env	  and	  (E)	  Regulatory	  (Rev,	  Tat)	  and	  Accessory	  (Vpr,	  Vpu,	  and	  
Vif)	  proteins	  HIV-­‐during	  the	  1	  year	  follow-­‐up	  period.	  measured	  from	  4-­‐52	  weeks	  post	  
infection	  in	  a	  cohort	  of	  18	  subjects.	  Each	  symbol	  represents	  a	  single	  response	  against	  
an	   epitope	   in	   the	   specified	   protein.	   	   	  P	  values	   are	   indicated	   (Repeated	   measures	  
ANOVA	  test	  followed	  by	  Bonferroni	  adjustment).	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We	  next	  examined	  the	  relationship	  between	  evolving	  breadth	  of	  responses	  and	  
viral	   load.	   	   Responses	   against	   Pol,	   Nef	   and	   Env	   peaked	   at	   12	   weeks	   and	  
subsequently	   declined;	   yet	   with	   increased	   duration	   of	   infection	   there	   was	   a	  
steady	  rise	  in	  the	  overall	  number	  of	  Gag	  epitopes	  targeted	  (Figure	  3.2	  and	  3.3C).	  
The	  highest	  breadth	  of	  Gag-­‐specific	   responses	  was	   recorded	  at	  52	  weeks	  post-­‐
infection,	  the	  last	  time	  point	  to	  be	  analyzed	  in	  this	  study	  (Figure	  3.3C).	  We	  next	  
aimed	   to	   identify	  whether	   the	  magnitude	   or	   breadth	   of	   CD8+	   T-­‐cell	   responses	  
against	  epitopes	  in	  all	  HIV-­‐1	  regions	  had	  any	  impact	  on	  early	  disease	  progression	  
in	   the	   first	   12	   months	   post	   infection.	   	  We	   observed	   no	   correlation	   between	  
magnitude	  and	  breadth	  of	  all	  of	  responses	  to	  Pol,	  Env,	  Rev,	  Tat,	  Vpu,	  Vpr	  and	  Vif	  
and	   viral	   load	   set	  point.	   There	  was	   also	  no	   significant	   association	  between	   the	  
breadth	  of	  Nef	  T-­‐cell	   responses	  and	  viral	  set	  point	  at	  all	  measured	  time	  points,	  
yet	  a	  trend	  towards	  significance	  was	  observed	  at	  8	  weeks	  (p=0.098;	  r=0,4)(Figure	  
3.4A).	  	  Although	  there	  was	  no	  correlation	  observed	  between	  the	  breadth	  of	  Gag-­‐
specific	  responses	  measured	  up	  to	  18	  weeks	  and	  viral	  set	  point	  (Figure	  3.4B	  and	  
data	  not	  shown),	  subsequent	  measures	  showed	  a	  significant	  negative	  association	  
from	  26	  weeks	   (p=0.0081;	   r=-­‐0.61)	  and	  at	  52	  weeks	   (p=0.027;	   r=	   -­‐0.52)	   (Figure	  
3.4B-­‐D).	   When	   we	   fitted	   a	   linear	   regression	   model	   to	   viral	   load	   set	   point,	  
accounting	   for	   the	   repeated	   measurements	   and	   adjusting	   for	   weeks	   post	  
infection,	   there	   remained	   a	   significant	   association	   between	   breadth	   and	   viral	  
load	   set	   point	   in	   this	   analysis.	   For	   every	   1	   unit	   increase	   in	   breadth,	   viral	   load	  
decreases	  by	  0.15	  log	  copies/ml	  (SE=0.067;	  p=0.0225).	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Table	   3.2.	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	   responses	   in	   acute	   and	   early	   infection,	   the	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Figure	  3.4.	  Association	  of	   the	  breadth	  of	  HIV-­‐specific	  CD8+	  T-­‐cell	   responses	  and	  viral	  
load	   set	   point.	   (A)	   The	   breadth	   of	   Nef-­‐specific	   T-­‐cell	   responses;	   (B,	   C	   and	   D)	   The	  
breadth	  of	  Gag-­‐specific	  T-­‐cell	  responses.	  Each	  symbol	  represents	  the	  total	  number	  of	  
epitopes	   targeted	   per	   participant.	   Spearman	   correlations	   between	   the	   breadth	   of	  
responses	  and	  viral	  load	  set	  point	  at	  8,	  26,	  and	  56	  weeks	  post	  infection.	  
	  
4.2. Fate	  of	  the	  early	  T-­‐cell	  IFN-­‐γ 	  ELISPOT	  responses	  	  
As	  illustrated	  in	  Figure	  3.3	  over	  the	  first	  year	  of	  infection,	  CD8+	  T-­‐cell	  responses	  
are	  highly	  variable	  following	  acute	   infection,	  with	  an	  ultimate	  overall	  decline	  of	  
anti-­‐Nef	   and	   Pol	   responses	   and	   a	   gradual	   increase	   of	   Gag-­‐specific	   T-­‐cell	  
responses.	   	   It	   is	   noteworthy	   that	   even	   at	   an	   epitope-­‐specific	   level	  within	   each	  
viral	   protein,	   immune	   responses	   fluctuated	   with	   some	   persisting	   throughout,	  
some	  no	   longer	  detectable	  at	   later	  time	  points	  while	  others	  were	  undetectable	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at	   some	   time	   points	   and	   later	   re-­‐emerged	   (Radebe	   et	   al.,	   2011).	   Few	   studies	  
have	   examined	   the	   relationship	   between	   early	   loss	   and	   gain	   in	   CD8+	   T-­‐cell	  
responses	   and	   viral	   load	   (Turnbull	   et	   al.,	   2009,	   Mlotshwa	   et	   al.,	   2010,	  
Goonetilleke	  et	  al.,	  2009)	  and	  this	  led	  us	  to	  investigate	  the	  fate	  of	  these	  early	  T-­‐
cell	  responses	  and	  their	   impact	  on	  viral	   load	  set	  point	  over	  the	  one	  year	  follow	  
up	   period.	   	   	   We	   focused	   our	   analysis	   on	   two	   distinct	   recognition	   profiles,	  
persistent	  and	   lost	   responses.	   	  Persistent	   responses	  were	  defined	  as	   responses	  
that	   were	   detected	   as	   early	   as	   6	   weeks	   and	   persisted	   up	   to	   52	   weeks.	   	   Lost	  
responses	   were	   defined	   as	   responses	   which	   appeared	   at	   any	   time	   during	   the	  
follow	  up	  period	  but	  had	  decreased	  by	  more	  than	  80%	  and/or	  had	  fallen	  below	  
the	  threshold	  of	  100	  SFC/106	  PBMC	  when	  the	   last	  evaluation	  was	  performed	  at	  
52	  weeks	  post	  infection.	  	  	  
	  
Analysis	  of	  persistent	  HIV-­‐1-­‐specific	  CD8+	  T-­‐cell	  responses	  revealed	  that	  although	  
92	  responses	  were	  measured	  at	  6	  weeks,	  only	  45%	  (41)	  of	  these	  responses	  were	  
still	   detectable	   at	   52	  weeks.	   	   Of	   the	   16	   Gag-­‐specific	   responses	  measured	   at	   6	  
weeks,	  at	   least	  12	   (75%)	  persisted	  and	  were	  still	  detectable	  at	  52	  weeks.	  Table	  
3.4	  shows	  the	  epitopes	  that	  were	  persistently	  targeted	  by	  all	  the	  subjects	  in	  the	  
cohort	   and	   the	   HLA	   class	   I	   alleles	   restricting	   these	   responses.	   	   All	   eighteen	  
subjects	   had	   persisting	   T-­‐cell	   responses	   against	   either	   optimal	   epitopes	   (36	   in	  
total)	  and/or	  OLPs	  (5	  in	  total),	  ranging	  from	  1	  to	  5	  responses	  per	  subject.	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Table	   3.4.	   Confirmed	   persistent	  HLA	   class	   I-­‐restricted	   CD8+	   T-­‐cell	   epitopes	   and	  OLPs	  
targeted	  between	  4-­‐52	  weeks	  post	  infection.	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Responses	   to	   Pol	  made	   up	   34%	   of	   all	   the	  HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	   responses	  
that	  were	  classified	  as	  persistent,	  followed	  by	  Gag	  (29%),	  and	  Nef	  (15%).	  When	  T-­‐
cell	   responses	   were	   analysed	   irrespective	   of	   viral	   protein	   or	   region	   targeted,	  
there	   was	   no	   significant	   negative	   association	   between	   the	   breadth	   of	   these	  
responses	   and	   viral	   load	   set	   point	   (P=0.37;	   r=-­‐0.22)	   (Figure	   3.5A).	   Even	   though	  
Pol-­‐specific	   responses	  made	   up	   35%	   of	   all	   persistent	   responses,	   there	   was	   no	  
correlation	   between	   the	   breadth	   of	   these	   responses	   and	   viral	   load	   set	   point	  
(P=0.77;	   r=-­‐0.073)	   (Figure	   3.5B).	   	   In	   contrast,	   a	   significant	   association	   was	  
observed	   between	   persistent	   responses	   targeting	   Gag	   and	   viral	   set	   point	  
(P=0.010;	  r=-­‐0.59)	  (Figure	  3.5C).	  	  These	  data	  suggest	  that	  persistent	  Gag-­‐specific	  
CD8+	  T-­‐cell	  responses	  may	  be	  advantageous	  in	  providing	  a	  sustained	  reduction	  in	  
viremia.	  	  	  
	  
Whilst	  some	  of	  the	  early	  HIV-­‐1-­‐specific	  IFN-­‐γ	  ELISPOT	  CD8+	  T-­‐cell	  responses	  were	  
shown	   to	   persist,	   55%	   of	   these	   T-­‐cell	   responses	   waned	   and	   were	   below	   the	  
threshold	  of	  detection	  at	  52	  weeks.	   	   In	  order	  to	  determine	  the	  fate	  of	  some	  of	  
these	  T-­‐cell	   responses	  which	  were	  no	   longer	  detectable	   in	  circulation,	  we	  used	  
the	   cultured	   IFN-­‐γ	   ELISPOT	   assay	   which	   assesses	   the	   proliferation	   of	   low	  
frequency	  T-­‐cells	  which	  may	  be	  missed	  by	  the	  ex	  vivo	  ELISPOT	  assay	  (Calarota	  et	  
al.,	   2008,	   Pala	   et	   al.,	   2013,	   Ndhlovu	   et	   al.,	   2012).	   	   Due	   to	  sample	   availability	  
limitations,	  not	  all	  subjects	  could	  be	  evaluated	  for	   immune	  responses	  using	  the	  
cultured	   IFN-­‐γ	   ELISPOT	   assay.	   	   In	   the	   8	   subjects	   evaluated,	   a	   total	   of	   96	  
(median=11)	  ex	  vivo	  IFN-­‐γ	  ELISPOT	  responses	  were	  measured	  between	  the	  4	  and	  
26	   weeks	   post	   infection	   (Table	   3.5).	   	   With	   the	   duration	   of	   infection,	   these	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responses	  fluctuated	  over	  time	  and	  only	  30%	  of	  these	  T-­‐cell	  responses	  were	  still	  
detectable	   by	   the	   ex	   vivo	   ELISPOT	   assay	   at	   52	   weeks.	   	   At	   least	   40%	   of	   T-­‐cell	  
responses	   (27	  of	   the	  67	   individual	  epitope-­‐specific	  T-­‐cell	   responses),	  which	  had	  
disappeared	   and	   were	   presumed	   lost,	   could	   be	   detected	   with	   the	   cultured	  
ELISPOT	  assay.	  	  These	  T-­‐cell	  responses	  were	  directed	  against	  epitopes	  in	  all	  HIV-­‐1	  
regions	   (magnitude	   of	   response	   ranging	   from	   200–4,000	   SFC/106	   PBMC),	   and	  
30%	   of	   these	   responses	   targeted	   epitopes	   in	   Gag.	   	   There	   was	   no	   significant	  
correlation	   between	   the	   presence	   of	   cultured	   ELISPOT	   responses	   targeting	   all	  
HIV-­‐1	  regions	  and	  viral	  set	  point	  (P=0.24;	  r=0.47	  and	  data	  not	  shown).	  	  However,	  
a	   significant	   negative	   correlation	   between	   cultured	   ELISPOT	   Gag-­‐specific	  
responses	  and	  viral	  set	  point	  (P=0.017;	  r=-­‐0.85)	  (Figure	  3.5D)	  was	  observed.	  	  Our	  
data	  show	  that	  the	  cultured	  ELISPOT	  could	  amplify	  and	  enhance	  the	  detection	  of	  
at	  least	  40%	  of	  low	  frequency	  T-­‐cell	  responses	  which	  had	  become	  undetectable	  
when	  measured	  by	  the	  ex	  vivo	  ELISPOT.	  	  	  It	  is	  also	  plausible	  that	  these	  effector	  T-­‐
cell	   responses	   that	   were	   below	   the	   limit	   of	   detection	   by	   ex	   vivo	   ELISPOT	   had	  
converted	  to	  a	  memory	  phenotype,	  which	  is	  not	  detectable	  by	  standard	  ELISPOT	  
(Godkin	  et	  al.,	  2002,	  Reece	  et	  al.,	  2004,	  Todryk	  et	  al.,	  2008,	  Ndhlovu	  et	  al.,	  2012).	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Figure	  3.5.	  The	  impact	  of	  persistent	  T-­‐cell	  responses	  measured	  between	  4	  weeks	  and	  
52	   weeks	   post	   infection	   on	   viral	   load	   set	   point.	   (A)	   A	   lack	   of	   association	   between	  
persistent	  responses	  targeting	  epitopes	  within	  all	  proteins	  and	  viral	  load	  set	  point;	  (B)	  
A	   lack	  of	  association	  between	  persistent	  responses	  targeting	  epitopes	  within	  Pol	  and	  
viral	  load	  set	  point;	  (C)	  A	  significant	  negative	  association	  between	  the	  breadth	  of	  Gag-­‐
specific	  persistent	  T-­‐cell	   responses	  and	  viral	   load	  set	  point;	   (D)	  A	  significant	  negative	  
association	  between	  the	  breadth	  of	  Gag-­‐specific	  cultured	  ELISPOT	  T-­‐cell	  responses	  and	  
viral	  load	  set	  point.	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Table	   3.5.	   HIV-­‐1-­‐specific	   T-­‐cell	   responses	   determined	   by	   the	   ex	   vivo	   ELISPOT	   assay	  
during	   the	   entire	   follow	   up	   period	   and	   responses	  measured	   using	   cultured	   ELISPOT	  
assay	  at	  52	  weeks.	  
	  
	  
4.3. Gag	  immune	  responses	  and	  viral	  evolution	  	  
To	   investigate	   the	   relationship	   between	   the	   dynamics	   of	   Gag-­‐specific	   T-­‐cell	  
responses	  and	  sequence	  evolution	  within	  targeted	  Gag	  epitopes,	  we	  sequenced	  
HIV-­‐1	   Gag	   from	   plasma	   samples	   obtained	   at	   2-­‐6	   weeks	   and	   52	   weeks	   post	  
infection.	  	  We	  evaluated	  a	  cumulative	  total	  of	  210	  epitopes	  restricted	  by	  the	  HLA	  
class	  I	  alleles	  expressed	  by	  subjects	  in	  the	  cohort.	  Of	  the	  epitope	  sequences	  we	  
assessed	  at	  2-­‐6	  weeks,	   in	  spite	  of	  expression	  of	  the	  restricting	  HLA	  class	   I	  allele	  
and	   the	   presence	   of	   the	   cognate	   viral	   sequence,	   T-­‐cell	   responses	   were	   only	  
mounted	  against	  14%	  (11	  of	  78)	  of	  the	  wild	  type	  epitopes	  known	  to	  be	  presented	  
in	   the	   context	   of	  HLA	   alleles	   expressed	   by	   the	   subject.	   	   Interestingly,	   7%	   (9	   of	  
135)	  of	  epitopes	  with	  variant	  sequences	  either	  in	  the	  putative	  epitope	  or	  in	  the	  
flanking	  region	  also	   induced	  a	  detectable	  T-­‐cell	  response.	   	  Analysis	  at	  52	  weeks	  
showed	   that	   a	   significantly	   higher	   number	   of	   both	   wild	   type	   (24	   of	   75,	   32%)	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detectable	   CD8+	   T-­‐cell	   immune	   response	   at	   this	   time.	   	   Although	   a	   total	   of	   11	  
Gag-­‐specific	   T-­‐cell	   responses	   against	  wild	   type	   epitopes	  were	  measured	   at	   2-­‐6	  
weeks,	  at	  one	  year	  post	   infection	  mutations	  had	  occurred	   in	  only	   two	  of	   these	  
epitopes,	  the	  HLA-­‐B*57	  restricted	  TW10	  and	  B*81-­‐TL9;	  yet	  these	  epitopes	  were	  
still	  able	  to	  induce	  a	  detectable	  response	  at	  52	  weeks	  (Figure	  3.6A).	  	  In	  contrast,	  
initial	   CD8+	   T-­‐cell	   responses	   against	   HLA-­‐B*8	   restricted	   EV9	   and	   HLA-­‐B*15:10-­‐
VL10	  were	   lost	   after	   6	  weeks	   and	   these	  wild	   type	   epitope	   sequences	   failed	   to	  
induce	   a	   detectable	   response	   even	   up	   to	   52	  weeks	   post	   infection.	   	   Responses	  
targeting	   6	   of	   the	   epitopes	  with	   variant	   sequences	   at	   2-­‐6	  weeks	   declined	  over	  
time	   yet	   this	   loss	   of	   response	   did	   not	   coincide	  with	   further	   sequence	   changes	  
within	   the	   epitopes	   or	   their	   flanking	   regions	   (Figure	   3.6B).	   	   Further	   analysis	  
showed	   that	   there	   was	   no	   significant	   difference	   in	   viral	   set	   point	   between	  
participants	  who	  made	  early	  T-­‐cell	  responses	  to	  wild	  type	  epitopes	  and	  retained	  
these	  responses	  even	  when	  variant	  sequences	  arose	   (median=	  4	   log	  copies/ml)	  
and	   participants	   who	   made	   early	   T-­‐cell	   responses	   against	   variant	   epitope	  
sequences	  and	  retained	  these	  responses	   (median=	  5	   log	  copies	  RNA	  copies/ml)	  
(p=0.416).	   However,	   the	   former	   had	   a	   significantly	   lower	   viral	   load	   set	   point	  
values	   (median=4	   log	   copies/ml)	   in	   comparison	   to	   participants	   who	   made	  
responses	   to	   epitopes	   with	   variant	   sequences	   but	   subsequently	   lost	   these	  






















Figure	  3.6.	  	  Recognition	  patterns	  associated	  with	  wild	  type	  and	  variant	  Gag	  sequences	  
at	  2-­‐4	  weeks	  and	  52	  weeks	  post	  infection.	  (A)	  T-­‐cell	  recognition	  in	  relation	  to	  wild	  type	  
Gag	  sequences	  shown	  as	  the	  magnitudes	  of	  IFN-­‐γ 	  ELISPOT	  responses	  at	  2-­‐4	  weeks	  and	  
52	  weeks	   post	   infection.	   	   (B)	   T-­‐cell	   recognition	   in	   relation	   to	   sequence	   variations	   in	  
Gag	   at	   2-­‐4	   weeks	   and	   52	   weeks	   post	   infection.	   Each	   line	   represents	   the	   specific	  
epitope	  targeted.	  	  The	  sequences	  of	  the	  targeted	  epitopes	  at	  2-­‐4	  weeks	  and	  52	  weeks	  
post	   infection	   are	   shown	   underneath	   the	   graphs.	   The	   underlined	   areas	   indicate	   the	  
putative	  targeted	  epitope.	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5. Discussion:	  
Data	  accumulated	  over	  the	  past	  years	  have	  established	  that	  early	  immune	  events	  
determine	  the	  rate	  of	  disease	  progression	  and	  thus	  a	  detailed	  understanding	  of	  
the	  patterns,	  fate,	  functions	  and	  phenotypes	  of	  early	  CD8+	  T-­‐cell	  subsets	  which	  
best	   correlate	   with	   control	   of	   viremia	   is	   needed	   to	   inform	   vaccine	   and	  
therapeutic	   strategies	   that	   aim	   to	   contain	   the	  AIDS	  pandemic	   (McDermott	   and	  
Koup,	  2012,	  Freel	  et	  al.,	  2011,	  McMichael	  et	  al.,	  2010).	  	  	  	  In	  the	  current	  study	  we	  
have	  analysed	  the	  evolution	  and	  fate	  of	  HIV-­‐specific	  T-­‐cell	  responses	  during	  the	  
first	  year	  of	  infection,	  investigated	  their	  association	  with	  viral	  load	  set	  point	  and	  
their	   ability	   to	   induce	   viral	   escape	   or	   persist	   in	   the	   presence	   of	   escape.	   	   We	  
report	  that	  a	  diverse	  pattern	  of	  T-­‐cell	  recognition	  across	  the	  HIV-­‐1	  proteome	  was	  
evident	   during	   primary	   infection.	   	   Despite	   significant	   heterogeneity	   among	  
participants	   in	   the	   timing	  of	   appearance	   and	  dominance	  of	   virus	   specific	   T-­‐cell	  
responses,	   Nef	   and	   responses	   were	   dominant	   during	   earliest	   phase	   of	   HIV-­‐1	  
infection,	   however,	   the	   breadth	   of	   Gag-­‐specific	   responses	   increased	   over	   time	  
and	  by	  one	  year	  Gag	  responses	  were	  dominant	  and	  contributed	  over	  40%	  to	  the	  
total	  magnitude	  of	  response.	   	  We	  cannot	  rule	  out	  that	  the	  true	  magnitude	  and	  
breadth	  of	  T-­‐cell	   responses	  may	  have	  been	  underestimated	   through	   the	  use	  of	  
consensus	  virus	  sequences	  (Goonetilleke	  et	  al.,	  2009,	  Altfeld	  et	  al.,	  2003).	  
	  
	  A	  significant	  finding	  in	  the	  current	  study	  is	  the	  inverse	  association	  between	  the	  
breadth	   of	   Gag	   responses	   measured	   during	   primary	   infection	   (26	   weeks	   and	  
later)	   but	   not	   at	   the	   acute	   phase	   of	   infection	   (within	   the	   first	   12	   weeks	   post	  
infection).	  Our	  findings	  provide	  a	  clear	  demonstration	  of	  the	  broadening	  of	  Gag–
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specific	   T-­‐cell	   responses	  over	   the	   course	  of	   one	   year	   following	  HIV-­‐1	   infection,	  
with	  this	  increased	  immunogenicity	  associated	  with	  better	  control	  of	  viremia	  and	  
lower	   viral	   load	   set	   point.	   	   Our	   findings	   are	   in	   line	   with	   reports	   from	   other	  
studies,	  which	  have	  shown	  that	  the	  presence	  of	  a	  high	  proportion	  of	  Gag-­‐specific	  
CD8+	   T-­‐cell	   responses	   correlates	  with	   delayed	   disease	   progression	   (Turk	   et	   al.,	  
2013,	  Perez	  et	  al.,	  2013,	  Zuniga	  et	  al.,	  2006,	  Geldmacher	  et	  al.,	  2007,	  Kiepiela	  et	  
al.,	   2007,	   Masemola	   et	   al.,	   2004a,	   Streeck	   et	   al.,	   2009b,	   Mudd	   et	   al.,	   2012).	  	  
Possible	   mechanisms	   by	   which	   Gag-­‐specific	   responses	   in	   reducing	   viral	  
replication	  include	  Gag	  fitness	  constrains	  to	  escape	  immune	  pressure	  (Wright	  et	  
al.,	   2010,	   Miura	   et	   al.,	   2010,	   Henn	   et	   al.,	   2012)	   and	   the	   efficacious	   antiviral	  
activity	  of	  Gag-­‐specific	  CD8+	  T-­‐cells	  (Sacha	  et	  al.,	  2007,	  Payne	  et	  al.,	  2010,	  Julg	  et	  
al.,	  2010,	  Turk	  et	  al.,	  2013).	  However,	  because	  responses	  were	  measured	  in	  the	  
peripheral	  blood	  we	  cannot	  rule	  out	  that	  Gag	  responses	  were	  already	  present	  in	  
mucosal	  and	  lymphoid	  tissues	  in	  higher	  levels	  in	  comparison	  to	  the	  responses	  in	  
the	  blood	  as	  has	  been	  observed	  (Altfeld	  et	  al.,	  2002).	  
	  
We	   also	   show	   that	   individuals	   with	   controlled	   viremia	   had	   significantly	   higher	  
levels	  of	  Gag-­‐specific	  T-­‐cell	  responses,	  which	  persisted	  from	  the	  first	  6	  weeks	  up	  
to	  52	  weeks	  post	  infection.	  	  These	  findings	  confirm	  that	  fluctuations	  in	  levels	  of	  
T-­‐cell	   responses	   and	   viral	   load	   are	   related	   even	   in	   early	   HIV-­‐1	   infection.	   The	  
paucity	  of	  Gag-­‐specific	  responses	  during	  the	  acute	  stages	  of	  HIV-­‐1	  infection	  when	  
dramatic	   declines	   in	   viremia	   are	   recorded	   suggest	   that	   Gag-­‐specific	   T-­‐cell	  
responses	  may	  be	  more	  important	  in	  maintaining	  the	  viral	   load	  at	  the	  set	  point	  
than	  for	  controlling	  early	  viremia	  (Goonetilleke	  et	  al.,	  2009,	  Turnbull	  et	  al.,	  2009,	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Wang	   et	   al.,	   2009).	   	   	   Importantly,	   and	   relevant	   for	   vaccine	   design,	   our	   results	  
imply	   that	   relatively	   limited	   Gag	   immunogenicity	   during	   acute	   HIV-­‐1	   infection	  
may	  lead	  to	  suboptimal	  viral	  control.	  	  Thus,	  a	  vaccine	  designed	  to	  induce	  greater	  
breadth	  of	  CD8+	  T-­‐cell	  responses	  recognizing	  Gag	  epitopes,	  may	  tip	  the	  balance	  
towards	   control	  during	   the	  earliest	  phases	  of	   infection	  and	   result	   in	   viremic	  or	  
elite	   controller	   phenotype	  more	   efficiently	   than	   would	   be	   expected	   in	   natural	  
infection.	  	  	  	  
The	  fluctuation	  of	  the	  recognition	  patterns	  of	  HIV-­‐specific	  CD8+	  T-­‐cell	  responses	  
during	   primary	   infection	   led	   us	   to	   investigate	   the	   impact	   of	   these	   changes	   on	  
disease	  progression.	   	  We	  used	  the	  peptide-­‐based	  cultured	   IFN-­‐γ	  ELISPOT	  assay,	  
(Godkin	  et	  al.,	  2002,	  Keating	  et	  al.,	  2005,	  Calarota	  et	  al.,	  2008)	  to	  determine	  the	  
fate	   the	   HIV-­‐1	   specific	   T-­‐cell	   responses	   which	   had	   decreased	   and	   had	   fallen	  
below	  the	  threshold	  of	  100	  SFC/106	  PBMC	  at	  one	  year.	  Previous	  studies	  indicate	  
that	   some	   antigen-­‐specific	   CD8+	   T-­‐cell	   responses,	   undetectable	   by	   the	   ex	   vivo	  
18h	   ELISPOT	   assay,	   may	   be	   maintained	   as	   low	   frequency	   central	   memory	  
precursors	  (Calarota	  et	  al.,	  2008,	  Ndhlovu	  et	  al.,	  2012),	  suggesting	  that	  these	  are	  
the	  responses	  detected	  using	  the	  cultured	  ELISPOT	  assay	  in	  our	  study.	  	  However,	  
because	   we	   did	   not	   phenotypically	   characterize	   the	   T-­‐cells	   detected	   in	  the	  
cultured	   ELISPOT	   assay,	   we	   cannot	   rule	   out	   the	   possibility	   that	   these	   may	  
represent	   low	   frequency	   HIV-­‐1–specific	   CD8+	  T-­‐cells	   functionally	   and	  
phenotypically	   indistinguishable	   from	   those	   detected	   by	   the	   regular	   ELISPOT	  
assay	  (Lichterfeld	  et	  al.,	  2004a).	  	  
Although	  we	  observed	  a	  significant	  negative	  correlation	  between	  the	  presence	  of	  
cultured	   ELISPOT	   Gag-­‐specific	   T-­‐cell	   responses	   and	   viral	   set	   point,	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the	  small	  sample	  size	  limits	   our	   ability	   to	  draw	  conclusions	   from	   this	   data. Our	  
findings	  however,	  are	  in	  line	  with	  data	  which	  show	  that	  preservation	  of	  memory	  
T-­‐cells	  is	  essential	  for	  better	  outcome	  and	  survival	  in	  HIV-­‐1	  (Burgers	  et	  al.,	  2009,	  
Champagne	  et	  al.,	  2001,	  Northfield	  et	  al.,	  2007,	  Addo	  et	  al.,	  2007,	  Calarota	  et	  al.,	  
2008)	   as	   the	   memory	   subset	   of	   Gag-­‐specific	   CD8+	   T-­‐cells	   have	   viral	   inhibition	  
properties	  in	  HIV-­‐1	  infected	  individuals	  (Ndhlovu	  et	  al.,	  2012).	   
	  
We	   sequenced	   HIV-­‐1	   Gag	   from	   plasma	   samples	   obtained	   during	   acute	   HIV-­‐1	  
infection	  and	  at	  one	  year	  post	  infection.	  In	  agreement	  with	  our	  earlier	  findings,	  
we	  report	  that	  despite	  the	  expression	  of	  the	  restricting	  HLA	  class	  I	  alleles	  and	  the	  
presence	  of	  the	  wild	  type	  epitopes,	  T-­‐cell	  responses	  were	  only	  mounted	  against	  a	  
few	  of	  the	  wild	  type	  epitopes	  and	  analysis	  at	  1	  year	  revealed	  that	  a	  significantly	  
higher	  but	  still	  relatively	  low	  number	  of	  both	  wild	  type	  and	  variant	  epitopes	  were	  
targeted.	   	   Because	   of	   limited	   immunogenicity	   observed	   during	   acute	   HIV-­‐1	  
infection	  we	  are	  unable	  to	  draw	  definitive	  conclusions	  about	  the	  overall	   impact	  
of	   acute	   T-­‐cell	   responses	   on	   viral	   evolution.	   However,	   our	   data	   show	   that	   the	  
initial	  lack	  of	  induction	  of	  Gag-­‐specific	  T-­‐cell	  responses	  is	  not	  primarily	  the	  result	  
of	   sequence	  mismatch	  within	   the	   targeted	  epitopes.	  Given	   that	  our	  analysis	  of	  
CD8+	  T-­‐cell-­‐mediated	  viral	  escape	  was	  restricted	  to	  the	  Gag	  protein,	  it	  is	  possible	  
that	  CD8+	  T-­‐cells	  induced	  escape	  in	  other	  proteins	  (Goonetilleke	  et	  al.,	  2009,	  Liu	  
et	   al.,	   2013).	   	   A	   variant	  was	   considered	   full	  escape	  only	  when	  it	  was	  no	   longer	  
recognized	   by	   CD8+	   T-­‐cells,	   thus	   not	   all	   variants	   constituted	   escape.	    Although	  
mutations	  had	  occurred	   in	   some	  of	   the	   initially	   targeted	  wild	   type	  epitopes	  by	  
one	   year,	   these	   epitopes	   still	   induced	   a	   detectable	   T-­‐cell	   response,	   suggesting	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that	   whilst	   selection	   pressure	   mediated	   by	   early	   T-­‐cell	   responses	   led	   to	   viral	  
escape,	  HIV-­‐1-­‐specific	  T-­‐cell	  responses	  persisted,	  resulting	  in	  the	  relative	  control	  
of	  viral	  replication	  (Haas	  et	  al.,	  1996,	  Turnbull	  et	  al.,	  2006).	   	  Since	  66%	  of	  T-­‐cell	  
responses	   targeting	   epitopes	  with	   variant	   sequences	   at	   the	   earliest	   time	   point	  
subsequently	   declined,	   this	   may	   suggest	   that	   there	   was	   immune	   selection	  
pressure	   already	   being	   applied	   to	   these	   epitopes	   during	   AHI	   and	   the	   virus	  
successfully	   escaped	   recognition,	   as	   indicated	  by	   the	  declining	   T-­‐cell	   responses	  
and	  higher	  viral	   loads.	   	   Interestingly,	   the	  participants	  with	  persisting	  detectable	  
T-­‐cell	  responses	  against	   invariant	  epitopes,	  had	  significantly	   lower	  viral	   load	  set	  
point	   values	   when	   compared	   to	   participants	   with	   responses	   to	   epitopes	  
containing	  variant	  sequences	  during	  acute	  HIV-­‐1	  infection	  but	  subsequently	  lost	  
these	   responses.	   	   These	   data	   suggest	   that	   persisting	   Gag-­‐specific	   T-­‐cell	  
responses,	   which	   may	   be	   the	   result	   of	   continual	   invariant	   viral	   epitope	  
presentation	  or	  the	  generation	  of	  de	  novo	  responses	  to	  arising	  variant	  epitopes,	  
bear	   the	   greatest	   burden	   on	   control	   of	   early	   HIV-­‐1	   replication	   and	   disease	  
progression	  (Wang	  et	  al.,	  2009,	  Mlotshwa	  et	  al.,	  2010,	  Perez	  et	  al.,	  2013).	  	  Thus	  
although	   the	   quality	   (in	   terms	   of	   breadth	   and	   capacity	   to	   respond	   upon	  
stimulation)	   of	   HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	   responses	   during	   acute	   infection	   is	  
generally	  poor,	   it	   is	  not	  entirely	   ineffective.	  Thus,	   indicating	   the	  need	   to	  better	  
understand	   what	   distinguishes	   ineffective	   from	   ineffective	   CD8+	   T-­‐cells	   and	  
raising	  the	   intriguing	  possibility	  that	  there	   is	  room	  for	   improvement	  of	  vaccine-­‐
induced	   CD8+	   T-­‐cells	   to	   achieve	   better	   immune	   control	   than	   that	   achieved	   by	  
natural	  infection	  induced	  CD8+	  T-­‐cells.	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Conclusions	  
	  The	  data	   indicate	   that	   induction	   and	  preservation	  of	  Gag-­‐specific	   effector	   and	  
central	  memory	   type	  CD8+	  T-­‐cell	   responses	   is	   required	   for	   the	  maintenance	  of	  
low	   viral	   load	   levels	   in	   primary	   infection.	   	   Acute	   and	   primary	   infection	   phase	  
CD8+	  T-­‐cells	   in	   this	   study	  mostly	   failed	   to	   induce	   immune	  escape	  over	   the	   first	  
year	  of	   infection,	  highlighting	  the	  need	  to	  better	  understand	  the	  characteristics	  
of	   effective	   HIV-­‐specific	   CD8+	   T-­‐cells.	   	   	   Our	   study	   suggests	   that	   an	   early	   and	  
broadly	   directed	   Gag-­‐specific	   CD8+	   T-­‐cell	   response	   in	   acute	   infection	   may	  
augment	   early	   control,	   and	   provide	   a	   rational	   goal	   for	   both	   prophylactic	   and	  
therapeutic	  vaccination.	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Chapter	  4 :	  The	  prognostic	  value	  of	  plasma	  and	  T-­‐
cell	  markers	  of	  immune	  activation	  in	  predicting	  viral	  
load	  set	  point	  and	  CD4+	  T-­‐cell	  loss	  in	  HIV	  infection	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1. Abstract	  
Background:	  Few	  studies	  have	  investigated	  the	  coupled	  effect	  of	  acute	  phase	  T-­‐
cell	   activation	   and	   cytokine	   expression	   on	   disease	   progression.	   We	   sought	   to	  
determine	   the	   prognostic	   value	   of	   combinations	   of	   these	   immunologic	  
parameters	   in	   predicting	   viral	   load	   set	   point	   and	   CD4+	   T-­‐cell	   loss	   during	   acute	  
HIV-­‐1	  infection.	  	  	  	  
Methods:	  	  The	  study	  included	  33	  subjects	  that	  were	  followed	  longitudinally	  from	  
acute	  HIV-­‐1	   infection,	  up	   to	  1-­‐year	  post	   infection.	  Plasma	  concentrations	  of	  11	  
cytokines	  and	  T-­‐cell	  markers	  of	   immune	  activation	  were	  assessed.	   	  Associations	  
between	   acute	   phase	  markers	   of	   immune	   activation	   and	   T-­‐cell	   responses	   and	  
markers	  of	  disease	  progression	  (viral	  load	  and	  CD+	  T-­‐cell	  counts)	  were	  assessed.	  	  
Results:	  Analyses	  were	  performed	  using	  general	   linear	  models.	   	  Acute	  CD8+	  T-­‐
cell	   responses	   were	   inversely	   associated	   with	   MIP-­‐1β	   plasma	   concentrations	  
(p=0.001).	  Expression	  of	  IL-­‐12p70	  was	  associated	  with	  lower	  viral	   load	  set	  point	  
(P=0.026),	   whereas	   IP-­‐10	   and	   IL-­‐10	   were	   associated	   with	   higher	   viral	   load	   set	  
point	   (P=0.024	   and	   P=0.015,	   respectively).	   PD-­‐1	   expression	   on	   CD8+	   T-­‐cells	  
during	   acute	   infection	   was	   associated	   with	   preservation	   of	   CD4+	   T-­‐cells	  
(p=0.029),	  whereas	  IL-­‐10	  and	  TNF-­‐α	  were	  associated	  with	  more	  rapid	  CD4+	  loss	  
(p=0.016	  and	  p=0.0057,	  respectively).	  	  
Conclusion:	  Our	  study	  identifies	  immune	  signatures	  that	  are	  stronger	  predictors	  
of	   long-­‐term	   HIV	   disease	   progression	   than	   CD8+	   T-­‐cell	   responses	   measured	  
during	  acute	  HIV-­‐1	   infection.	   	   In	  combination	  with	  canonical	  parameters,	   these	  
early	  biomarkers	  may	  inform	  approaches	  for	  evaluating	  the	  ability	  of	  therapeutic	  
HIV-­‐1	  vaccines	  to	  control	  HIV	  infection.	  
	   106	  
2. Introduction	  
Human	  immunodeficiency	  virus	  (HIV-­‐1)	   infection	  is	  characterized	  by	  CD4+	  T-­‐cell	  
depletion,	   CD8+	   T-­‐cell	   expansion	   and	   chronic	   immune	   activation	   resulting	   in	  
immune	  dysfunction	  demonstrated	  by	   increased	  T-­‐cell	  proliferation	  and	  high	  T-­‐
cells	  death	  rates	  (Hellerstein	  et	  al.,	  2003,	  Grossman	  and	  Paul,	  2000).	  	  This	  HIV-­‐1-­‐
induced	   expansion	   and	   increased	   turnover	   of	   T-­‐cells	   ultimately	   results	   in	   the	  
exhaustion	  of	  the	  regenerative	  capacity	  of	  the	  immune	  system	  (Alter	  et	  al.,	  2004,	  
Brenchley	  et	  al.,	  2006b,	  Douek	  et	  al.,	  2003,	  Hellerstein	  et	  al.,	  2003,	  Deeks	  et	  al.,	  
2004).	   Chronic	   immune	   activation	   is	   therefore	   a	   hallmark	   of	   pathogenic	   HIV	  
infection	   and	   the	   level	   of	   immune	   activation	   has	   been	   shown	   to	   be	   the	   best	  
predictor	  of	  progression	  to	  AIDS	  and	  death	  independent	  of	  HIV	  viral	  load	  (Fahey	  
et	  al.,	  1990,	  Liu	  et	  al.,	  1998,	  Hazenberg	  et	  al.,	  2003,	  Giorgi	  et	  al.,	  1999,	  Zangerle	  
et	   al.,	   1998,	   Deeks	   et	   al.,	   2004).	   	   The	   mechanisms	   of	   HIV-­‐associated	   immune	  
activation	  are	  not	  completely	  understood,	  however,	  studies	  have	  suggested	  that	  
HIV-­‐1	   infection	   induces	   chronic	   immune	   activation	   through	   activation	   of	   the	  
innate	  and	  the	  adaptive	  immune	  system,	  via	  single-­‐stranded	  (ss)	  RNA	  or	  through	  
intracellular	   viral	   DNA	   which	   activate	   plasmacytoid	   dendritic	   cells	   (pDCs)	   via	  
endosomal	  Toll-­‐like	  receptors	  7	  and	  8	   (Grossman	  and	  Paul,	  2000,	  Hazenberg	  et	  
al.,	   2000).	   	   Translocation	   of	   bacterial	   products	   from	   the	   gut	   is	   thought	   to	   also	  
contribute	   to	   the	   systemic	   immune	   activation	   associated	   with	   HIV	   infection	  
through	   the	   stimulation	   of	   innate	   immune	   cells	   via	   the	   Toll-­‐like	   receptors	   2,	   4	  
and	  5	  pathways	  (Brenchley	  et	  al.,	  2004b,	  Li	  et	  al.,	  2005,	  Brenchley	  et	  al.,	  2006b).	  	  
The	  activation	  of	   innate	  and	  adaptive	   immune	  systems	  enhances	  expression	  of	  
cell	  surface	  molecules	  such	  as	  programmed	  death-­‐1	  (PD-­‐1),	  CD95,	  CD38,	  HLA-­‐DR,	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CD69	  and	  CD57;	  and	  high	  expression	  of	   these	  markers	   is	  often	  predictive	  of	  an	  
adverse	  prognosis	  (Giorgi	  et	  al.,	  1993,	  Hazenberg	  et	  al.,	  2003,	  Deeks	  et	  al.,	  2004,	  
Lederman	  et	  al.,	  2000,	  Kaufmann	  et	  al.,	  2007,	  Day	  et	  al.,	  2006,	  Brenchley	  et	  al.,	  
2003,	   Kestens	   et	   al.,	   1992,	   Krowka	   et	   al.,	   1996,	   Westendorp	   et	   al.,	   1995).	  
Cytokines	  have	  been	  shown	  to	  play	  a	  key	  role	   in	  numerous	   infectious	  diseases,	  
by	   shaping	   the	   immune	   response	   mounted	   against	   pathogens	   and	   also	  
contributing	  to	  disease	  pathogenesis	  (Murdoch	  and	  Finn,	  2000,	  Dinarello,	  1992,	  
Kedzierska	  and	  Crowe,	  2001).	   	  HIV-­‐associated	   immune	  activation	  contributes	  to	  
the	   induction	  of	   a	   potent	   inflammatory	   response	  marked	  by	   elevated	   levels	   of	  
pro-­‐inflammatory	   cytokines,	   and	   this	   inflammatory	   response	   induces	   a	   potent	  
and	   sustained	   immunoregulatory	   response	   marked	   by	   production	   of	   anti-­‐
inflammatory	  cytokines	   (Stacey	  et	  al.,	  2009,	  Roberts	  et	  al.,	  2010,	  Nilsson	  et	  al.,	  
2007,	   Boasso	   and	   Shearer,	   2008).	   Some	   reports	   have	   established	   that	   plasma	  
cytokine	   levels	   measured	   during	   acute	   HIV	   infection	   may	   predict	   subsequent	  
disease	  progression	  and	  a	  marked	   increase	   in	  pro-­‐inflammatory	   cytokine	   levels	  
can	  be	  used	  as	  a	  surrogate	  marker	   for	  HIV-­‐disease	  progression	  (Godfried	  et	  al.,	  
1993,	  Fahey	  et	  al.,	  1990,	  Miedema	  et	  al.,	  2013,	  Stacey	  et	  al.,	  2009,	  Roberts	  et	  al.,	  
2010,	  Ausiello	  et	  al.,	  1996).	  	  
	  
Our	  earlier	   findings	   revealed	   that	   acute	  HIV-­‐1	   subtype	  C	  CD8+	  T-­‐cell	   responses	  
were	  very	  narrow	  in	  breadth	  and	  that	  early	  Nef	  responses	  were	  associated	  with	  
higher	  viral	  loads.	  	  In	  light	  of	  these	  findings,	  we	  aimed	  to	  determine	  whether	  an	  
association	  exists	  between	  acute	  plasma	  and	  T-­‐cell	  immune	  activation	  levels	  and	  
the	   magnitude	   and	   breadth	   of	   CD8+	   T-­‐cell	   responses	   during	   acute	   HIV-­‐1	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infection.	   	   In	   addition,	   we	   aimed	   to	   identify	   acute	   phase	   plasma	   and	   T-­‐cell	  
immune	   activation	   signatures	   associated	   with	   rapid	   disease	   progression.	  	  
Although	  studies	  have	  reported	  that	  a	  number	  of	  plasma	  and	  T-­‐cell	  markers	  of	  
immune	  activation	  predict	  disease	  progression,	  no	  single	  study	  has	  assessed	  the	  
combined	  predictive	  value	  of	  these	  parameters	  during	  acute	  HIV-­‐1	  infection.	  The	  
predictive	  value	  of	   immune	  activation	  biomarkers	  has	   largely	  been	   investigated	  
during	   chronic	   HIV	   infection,	   but	   the	   benefits	   of	   being	   able	   to	   predict,	   and	  
perhaps	  modify,	  disease	  course	  during	  early	  HIV	  infection	  would	  be	  beneficial.	  In	  
addition	  to	  shedding	  light	  on	  the	  narrowness	  and	  general	   ineffectiveness	  of	  the	  
early	   immune	  response,	  determining	  which	  biomarkers	  are	  dysregulated	  during	  
acute	   and	   primary	   HIV-­‐1	   infection	   may	   provide	   direction	   in	   understanding	  
mechanisms	  of	  pathogenesis.	  	  
	  
Using	   a	   cohort	   of	   acutely	   infected,	   antiretroviral	   therapy-­‐naive	   individuals,	   we	  
sought	  to	  establish	  the	  impact	  of	  cytokine	  expression	  patterns	  on	  the	  quality	  of	  
the	   CD8+	   T-­‐cell	   responses	   during	   acute	   HIV-­‐1	   infection	   and	   determine	   the	  
prognostic	   value	   of	   coupled	   estimates	   of	   T-­‐cell	   activation	   and	   plasma	   cytokine	  
levels	  in	  predicting	  viral	  load	  set	  point	  and	  CD4+	  T-­‐cell	  decline	  during	  acute	  HIV-­‐1	  
infection.	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3. Materials	  and	  methods	  
3.1. Study	  cohort	  
The	   study	   population	   for	   this	   analysis	   consisted	   of	   33	   participants	   from	  
the	  previously	  described	  cohort	   (Chapter	  2	  and	  3).	   	  The	  median	  age	  at	  baseline	  
was	   27	   years	   (IQR,	   25–34	   years)	   and	   seventeen	   of	   the	   subjects	   (58%)	   were	  
female.	  	  A	  median	  of	  seven	  CD4+	  T-­‐cell	  counts	  per	  individual	  was	  performed	  over	  
the	   first	   year	   of	   infection.	   	   	   	   The	   rate	   of	   CD4+	   T-­‐cell	   decline	   (median	   of	   -­‐4	  
cells/mm3	   per	   month;	   IQR,	   -­‐8	   to	   0.3	   cells/mm3	   per	   month)	   was	   calculated	   by	  
linear	   regression	   over	   a	   median	   treatment-­‐free	   follow	   up	   period	   of	   234	   days	  
(IQR,	   58	   to	   362	  days).	   	   Viral	   load	   set	   point	  was	   calculated	   as	   the	   average	   viral	  
load	  from	  3	  to	  12	  months	  post-­‐infection	  (median	  of	  4.5	  log10	  copies/ml;	  IQR,	  4	  
to	  5	  log10	  copies/ml).	  	  Sequential	  plasma	  samples	  collected	  at	  4	  weeks,	  16	  weeks	  
and	  52	  weeks	  post	   infection	  were	  assayed	   for	  cytokine	   levels.	  T-­‐cell	  expression	  
markers	  of	  immune	  activation	  and	  dysfunction	  were	  measured	  on	  PBMC	  samples	  
collected	   at	   4	   weeks	   post	   infection.	   Of	   the	   33	   participants	   in	   the	   study,	   IFN-­‐γ	  
ELISPOT	   CD8+	   T-­‐cell	   responses	   to	   the	   entire	   proteome	   were	   measured	   in	   25	  
subjects	  as	  explained	   in	  chapters	  2	  and	  3,	  plasma	  samples	   for	  cytokine	  analysis	  
were	  available	  for	  21	  subjects,	  and	  only	  19	  PBMC	  samples	  were	  available	  for	  the	  
evaluation	   of	   cell	   expression	   markers	   of	   immune	   activation	   and	   dysfunction	  
(Figure	  4.1).	  	  












Figure	  4.1.	  Summary	  of	  the	  distribution	  of	  the	  data	  sets	  used	  for	  analyses	  and	  general	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3.2. 	  Viral	  load	  determination,	  CD4+	  T-­‐cell	  counts	  and	  HLA	  typing	  
Plasma	   viral	   loads	   were	   measured	   using	   either	   the	   Roche	   Amplicor	   Monitor	  
Assay	  detection	   limit	  of	  400	  HIV-­‐1	  RNA	  copies/ml	  plasma,)	  or	   the	  Roche	  Ultra-­‐
sensitive	   assay	   detection	   limit	   of	   50	   RNA	   copies/ml	   plasma),	   according	   to	   the	  
manufacturer’s	   instructions.	   CD4	   counts	   were	   determined	   from	   fresh	   whole	  
blood	  using	  Tru-­‐Count	   technology	  and	  analyzed	  on	  a	   four-­‐color	   flow	  cytometer	  
(Becton	  Dickinson)	  according	  to	  the	  manufacturer’s	  instructions.	  	  High-­‐resolution	  
HLA	  class	  I	  typing	  was	  performed	  as	  previously	  described	  (Radebe	  et	  al.,	  2011).	  	  
	  
3.3. Measurement	  of	  plasma	  cytokines	  
Eleven	   cytokines	   were	   measured	   in	   plasma	   from	   the	   cohort	   using	   the	  
MILLIPLEX™	   MAP	  high	   sensitivity	   human	  cytokine/chemokine	   kits	   (Millipore,	  
Melbourne,	   Australia)	   according	   to	   the	  manufacturer’s	   instructions	   for	   plasma	  
samples.	   The	   following	   cytokines	   were	   assessed	   (minimal	   detection	   limits	   are	  
shown	  in	  brackets	  in	  pg/ml):	  	  interleukin	  (IL)-­‐1beta	  (0.06),	  IL-­‐2	  (0.16),	  IL-­‐8	  (0.11),	  
IL-­‐10	   (0.15),	   IL-­‐12p70	   (0.11),	   granulocyte	  macrophage-­‐colony	   stimulating	   factor	  
(GM-­‐CSF)	  (0.46),	  interferon	  (IFN)-­‐gamma	  (0.10),	  IFN-­‐gamma-­‐induced	  protein	  (IP-­‐
10)	   (1.20),	  macrophage	   inflammatory	   protein	   (MIP)-­‐1	   alpha	   (4.50),	  MIP-­‐1	   beta	  
(3.50)	   and	   tumour	   necrosis	   factor	   (TNF)-­‐alpha	   (0.40).	   	   Samples	   were	   studied	  
undiluted	   in	   triplicates	   and	   the	   average	   value	   computed	   for	   each	   individual	  
analyte.	   	   Data	   were	   collected	   and	   read	   on	   a	   Bio-­‐Plex	   200	   reader	   (Bio-­‐Rad	  
Laboratories).	   	   Concentration	   values	   below	   the	   lower	   limits	   of	   detection	   were	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reported	   as	   the	  midpoint	   between	   the	   lowest	   concentration	   for	   each	   cytokine	  
measured	  and	  zero	  (Roberts	  et	  al.,	  2010,	  Bebell	  et	  al.,	  2008).	  
	  
3.4. Assessment	  of	  T-­‐cell	  activation	  by	  multicolor	  flow	  cytometry	  
Ex	  vivo	  measurement	  of	  T-­‐cells	  for	  the	  expression	  of	  markers	  of	  activation	  (CD38,	  
HLA-­‐DR,	  CD69)	  (Kestens	  et	  al.,	  1992,	  Krowka	  et	  al.,	  1996),	  exhaustion	  (PD-­‐1)	  (Day	  
et	   al.,	   2006),	   senescence	   (CD57)	   (Brenchley	   et	   al.,	   2003)	   and	   apoptosis	   (CD95)	  
(Westendorp	   et	   al.,	   1995)	   were	   performed.	   	   Briefly,	   thawed	   cryopreserved	  
PBMCs	   were	   resuspended	   to	   1-­‐2	   x	   106	   cells/ml	   in	   R10	   media	   (RPMI	   1640	  
supplemented	   with	   10%	   heat-­‐inactivated	   FCS),	   100	   U/ml	   penicillin,	   1.7mM	  
sodium	   glutamate,	   5.5ml	  HEPES	   buffer)	   and	   rested	   overnight	   at	   370C;	   5%	  CO2.	  
Cells	   were	   then	   adjusted	   to	   1x106	   cells/ml,	   washed	   with	   PBS	   (2%	   PBS/FCS),	  
stained	   for	   intracellular	   amine	   groups	   to	   differentiate	   between	   live/dead	  using	  
the	   violet	   viability	   dye	   (Invitrogen)	   and	   incubated	   for	   30	  min	   at	   40C.	   Following	  
incubation,	  cells	  were	  washed	  and	  stained	  with	  the	  following	  surface	  antibodies:	  
CD3-­‐phycoerithrincarbocyanin	   (PE-­‐Cy5.5),	   CD8	   phycoerithrincarbocyanin	   (PE-­‐
Cy7)	  and	  CD4	  quantum	  dot	  (Qdot	  605),	   in	  addition	  to:	  CD38	  phytoerythrin	  (PE),	  
CD57	   allophycocyanin	   (APC),	   CD69	   allophycocyanin	   carbocyanin,	   CD95	  
fluorescein	   isothiocyanate	   (FITC),	   HLA-­‐DR-­‐	   peridin	   chlorophyll	   protein	   (PerCP)	  
and	   PD-­‐1	   pacific	   blue	   (Pac	   Blue)	   all	   from	  BD	   PharMingen	   (BD	   BioSciences,	   San	  
Jose,	  CA,	  USA).	  	  Cells	  were	  again	  washed	  and	  fixed	  in	  1%	  paraformaldehyde	  (Fix	  
Perm	   A,	   Caltag)	   for	   20	   min	   in	   the	   dark	   at	   room	   temperature.	   Following	  
incubation,	  cells	  were	  washed	  twice	  with	  PBS	  and	  resuspended	  in	  200µl	  of	  PBS.	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Samples	  were	   acquired	   on	   the	   LSR	   II	   flow	   cytometer,	   using	   FACSDiva	   software	  
(BD	  Biosciences),	  and	  analyzed	  with	  FlowJo	  software	   (Tree	  Star,	  San	  Carlo,	  CA).	  
Fluorescence	   voltages	   were	   determined	   using	   matched	   unstained	   cells.	  	  
Fluorescence-­‐minus-­‐one	   (FMO)	   was	   used	   for	   gating	   strategy	   (Figure	  
4.2)	  (Roederer,	   2001).	   For	   each	   sample	   a	   minimum	   of	   300,000	   events	   we	  
acquired.	  
	  
3.5. Statistical	  analysis	  
Univariate	   analyses	   were	   performed	   using	   GraphPad	   Prism	   5	   (GraphPad	  
Software,	  San	  Diego,	  California,	  USA).	  	  Spearman	  rank	  tests	  were	  used	  to	  test	  for	  
correlations.	  P	  values	   less	   than	  0.05	  were	  considered	  significant.	  General	   linear	  
models	  were	  performed	  using	  Stata	  (Stata	  Corp.,	  College	  Station,	  Texas,	  USA).	  	  A	  
general	   linear	  model	   was	   used	   to	   determine	   the	   cytokines	   and	   T-­‐cell	   markers	  
that	  best	  correlated	  with	  magnitude	  or	  breadth	  of	  acute	  CD8+	  T-­‐cell	  responses,	  
viral	   load	   set	   points	   and	   the	   rate	   of	   CD4+	   T-­‐cell	   decline.	   Log	   transformed	   viral	  
loads	  and	  cytokine	  concentrations	  were	  used.	  	  Using	  a	  univariate	  regression	  as	  a	  
starting	  point,	   variables	   that	  were	   significantly	  associated	  with	   (1)	  breadth	  and	  
magnitude	  of	  CD8+	  T-­‐cell	  responses	  or	  (2)	  viral	   load	  set	  point	  or	  (3)	  CD4+	  T-­‐cell	  
loss,	  while	  controlling	   for	  each	  of	   the	  markers	  already	   included,	  were	  added	  to	  
the	  model	  in	  a	  stepwise	  manner.	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Figure	   4.2.	   Gating	   strategy	   for	   identification	   of	   CD4+	   and	   CD8+	   T-­‐cell	   subsets.	  
Representative	  flow	  cytometry	  plots	  from	  the	  PBMCs	  of	  one	  subject	  within	  the	  cohort	  
to	  demonstrate	  the	  gating	  strategy.	  Gating	  Strategy	  on	  (A)	  lymphocyte	  population,	  (B)	  
singlet,	   (C)	  CD3+	  cells	   (D)	  CD4+	  and	  CD8+	   	  cells	  and	  (E)	  CD8+	  T-­‐cells	  expressing	  CD57,	  
(F)	   CD8+	   T-­‐cells	   expressing	   CD69	   (G)	   CD8+	   T-­‐cells	   expressing	   CD95,	   (H)	   CD8+	   T-­‐cells	  
expressing	  HLA-­‐DR	  and	  CD38	  (I)	  CD8+	  T-­‐cells	  expressing	  PD-­‐1.	  
	   115	  
4. Results	  
4.1. Exponential	  viral	  load	  expansion	  in	  plasma	  donors	  with	  acute	  HIV	  infection	  
Sequential	   samples	   collected	   during	   acute	   HIV	   infection	   present	   a	   rare	  
opportunity	   to	   analyze	   kinetic	   changes	   in	   cytokine	   levels	   during	   the	   earliest	  
stages	  of	   infection.	   Plasma	  panels	   from	  33	  participants	   enrolled	   into	   the	   study	  
during	  acute	  HIV-­‐1	   infection	  were	  studied.	   	  At	   the	   time	  when	   the	   first	   samples	  
were	   taken,	   subjects	   were	   Fiebig	   stages	   III	   or	   IV	   (Fiebig	   et	   al.,	   2003)	   and	   the	  
median	  plasma	  viral	   load	  was	  elevated	  at	  6	   log10copies/ml	   (IQR	  4.7	  to	  6.1	   log10	  
copies/ml),	  thus	  indicative	  of	  acute	  HIV	  infection.	  	  The	  level	  of	  viremia	  decreased	  
over	  time,	  to	  a	  median	  of	  4	  log10	  copies/ml	  (IQR	  3.5	  to	  4.6	  log10	  copies/ml)	  at	  1	  
year	  post	  infection.	  	  CD4+	  T-­‐cell	  kinetics	  over	  time	  were	  less	  pronounced,	  with	  a	  
decrease	  from	  420	  T-­‐cells/mm3	  (IQR	  383	  to	  586	  cells/mm3)	  to	  419	  cells/mm3	  (IQR	  
316-­‐466	  cells/mm3)	  at	  one	  year.	  	  The	  relationship	  between	  viremia	  and	  CD4+	  T-­‐
cell	  counts	  at	  baseline	  was	  examined	  using	  data	  from	  all	  33	  subjects.	  There	  was	  a	  
negative	   correlation	  between	  plasma	  HIV	  RNA	   levels	   and	  CD4+	  T-­‐cell	   counts	   at	  
study	   baseline	   (Figure	   4.3A)	   (Spearman	   rho	   =–0.40,	  P	  =0.04,	   n	   =	   33).  We	  
performed	  a	  linear	  regression	  analysis	  to	  estimate	  the	  independent	  associations	  
between	  CD4+	  T-­‐cell	  counts	  and	  contemporaneous	  viral	  load	  during	  acute	  HIV-­‐1	  
infection.	  	  A	  linear	  regression	  analysis	  showed	  that	  on	  average,	  there	  was	  a	  0.2-­‐
log10	  drop	  in	  viral	   load	  per	  100	  cells/mm3	  increase	  in	  CD4+	  T-­‐cell	  count.	   	  There	  
was	   no	   correlation	   observed	   between	   the	   CD4+	   T-­‐cell	   count	   measured	   at	  
baseline	  and	  viral	   load	  set	  point,	  however	  a	  marginal	   trend	  toward	  significance	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was	   observed	   for	   higher	   CD4+	   T-­‐cell	   counts	   and	   lower	   viral	   load	   set	   point	  




Figure	  4.3.	  The	  relationship	  between	  CD4+	  T-­‐cell	  counts	  and	  (A)	  concurrent	  plasma	  HIV	  
RNA	  levels	  and	  (B)	  viral	  load	  set	  point	  (both	  log10	  transformed)	  during	  acute	  and	  early	  




4.2. Plasma	  levels	  of	  cytokines	  and	  chemokines	  in	  primary	  	  HIV-­‐1	  infection.	  	  
At	  4	  weeks	  post	   infection,	  a	  total	  of	  11	  plasma	  cytokines	  and	  chemokines	  were	  
quantified	   in	   the	   plasma	   of	   21	   subjects.	   	   Figures	   4.4	   shows	   examples	   of	   the	  
changes	  occurring	  in	  all	  analytes	  in	  each	  of	  the	  21	  subjects.	  	  Baseline	  expression	  
levels	  were	  measured	  at	  4	  weeks	  post	  infection,	  and	  analyte	  levels	  measured	  at	  
16	   and	   52	  weeks	  were	   deemed	   elevated	   if	   there	  was	   a	   >2	   fold	   increase	   from	  
baseline.	  	  Between	  4	  and	  16	  weeks	  post	  infection	  we	  observed	  an	  increase	  (>2)	  
in	  the	  levels	  of	  IL-­‐12p70,	  GM-­‐CSF	  and	  IL-­‐1	  beta,	  the	  increase	  in	  these	  factors	  was	  
sustained	  up	  to	  52	  weeks	  post	   infection	  (Figure	  4.4	  and	  4.5).	   	  There	  was	  also	  a	  
notable	   increase	   in	   the	   expression	   of	   the	   anti-­‐inflammatory	   cytokine	   IL-­‐10	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between	   16	   weeks	   and	   52	   weeks	   post	   infection.	   However,	   although	   modest	  
changes	   in	  the	   levels	  of	  a	  handful	  of	  cytokines	  and	  chemokines	  were	  observed,	  
no	  significant	  changes	   in	  the	  kinetics	  of	  many	  of	   the	  cytokines	  and	  chemokines	  
known	  to	  be	  produced	  very	  early	  on	   in	  acute	  and	  primary	  HIV-­‐1	   infection	  were	  
detected	  (Stacey	  et	  al.,	  2009,	  Gay	  et	  al.,	  2011).	  	  The	  modest	  changes	  in	  the	  levels	  
of	   cytokines	   may	   be	   explained	   by	   the	   fact	   that	   the	   time	   points	   analyzed	  
corresponded	  to	  Fiebig	  stages	  III	  and	  IV	  instead	  of	  the	  earliest	  (eclipse	  and	  Fiebig	  


















































Figure	  4.4.	  The	  mean	  fold	  changes	  of	  analytes	  from	  baseline	  (4	  weeks)	  up	  to	  52	  weeks	  
post	  infection.	  	  The	  graph	  is	  a	  composite	  of	  the	  results	  for	  all	  11	  analytes.	  	  




























































































Figure	  4.5.	  	  Changes	  of	  plasma	  analyte	  levels	  relative	  to	  baseline	  during	  primary	  HIV-­‐1	  
infection.	   Plasma	   levels	   of	   11	   cytokines	   (IL-­‐1β ,	   TNF-­‐α ,	   IL-­‐8,	   IFN-­‐γ 	   and	   IL-­‐10,	  MIP-­‐1α ,	  
MIP-­‐1β ,	  IL-­‐12p70)	  collected	  at	  3	  sequential	  time	  points	  from	  21	  HIV-­‐infected	  subjects	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4.3. Cytokine	  expression	  is	  associated	  with	  	  CD8+	  T-­‐cell	  magnitude	  and	  breadth	  
Univariate	   regression	  analysis	  was	  used	   to	  determine	   the	   relationship	  between	  
plasma	  and	  T-­‐cell	  markers	  of	   immune	  activation	  and	  the	  breadth	  of	  CD8+	  T-­‐cell	  
responses	  during	  acute	  HIV-­‐1	  infection.	  	  Interestingly,	  MIP-­‐1β,	  a	  cytokine	  that	  is	  
produced	   by	   HIV-­‐specific	   CD8+	   T-­‐cells	   was	   the	   only	   marker	   significantly	  
associated	   with	   the	   breadth	   CD8+	   T-­‐cell	   responses	   in	   the	   unadjusted	   analysis,	  
and	  this	  was	  an	  inverse	  relationship	  such	  that	  with	  every	  one	  log	  increase	  in	  MIP-­‐
1β,	  breadth	  decreased	  by	  1.36	  units	  (p=0.0240)	  (Table	  4.1).	  IL-­‐10	  showed	  a	  trend	  
of	   positive	   association	   with	   breadth	   (p=0.0720).	   	   No	   other	   variables	   were	  
associated	   with	   breadth.	   	   When	   both	   MIP-­‐1β	   and	   IL-­‐10	   were	   added	   to	   the	  
general	  linear	  model,	  MIP-­‐1β	  remained	  statistically	  significant	  (p=0.0335).	  	  
	  
A	   univariate	   regression	   analysis	   was	   used	   to	   determine	   the	   impact	   of	   acute	  
phase	   plasma	   and	   T-­‐cell	   markers	   of	   immune	   activation	   cytokines	   on	   the	  
magnitude	  of	  CD8+	  T-­‐cell	  responses.	  	  A	  square	  root	  transformation	  was	  applied	  
to	   the	  magnitude	   in	   order	   to	   ensure	   normality.	   	   As	   observed	   previously,	   only	  
MIP-­‐1β	  was	   significantly	  associated	  with	   the	  magnitude	  of	   the	  earliest	  CD8+	  T-­‐
cell	  response	  in	  the	  unadjusted	  analysis;	  with	  every	  one	  log	  increase	  in	  MIP-­‐1β,	  
magnitude	   decreases	   by	   32.96	   square	   root	   units	   –	   or	   1,086	   SFU/106	   PBMCs.	  	  
When	   we	   fitted	   an	   adjusted	   model	   with	   MIP-­‐1β	   and	   IL-­‐10,	   MIP-­‐1β	   remained	  
statistically	  significant	  (p=0.0015)	  (Table	  4.1).	  	  
	   121	  
Table	  4.1.	  General	   linear	  model	  analysis	   showing	  associations	  between	  plasma	  T-­‐cell	  
markers	  of	  immune	  activation	  and	  the	  acute	  phase	  CD8+	  T-­‐cell	  response.	  	  
	  
	  
4.4. Early	  cytokine	  expression	  patterns	  predict	  viral	  load	  set	  point	  
A	  general	  linear	  model	  was	  used	  to	  determine	  the	  relationship	  between	  plasma	  
cytokine	  concentrations	  at	  4	  weeks	  post	  infection	  and	  viral	  load	  set	  point.	  Using	  
univariate	   regression	   as	   a	   starting	   point,	   cytokines	   that	   were	   significantly	  
associated	   with	   viral	   load	   set	   point	   were	   added	   to	   the	   model	   in	   a	   stepwise	  
manner.	   Only	   a	   handful	   of	   the	   11	   variables	   were	   significantly	   associated	   with	  
changes	  in	  viral	  load	  set	  point	  (Figure	  4.6	  B,	  F,	  G	  and	  K).	  	  Higher	  plasma	  levels	  of	  
IL-­‐10,	   IL-­‐12p70	  and	   IP-­‐10	  were	   significantly	   associated	  with	   an	   increase	   in	   viral	  
load	  set	  point	  (p=0.0003,	  p=0.0398	  and	  p=0.0529,	  respectively)	  whilst	  high	  TNF-­‐α	  
expression	   was	   associated	   with	   a	   significant	   decrease	   in	   viral	   load	   set	   point	  
(p=0.0001)	  (Table	  4.2).	  	  When	  we	  adjusted	  for	  other	  cytokines,	  TNF-­‐α	  came	  up	  as	  
negatively	   associated	   with	   viral	   set	   point	   (p=0.0136),	   while	   the	   effect	   of	   IL-­‐10	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Figure	  4.5.	  The	  relationship	  between	  viral	  load	  set	  point	  and	  cytokines	  measured	  at	  4	  
weeks	   post	   infection	   in	   21	   individuals.	   A	   smooth	   line	   was	   generated	   by	   linear	  
regression	  with	  quadratic	  equations.	  
R = 0.32
P = 0.0529
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4.5. T-­‐cell	  markers	  of	  immune	  activation	  and	  viral	  load	  set	  point	  
In	  order	  to	  assess	  the	  impact	  of	  T-­‐cell	  markers	  of	  activation	  measured	  at	  4	  weeks	  
post	   infection	   on	   viral	   load,	  we	   fitted	   a	   general	   linear	  model	   to	   viral	   set	   point	  
using	  data	  from	  19	  subjects.	  Using	  a	  univariate	  regression	  as	  a	  starting	  point,	  T-­‐
cell	   markers	   that	   were	   significantly	   associated	   with	   viral	   load	   set	   point	   were	  
added	   to	   the	   model	   in	   a	   stepwise	   manner.	   	   We	   observed	   no	   associations	  
between	  the	  expression	  of	  the	  various	  markers	  on	  CD4+	  T-­‐cells	  and	  viral	  load	  set	  
point.	  However,	  there	  was	  a	  positive	  correlation	  between	  viral	  load	  set	  point	  and	  
CD8+	  T-­‐cell	   activation	   levels	   as	   measured	   by	   CD38+HLA-­‐DR-­‐	   expression	  
(p=0.0240)	  (Figure	  4.7	  C)	  (Table	  4.2).	  Elevated	  CD38	  expression may	  be	  used	  as	  a	  
marker	  of	  CD8+	  T-­‐cell	   activation	  and	  appears	   to	  be	  a	  better	   correlate	  of	  HIV-­‐1	  
disease	   progression	   than	   when	   combined	   with	   HLA-­‐DR	   expression	   (Liu	   et	   al.,	  
1997).	   There	   was	   also	   a	   positive	   correlation	   between	   viral	   load	   set	   point	   and	  
CD8+	  T-­‐cell	  expression	  of	  CD95+	  (p=0.0267),	  PD1+	  (p=0.0312)	  (Figure	  4.7G	  and	  I).	  	  
However,	  when	  we	  adjusted	  the	  model	  for	  other	  T-­‐cell	  markers,	  none	  of	  the	  T-­‐
cell	  markers	  came	  up	  as	  significantly	  associated	  with	  viral	  set	  point	  (Table	  4.2).	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P = 0.0249 




























6 R = 0.019
P = 0.688























6 R = 0.041
P = 0.793




































































































Figure	   4.6.	   	   The	   relationship	   between	   CD8+	   and	   CD4+	   T-­‐cell	   activation	   (A-­‐F),	  
exhaustion	   (G-­‐H),	   apoptosis	   (I-­‐J)	   and	   senescence	   (K-­‐L)	   and	   viral	   load	   set	   point	  
(log10transformed)	   in	   19	   individuals	   during	   acute	   HIV	   infection.	  A	   smooth	   line	   was	  
generated	  by	  linear	  regression	  with	  quadratic	  equations.	  
R = 0.236
P = 0.0267
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Table	   4.2.	   General	   linear	  model	   analysis	   for	   the	   evaluation	   of	   associations	   between	  




Table	   4.3.	   General	   linear	  model	   analysis	   for	   the	   evaluation	   of	   associations	   between	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4.6. Plasma	  cytokine	  concentrations	  alone	  predict	  viral	  load	  set	  point	  
To	   assess	   the	   coupled	   impact	   of	   cellular	   expression	   markers	   and	   cytokines	  
measured	  during	  acute	  HIV-­‐1	  infection	  on	  viral	  load,	  a	  general	  linear	  model	  was	  
fitted	  to	  viral	  set	  point	  and	  the	  model	  was	  adjusted	  for	  both	  variables.	  Only	  12	  
individuals	   could	  be	   included	   in	   this	   analysis	   (i.e.,	   had	  both	   cytokine	   and	  T-­‐cell	  
surface	  expression	  data).	   	  Four	  cytokines	  (IL-­‐12p70,	  TNF-­‐α,	   IL-­‐10	  and	  IP-­‐10)	  and	  
cellular	  expression	  markers	   (CD38,	  PD-­‐1	  and	  CD95)	  were	   incorporated	   into	   this	  
model,	  each	  of	  which	  was	  significantly	  associated	  with	  viral	  load	  set	  point	  in	  the	  
unadjusted	  models.	  Higher	  levels	  of	  IL-­‐12p70	  were	  significantly	  associated	  with	  a	  
lower	  viral	  load	  set	  point	  –	  with	  every	  one	  log	  increase	  in	  IL-­‐12p70,	  viral	  set	  point	  
decreased	  by	  0.62	  log	  copies/ml	  (p=0.0259)	  (Table	  4.2).	  	  High	  expression	  levels	  of	  
IP-­‐10	   and	   IL-­‐10	  were	   significantly	   associated	  with	   an	   increase	   in	   viral	   set	   point	  
(p=0.0242	  and	  p=0.0158,	   respectively).	   	  After	  adjusting	   the	  model,	  none	  of	   the	  
cellular	   expression	   markers	   came	   up	   as	   significantly	   associated	   with	   viral	   set	  
point,	  however	  the	  small	  sample	  size	  may	  have	  been	  a	  limitation	  in	  this	  analysis.	  
	  
4.7. Variables	  predicting	  the	  rate	  of	  CD4+	  T-­‐cell	  decline	  
A	   general	   linear	  model	  was	   used	   to	   determine	   the	   effect	   of	   plasma	   and	   T-­‐cell	  
markers	  of	  immune	  activation	  measured	  during	  acute	  HIV-­‐1	  infection	  and	  on	  the	  
rate	  CD4+	  T-­‐cell	  decline	   (Table	  4.3).	   	  When	  the	  model	  was	  adjusted	   for	  plasma	  
and	  T-­‐cell	  markers	  of	   immune	  activation	  associated	  with	   viral	   load	   set	  point	   in	  
the	   univariate	   analysis,	   PD-­‐1	   expression	   on	   CD8+	   T-­‐cells	   was	   significantly	  
associated	  with	  CD4+	  T-­‐cell	  preservation	  (p=0.029).	  	  Plasma	  concentrations	  of	  IL-­‐
	   129	  
10	  and	  TNF-­‐α	  were	  significantly	  associated	  with	  a	  decline	   in	  CD4+	  T-­‐cell	  counts	  
(p=0.0057	  and	  p=0.0168,	  respectively),	  a	  notable	  but	  not	  significant	  trend	  for	  IP-­‐
10	   expression	   and	   lower	   CD4+	   T-­‐cell	   counts	   was	   also	   observed	   (p=0.083).	  We	  
observed	   no	   associations	   between	   the	   expression	   of	   the	   various	   markers	   on	  
CD4+	  T-­‐cells	  and	  the	  rate	  of	  CD4+	  decline.	  
	   130	  
5. Discussion:	  
Immune	   activation	   during	   HIV	   infection	   has	   been	   shown	   to	   be	   a	   major	  
contributor	   to	   HIV	   disease	   progression	   and	   is	   the	   product	   of	   inflammatory	  
responses	   to	   HIV-­‐1	   antigens,	   microbial	   translocation,	   HIV-­‐encoded	   Toll-­‐like	  
receptor	   ligands,	  and	   the	  homeostatic	   response	   to	  CD4+T-­‐cell	  depletion	   (Deeks	  
et	   al.,	   2004,	   Brenchley	   et	   al.,	   2006b,	   Meier	   et	   al.,	   2007).	   	   Although	   the	  
contribution	   of	   immune	   activation	   in	   HIV	   disease	   pathogenesis	   has	   been	  
extensively	   evaluated	   in	   chronic	   HIV	   infection,	   its	   role	   in	   primary	   infection	  
remains	   poorly	   defined.	   	   Moreover,	   the	   impact	   of	   cytokine	   and	   chemokine	  
expression	  patterns	  on	  the	  quality	  of	  the	  CD8+	  T-­‐cell	  responses	  during	  acute	  HIV-­‐
1	  infection	  is	  not	  well	  understood.	  	  One	  of	  the	  main	  findings	  of	  this	  study	  is	  that	  
the	   breadth	   and	   magnitude	   of	   the	   acute	   CD8+	   T-­‐cell	   response	   was	   inversely	  
correlated	  with	  plasma	  MIP-­‐1β.	  	  It	  is	  noteworthy	  to	  mention	  that	  the	  acute	  CD8+	  
T-­‐cell	   response	   was	   dominated	   by	   Nef-­‐specific	   responses	   and	   although	   we	  
cannot	  ascertain	   the	   type	  of	  cells	  which	  where	  responsible	   for	   the	  secretion	  of	  
this	   chemokine,	   these	   findings	  are	   in	   line	  with	  a	   recent	   report	   from	  Turk	  et	  al.	  
(2013)	   showing	   that	  Nef-­‐specific	   cells	   inversely	   correlated	  with	  plasma	  MIP-­‐1β.	  	  
These	   data	   are	   of	   importance,	   since	  MIP-­‐1β	   is	   produced	   by	   CD8+	   T-­‐cells	   upon	  
stimulation	   and	   the	   percentage	   of	   cells	   expressing	   MIP-­‐1β	   alone	   or	   in	  
combination	   with	   other	   functions	   have	   been	   previously	   associated	   with	   virus	  
control	  and	   inhibition	   (Ferrari	  et	  al.,	  2011,	  Betts	  et	  al.,	  2006,	  Freel	  et	  al.,	  2010,	  
Saunders	   et	   al.,	   2011).	   Previous	   studies	   have	   also	   demonstrated	   that	  MIP-­‐1β-­‐
producing	  CD8+	  T-­‐cells	  exert	  considerable	  immune	  pressure	  over	  viral	  replication	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(Ferrari	   et	   al.,	   2011,	   Almeida	   et	   al.,	   2009).	   It	   is	   intriguing	   that	   there	   exists	   an	  
inverse	   association	   between	   this	   important	   soluble	   antiviral	   mediator	   and	   the	  
acute	   CD8+	   T-­‐cell	   responses.	   	   Given	   that	  MIP-­‐1β	   has	   been	   identified	   as	   a	   key	  
determinant	  of	  protective	  immunity,	  our	  current	  findings	  are	  in	  line	  with	  earlier	  
reports	   (Chapters	   2	   and	   3),	   which	   indicate	   that	   early	   Nef	   CD8+	   T-­‐cell	   may	   be	  
ineffective	   and	   are	   related	   to	   higher	   viral	   loads.	   	   These	   data	   provide	   some	  
rationale	   for	   the	  association	  between	  early	  Nef	   responses	  and	  viremia.	   It	  could	  
also	  be	  that	  the	  MIP-­‐1β	  measured	  in	  plasma	  is	  not	  necessarily	  expressed	  by	  HIV-­‐
specific	   CD8+	   T-­‐cells	   but	   rather	   a	   product	   of	   bystander	   activated	   cells.	   	   Thus,	  
MIP-­‐1β	   in	   plasma	   may	   not	   reflect	   the	   potency	   of	   the	   HIV-­‐specific	   immune	  
response	  but	  just	  generalized	  immune	  activation.	   	  Further	   investigations	  will	  be	  
needed	  to	  determine	  the	  nature	  of	  the	  relationship	  between	  acute	  Nef-­‐specific	  
responses	  and	  MIP-­‐1β-­‐production,	  the	  lack	  of	  expression	  of	  this	  key	  chemokine	  
may	   be	   related	   to	   the	   generation	   of	   an	   ineffective	   antiviral	   immune	   response	  
leading	  to	  faster	  disease	  progression.	  	  
	  
We	   show	   that	   plasma	   pro-­‐inflammatory	   TNF-­‐α	   levels	   were	   directly	   associated	  
with	   rapid	  CD4+	  T-­‐cell	   loss	  and	  higher	   IP-­‐10	   levels	  were	  significantly	  associated	  
with	  higher	  HIV	  viral	  loads	  and	  rapid	  CD4+	  T-­‐cell	  loss.	  	  Recently,	  IP-­‐10	  was	  shown	  
to	  be	  the	  only	  cytokine	  among	  the	  26	  cytokines	  tested	  that	  was	  always	  positively	  
correlated	  with	  disease	  progression	  during	  Fiebig	   stages	   III-­‐V	   in	  HIV-­‐1	   infection	  
(Liovat	  et	  al.,	  2012,	  Jiao	  et	  al.,	  2012).	  	  The	  strong	  predictive	  capacity	  of	  IP-­‐10	  was	  
confirmed	   in	   an	   independent	   group	   of	   88	   HIV-­‐1	   infected	   individuals	   where	  
plasma	   IP-­‐10	   levels	   were	   an	   earlier	   marker	   with	   strong	   predictive	   value	   for	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disease	   progression	   (Liovat	   et	   al.,	   2012).	   Widespread	   acute-­‐phase	   CD4+	   T-­‐cell	  
destruction	   is	   a	   hallmark	   of	   pathogenic	   immunodeficiency	   virus	   infections	   in	  
humans	   and	   primates,	   and	   cytokines	   induced	   in	   acute	   HIV	   infection	   may	  
contribute	  to	  the	  high	  levels	  of	  CD4+	  T-­‐cell	  loss	  that	  occurs	  at	  this	  time	  (Klein	  et	  
al.,	   1996,	   Gasper-­‐Smith	   et	   al.,	   2008).	   	   Although	   the	   apoptosis	   of	   HIV-­‐infected	  
CD4+	  T-­‐cells	  may	  restrict	  viral	  spread,	  cytokines	  may	  also	  drive	  the	  destruction	  of	  
bystander	  uninfected	  CD4+	  T-­‐cells	  (Gasper-­‐Smith	  et	  al.,	  2008).	  	  The	  upregulation	  
of	   TNF-­‐α	   in	   acute/early	   HIV-­‐1	   infection	   is	   thought	   to	   drive	   apoptosis	   through	  
binding	   to	  cellular	  TNF	  receptors	   (Klein	  et	  al.,	  1996,	  Gasper-­‐Smith	  et	  al.,	  2008).	  	  
This	   is	   supported	   by	   the	   observation	   that	   peak	   plasma	   levels	   of	   apoptotic	  
microparticles,	  TNFR2,	  and	  Fas	  ligand	  were	  observed	  at	  the	  time	  of	  maximal	  TNF-­‐
α	  when	  viremia	  was	  also	  at	  its	  peak	  (Gasper-­‐Smith	  et	  al.,	  2008).	  
	  
Previous	  studies	  have	  demonstrated	  that	  HIV-­‐infected	  patients	  have	  significantly	  
higher	   circulating	   IL-­‐10	   levels	   than	   healthy	   controls,	   with	   the	   highest	   levels	   in	  
patients	  with	  a	  high	  viral	  load	  and	  a	  more	  rapid	  disease	  progression	  (Stylianou	  et	  
al.,	   1999,	   Brockman	   et	   al.,	   2009,	   Srikanth	   et	   al.,	   2000,	   Roberts	   et	   al.,	   2010).	  	  
Similarly, we	   report	   that	   high	   plasma	   immunoregulatory	   IL-­‐10	   levels	   were	  
significantly	  associated	  with	  higher	  HIV	  viral	  load	  and	  rapid	  CD4+	  T-­‐cell	  loss.	  	  Data	  
from	  HIV-­‐1	  and	  SIVmac	  infections	  have	  demonstrated	  that	  IL-­‐10	  is	  induced	  after	  
the	   first	   burst	   of	   pro-­‐inflammatory	   cytokines,	   possibly	   to	   dampen	   the	   acute	  
“cytokine	  storm”	  (Kornfeld	  et	  al.,	  2005,	  Katsikis	  et	  al.,	  2011,	  Stacey	  et	  al.,	  2009).	  	  
Production	   of	   this	   anti-­‐inflammatory	   cytokine	   might	   participate	   in	   disease	  
progression	   by	   inhibiting	   HIV-­‐1-­‐specific	   T-­‐cell	   responses	   during	   acute	   infection	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and	  thus	  contribute	  to	  viral	  persistence	   (Couper	  et	  al.,	  2008,	  Estes	  et	  al.,	  2006,	  
Brooks	   et	   al.,	   2008,	   Brooks	   et	   al.,	   2006).	   	   However,	   the	   role	   of	   IL-­‐10	   in	   HIV-­‐1	  
infection	   is	   complex	   as	   other	   studies	   have	   also	   shown	   that	   polymorphisms	  
associated	   with	   decreased	   IL-­‐10	   production	   are	   associated	   with	   an	   increased	  
likelihood	   of	   HIV-­‐1	   acquisition	   and	   an	   accelerated	   rate	   of	   CD4+	  T	   cell	   decline,	  
particularly	   in	   late-­‐stage	   disease,	   suggesting	   that	   high	   IL-­‐10	   expression	   may	  
reduce	  susceptibility	   to	  HIV-­‐1	   infection	  and	  protect	  against	  disease	  progression	  
(Erikstrup	   et	   al.,	   2007,	   Naicker	   et	   al.,	   2009,	   Shin	   et	   al.,	   2000).	   Based	   on	   our	  
findings,	  we	  hypothesize	  that	  high	  CD4+	  T-­‐cell	  loss	  rates	  and	  viral	  loads	  observed	  
in	  individuals	  with	  higher	  levels	  of	  IL-­‐10	  may	  be	  the	  result	  of	  a	  stunted	  adaptive	  
immune	   response	   or	   immunosuppression	   that	   allows	  
viruses	  to	  persist	  unchecked	  by	  the	  immune	  system.	  
	  
We	  found	  that	  higher	  concentrations	  of	  IL-­‐12p70	  associated	  with	  lower	  viral	  set	  
point.	   	   Our	   findings	  corroborate	   prior	   work	   describing	   the	   role	   of	   IL-­‐12p70	   in	  
delaying	  HIV-­‐1	  disease	  progression	  (Roberts	  et	  al.,	  2010).	  	  In	  the	  macaque	  model	  
of	  SIV	   infection,	   IL-­‐12p70	  treatment	  during	  acute	   infection	  was	  associated	  with	  
decreased	   viral	   loads,	   preservation	   of	   HIV-­‐specific	   CD8+	   T-­‐cells	   and	   survival	  
(Ansari	   et	   al.,	   2002)	   and	   data	   from	   in	   vitro	   studies	   also	   suggest	   that	   IL-­‐12	   can	  
restore	  HIV-­‐specific	  cell-­‐mediated	  immunity	  in	  HIV-­‐infected	  individuals	  (Clerici	  et	  
al.,	  1993).	  	  
Expression	  of	   the	   inhibitory	  marker	  PD-­‐1	   is	  known	  to	  play	  an	   important	   role	   in	  
resolving	  immune	  activation	  and	  T-­‐cell	  proliferation	  (Sharpe	  et	  al.,	  2007,	  Keir	  et	  
al.,	  2007,	  Estes	  et	  al.,	  2008,	  Freeman	  et	  al.,	  2000,	  Day	  et	  al.,	  2006).	  We	  show	  in	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this	   study	   that	   early	   elevation	   of	   PD-­‐1	   expression	   correlated	   directly	   with	  
preservation	  of	  CD4+	  T-­‐cells.	   	   	  Our	  results	  are	   in	   line	  with	  a	  report	   from	  an	  SIV	  
study,	  which	  demonstrated	  that	  the	  early	  upregulation	  of	  PD-­‐1	  is	  associated	  with	  
the	  resolution	  of	  immune	  activation	  and	  slower	  disease	  progression	  (Estes	  et	  al.,	  
2008).	  The	  study	  suggested	  that	  decreased	  immune	  activation	  mediated	  by	  early	  
PD-­‐1	  expression	   in	  sooty	  Mangabeys	  may	  represent	  an	   important	  cause	  for	  the	  
lower	  viral	  set	  point	  levels	  compared	  with	  rhesus	  macaques	  (Estes	  et	  al.,	  2008).	  	  
In	  this	  study,	  we	  hypothesize	  that	  early	  activation	  of	  PD-­‐1	  expression	  may	  lower	  
immune	   activation	   during	   acute	   infection	   and	   therefore	   attenuate	   the	  
immunopathogenic	   effects	   driven	   by	   persistent	   immune	   activation	   such	   as	  
CD4+	  T-­‐cell	   loss.	   	  The	  delayed	   induction	  of	  PD-­‐1	  possibly	   fails	   to	  diminish	  T-­‐cell	  
activation	  after	   the	  acute	  window	  of	   infection,	   resulting	   in	   sustained	  activation	  
and	  dysfunction	  seen	  in	  chronic	  HIV-­‐1	  infection	  (Estes	  et	  al.,	  2008,	  Zhang	  et	  al.,	  
2007,	  Day	  et	  al.,	  2006,	  Trautmann	  et	  al.,	  2006).	  Our	   findings	  suggest	   that	  early	  
control	  of	   immune	  activation	  by	  host	   immunoregulatory	  mechanisms	  may	  be	  a	  
determinant	   of	   disease	   outcomes.	   	   Although	   progression	   of	   HIV-­‐1	   infection	   in	  
terms	   of	   CD4+	   T-­‐cell	   decline,	   has	   been	   correlated	   to	   PD-­‐1	   T-­‐cell	   subsets	   in	  
chronic	  infection	  (Liovat	  et	  al.,	  2012,	  Palmer	  et	  al.,	  2013),	  to	  our	  knowledge,	  this	  
is	  the	  first	  time	  this	  association	  has	  been	  described	  in	  primary	  HIV-­‐1	  infection.	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6. Conclusion	  
In	  summary,	  the	  impact	  of	  acute	  phase	  immune	  activation	  and	  plasma	  cytokine	  
levels	  were	  characterized	  and	  an	  association	  of	  these	  factors	  with	  the	  magnitude	  
and	  breadth	  of	  CD8+	  T-­‐cell	  responses	  was	  studied.	  We	  showed	  that	  acute	  phase	  
expression	  of	  MIB-­‐1β	  was	  inversely	  associated	  with	  the	  magnitude	  and	  breadth	  
of	   acute	   CD8+	   T-­‐cell	   responses.	   	   We	   also	   demonstrate	   the	   potential	   to	   use	  
plasma	  cytokine	  concentrations	  and	  estimates	  of	  T-­‐cell	  dysfunction	  during	  acute	  
HIV-­‐1	  infection	  to	  predict	  subsequent	  disease	  progression.	  	  Early	  IL-­‐10,	  IP-­‐10	  and	  
IL-­‐12p70	  levels	  were	  more	  predictive	  of	  viral	  load	  set	  point	  than	  either	  CD38	  and	  
PD-­‐1	  expression	  or	  CD4+	  T-­‐cell	  counts	  and	  IL-­‐10,	  IP-­‐10	  and	  PD-­‐1	  expression	  levels	  
also	   correlated	   with	   CD4+T-­‐cell	   loss.	   	   The	   role	   of	   these	   markers	   as	   an	   early	  
independent	   predictor	   of	   rapid	   disease	   progression	  was	   detected	   here	   despite	  
the	   relatively	   small	   number	   of	   subjects	   evaluated,	   supporting	   their	   predictive	  
strength.	   	   These	   data	   suggest	   that	   high	   levels	   of	   antigenaemia	   in	   early	   HIV-­‐1	  
infection	   are	   associated	   with	   immune	   regulatory	   signals	   mediated	   through	  
and/or	   by	   these	   biomarkers	   and	   thus	   limit	   or	   impair	   the	   ability	   of	   HIV-­‐specific	  
cellular	  immune	  responses	  to	  effectively	  control	  viraemia	  to	  a	  low	  set	  point.	   	   In	  
addition	  to	  or	  in	  combination	  with	  canonical	  parameters,	  novel	  early	  biomarkers,	  
which	   are	   indicative	   of	   early	   immune	   dysfunction	   and	   are	   also	   predictive	   of	  
subsequent	   HIV	   disease	   prognosis,	   may	   inform	   approaches	   for	   evaluating	   the	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Chapter	  5 :	  General	  Discussion	  and	  Future	  
Directions	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1. Discussion	  and	  Future	  Directions	  
Three	   decades	   since	   research	   of	   the	   development	   of	   a	   vaccine	   to	   prevent	   or	  
control	  HIV-­‐1	  infection	  began	  and	  despite	  strong	  optimism	  from	  some,	  definitive	  
evidence	  that	  a	  robustly	  protective	  vaccine	  can	  be	  made	  is	  still	  lacking	  (Schiffner	  
et	  al.,	  2013).	   	  HIV	   is	  currently	  the	  most	  studied	  and	  most	  understood	  virus	  that	  
has	  affected	  humankind	  and	  we	  have	  seen	  many	  advances	   in	  the	  field	  of	  HIV-­‐1	  
immunology	  and	  virology.	  	  Recent	  advances	  in	  the	  understanding	  of	  the	  kinetics	  
and	   quality	   of	   early	   immune	   responses	   to	   HIV-­‐1	   have	   emphasized	   the	  
importance	   of	   events	   in	   early	   infection	   as	   determinants	   of	   the	   subsequent	  
disease	  course	   (McMichael	  et	  al.,	  2010).	   	   	   The	  acute	  phase,	  which	   includes	   the	  
eclipse	  phase	  before	  viremia	  is	  detected	  and	  the	  viremic	  phase	  before	  viral	  load	  
set-­‐point	   is	   reached,	   is	   crucial	   for	   target	   T-­‐cell	   availability,	   seeding	   of	   latent	  
reservoirs,	  and	  the	  initiation	  and	  expansion	  of	  antiviral	  immune	  responses	  by	  the	  
host	  (Katsikis	  et	  al.,	  2011).	  	  The	  appreciation	  of	  the	  role	  of	  acute-­‐phase	  immune	  
events	   in	  HIV	   pathogenesis	   highlights	   the	   need	   for	   vaccine-­‐associated	   immune	  
responses	   to	   intervene	   during	   the	   earliest	   stages	   of	   infection	   in	   order	   to	  
modulate	  these	  critical	  events.	  	  	  
	  
The	  key	  role	  of	  CD8+	  T-­‐cells	  in	  the	  initial	  control	  of	  HIV-­‐1	  replication	  is	  a	  concept	  
that	   has	   stood	   the	   test	   of	   time	   and	   multiple	   lines	   of	   evidence	   support	   the	  
importance	   of	   virus-­‐specific	   CD8+	   T-­‐cells	   in	   control	   of	   HIV	   replication.	   	   The	  
induction	  of	  HIV-­‐specific	  CD8+	  T-­‐cell	  responses	  in	  primary	  infection	  is	  temporally	  
associated	  with	  containment	  of	  the	  acute	  viremia	  and	  the	  depletion	  of	  CD8+	  T-­‐
cells	  from	  simian	  SIV-­‐infected	  macaques	  impairs	  control	  of	  viremia.	  	  In	  addition,	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strong	  HIV-­‐specific	   CD8+	   T-­‐cell	   responses	   are	   sustained	   in	   elite	   controllers	   and	  
the	   emergence	   of	   viral	   variants	   able	   to	   escape	   recognition	   by	   epitope-­‐specific	  
CD8+	   T-­‐cell	   responses	   in	   both	   HIV-­‐1	   and	   SIV	   illustrates	   the	   selective	   pressure	  
exerted	  by	  CD8+	  T-­‐cells	  on	  viral	  replication	  in	  vivo	  (Walker	  and	  McMichael,	  2012,	  
McMichael	  et	  al.,	  2010).	  	  However,	  the	  correlates	  of	  immune	  protection	  against	  
HIV-­‐1	   infection	   remain	   incompletely	   understood	   mainly	   because	   induction	   of	  
HIV-­‐1-­‐specific	   CD8+	   T-­‐cell	   responses	   in	   natural	   infection	   does	   not	   result	   in	  
protective	  immunity	  or	  complete	  control	  but	  results	  in	  a	  lifelong	  infection,	  which	  
in	  the	  absence	  of	  antiretroviral	  therapy,	  may	  lead	  to	  AIDS	  and	  death	  (Garber	  and	  
Feinberg,	  2006).	  The	  development	  of	  an	  efficacious	  vaccine	  will	  be	  facilitated	  by	  
knowing	  the	  type	  of	   immune	  responses	  that	  will	  be	  protective	  against	   infection	  
and/or	   disease	   progression	   (Plotkin,	   2013).	   	   Indeed,	   knowledge	   on	   the	   precise	  
functional	  profile	  of	  CD8+	  T-­‐cells	  that	  might	  lead	  to	  permanent	  control	  of	  HIV-­‐1,	  
or	  prevention	  of	  disseminated	  infection	  is	  still	  lacking.	  	  
	  
We	   aimed	   to	   characterize	   CD8+	   T-­‐cell	   responses	   measured	   during	   acute	   and	  
primary	  HIV-­‐1	  infection	  and	  assess	  their	  role	  in	  the	  control	  of	  HIV-­‐1	  infection	  in	  
subtype	  C	   infected,	   antiretroviral	   naive	   subjects	   from	  4	  weeks	   up	   to	   52	  weeks	  
post	   infection.	   The	   impact	   of	   acute	   phase	   cytokine	   expression	   and	   immune	  
activation	   on	   disease	   progression	   was	   also	   assessed.	   	   Our	   findings	   are	  
summarized	  below	  and	  depicted	  in	  Figure	  5.1,	  a	  number	  of	  recommendations	  for	  
future	  research	  are	  also	  given.	  	  	   
	  




















Figure	  5.1	  Schematic	  diagram	  summarising	  the	  main	  findings	  of	  the	  current	  study.	  (A)	  
The	   proposed	   model	   of	   control	   of	   viral	   replication	   or	   slow	   disease	   progression	   is	  
associated	  with	   the	  acute	  phase	  expression	  of	   IL-­‐12p70	  and	  high	  early	  expression	  of	  
PD-­‐1	  on	  CD8+	  T	  cells	  that	  subsequently	  resolves;	  the	  preservation	  of	  CD4+	  T-­‐cells	  and	  
induction	  of	   broad	   and	  persistent	  Gag-­‐specific	   effector	   and	   central	  memory	   CD8+	   T-­‐
cell	   responses;	   (B)	   Lack	   of	   control	   of	   viral	   replication	   or	   rapid	   disease	   progression	   is	  
associated	  with	  the	  acute	  phase	  expression	  of	  IL-­‐10,	  IP-­‐10,	  TNF-­‐α 	  and	  the	  rapid	  loss	  of	  
CD4+	  T-­‐cells;	  the	  majority	  of	  the	  epitopes	  targeted	  in	  primary	  infection	  are	  within	  Nef,	  
Gag-­‐specific	  CD8+	  T-­‐cell	  responses	  are	  narrow	  and	  do	  not	  persist,	  and	  PD-­‐1	  expression	  
kinetics	  on	  CD8+	  T	  cells	  are	  slow	  and	  fail	  to	  resolve	  following	  acute	  viremia.	  	  
	  
	   140	  
2. The	  acute	  CD8+	  T-­‐cell	  response	  and	  HIV-­‐1	  dynamics	  
Earlier	   studies	   have	   demonstrated	   the	   presence	   of	   HIV-­‐1	   specific	   CD8+	   T-­‐cells	  
with	   limited	   breadth	   during	   acute	  HIV-­‐1	   infection	   and	   our	   study	   confirms	   this.	  	  
Our	   data	   corroborate	   findings	   from	   a	   clade	   C	   cohort	   demonstrating	   that	   the	  
magnitude	   and	   breadth	   of	   IFN-­‐γ	   ELISPOT	   assay	   responses	   measured	   within	   3	  
months	  post-­‐infection	  are	  unrelated	  to	  the	  course	  of	  disease	  in	  the	  first	  year	  of	  
infection	  and	  have	  low	  predictive	  power	  for	  the	  viral	  set	  point	  (Gray	  et	  al.,	  2009).	  	  
Also	   consistent	   with	   previous	   reports,	   during	   the	   first	   weeks	   of	   infection	   Nef	  
protein	  was	  most	   frequently	   recognized	  by	  CD8+	  T-­‐cells	  and	  was	   the	   target	   for	  
the	   earliest	   response	   (Frahm	   et	   al.,	   2004,	   Lichterfeld	   et	   al.,	   2004b).	   The	   initial	  
HIV-­‐1-­‐specific	   CD8+	  T-­‐cell	   responses	  which	   are	   narrowly	   directed	   against	   a	   few	  
epitopes	  have	  been	   shown	   to	   suppress	  HIV-­‐1	   as	   viral	   load	   is	   declining	   from	   its	  
peak	   (Goonetilleke	  et	   al.,	   2009).	   In	   contrast,	   acute	  Nef-­‐specific	   responses	  were	  
not	  associated	  with	  control	  of	  viremia	  from	  its	  acute	  phase	  peak	  suggesting	  that	  
CD8+	   T-­‐cells	   targeting	  Nef	  during	   acute	  HIV-­‐1	   infection	   are	   ineffective.	   	   In	   fact,	  
we	  observed	  that	  an	  increase	  in	  the	  magnitude	  and	  breadth	  of	  Nef-­‐specific	  CD8+	  
T-­‐cell	  responses	  was	  associated	  with	  higher	  viral	  loads	  during	  acute	  and	  primary	  
infection.	  	  We	  also	  found	  no	  correlation	  between	  the	  presence	  of	  acute	  phase	  T-­‐
cell	   responses	   targeting	   all	   other	   regions	   of	   the	   HIV-­‐1	   proteome	   and	   the	  
concurrent	   decline	   in	   viremia.	   	   In	   addition,	   CD8+	   T-­‐cell	   responses	   measured	  
within	   the	   first	   18	   weeks	   of	   HIV-­‐1	   infection	   and	   their	   immunodominance	  
patterns	  did	  not	  have	  a	  significant	  demonstrable	  impact	  on	  viral	  load	  set	  point.	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3. Acute	  Nef-­‐specific	  CD8+	  T-­‐cell	  responses:	  the	  good	  and	  the	  bad	  
Our	  findings	  that	  Nef-­‐specific	  CD8+	  T-­‐cell	   responses	  were	  dominant	  but	  did	  not	  
suppress	  viral	   replication	  during	  and	  after	  acute	   infection	  are	  similar	  to	  findings	  
from	   other	   studies	  (Turk	   et	   al.,	   2013,	   De	   La	   Cruz	   et	   al.,	   2014,	   Novitsky	   et	   al.,	  
2003),	   but	  are	   also	   in	   contrast	   with	   recent	  data	   from	  Riou	   et	  al.	   (2014)	   and	  
Adland	  et	  al.	  (2013)	  which	  show	  a	  correlation	  between	  Nef-­‐specific	  CD8+	  T-­‐cells	  
and	   a	   lower	  levels	   of	   viral	   replication	   (Riou	   et	   al.,	   2014,	   Adland	   et	   al.,	   2013).	  
Similarly,	   SIV	   studies	  have	  also	  yielded	  conflicting	   results	  as	   shown	  by	  a	   recent	  
study	   which	   revealed	   that	  vaccine-­‐induced	   Nef-­‐specific	   T-­‐cells	   failed	   to	  
control	  viremia	  and	  easily	  escaped	  during	  acute	  infection	  (Iwamoto	  et	  al.,	  2014),	  
whilst	  results	  from	  a	  recent	  SIV-­‐macaque	  vaccine	  study	  suggest	  that	  Nef-­‐specific	  
CD8+	   T-­‐cell	   responses	   have	   an	   important	  contribution	   in	   the	  
control	  of	  viremia	  (Takahashi	   et	   al.,	   2013).	   	   Nef	   has	   been	   shown	   to	   exhibit	   a	  
variety	  of	  in	  vitro	  functions	  that	  may	  modulate	  pathogenesis,	  including	  HLA	  class	  
I	   down-­‐regulation	   (Schwartz	   et	   al.,	   1996),	   CD4+	   T-­‐cell	   down-­‐regulation	   (Garcia	  
and	  Miller,	   1991),	   enhancement	   of	   virion	   infectivity	   (Munch	   et	   al.,	   2007)	   and	  
stimulation	  of	   viral	   replication	   in	  PBMC	   (Miller	   et	   al.,	   1994).	   	  Although	   the	  Nef	  
protein	   is	   variable	   overall,	   its	   central	   region	   is	   as	   conserved	   as	   that	   of	   Gag	  
(Fischer	   et	   al.,	   2006)	   and	   the	   conflicting	   reports	   on	   the	   role	   of	   Nef	   in	   HIV-­‐1	  
infection	   may	   be	   attributed	   to	   the	   different	   targets	   of	   CD8+	   T-­‐cell	   responses	  
within	  the	  Nef	  region,	  where	  CD8+	  T-­‐cell	  responses	  implicated	  in	  reducing	  early	  
viremia	   are	   directed	   against	  more	   conserved	   functional	  domains	  that	   promote	  
viral	   persistence	  in	  vivo,	   such	  those	   for	  MHC	   class	   I	   downregulation	   (Adland	   et	  
al.,	   2013,	  Mothe	   et	   al.,	   2011,	   De	   La	   Cruz	   et	   al.,	   2014,	  Mwimanzi	   et	   al.,	   2013).	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There	   is	  enough	  data	   from	  acute	  HIV-­‐1	  and	  nonhuman	  primate	  vaccine	  studies	  
that	  clearly	  suggest	  that	  Nef-­‐specific	  CD8+	  T-­‐cell	  responses	  have	  the	  potential	  to	  
significantly	  control	  viral	  replication.	  Although	  limited	  by	  the	  number	  of	  subjects	  
in	   our	   cohort,	   our	   data	   suggest	   that	  even	   though	   epitopes	   in	   Nef	   are	   highly	  
immunogenic	  as	  well	  as	  immunodominant	  during	  acute	  HIV-­‐1	  infection,	  using	  the	  
whole	  Nef	  protein	  as	  a	  vaccine	   immunogen	  may	   likely	  lead	  to	  targeting	  of	  T-­‐cell	  
responses	  that	  are	   rapidly	   lost	   or	   escape	   with	   little	   effect	  on	   the	   course	   of	  
disease	  progression.	  	  Thus	  further	  studies	  should	  aim	  to	  characterize	  CD8+	  T-­‐cell	  
epitopes	   within	   conserved	   regions	   of	   Nef,	   likely	  representing	  
important	  functional	  domains.	   	   Epitopes	   within	   these	   conserved	   regions	   may	  
eventually	  be	  used	  as	  immunogens	  in	  future	  vaccines.	  
	  
4. Viral	  load	  kinetics	  mirror	  evolving	  Gag	  CD8+	  T-­‐cell	  responses	  	  
Consistent	  with	  previous	   studies,	   there	  was	  a	  broadening	  of	   the	  T-­‐cell	   immune	  
response	  within	  the	  follow	  up	  period.	  	  Similar	  to	  reports	  from	  elite	  controller	  SIV	  
and	   HIV-­‐1	   studies,	   the	   broadening	   and	   preservation	   of	   Gag–specific	   T-­‐cell	  
responses	   during	   the	   follow	   up	   period	   was	   associated	   with	   better	   control	   of	  
viremia	  and	  lower	  viral	  load	  set	  point	  (Turk	  et	  al.,	  2013,	  Perez	  et	  al.,	  2013,	  Zuniga	  
et	   al.,	   2006,	   Geldmacher	   et	   al.,	   2007,	   Kiepiela	   et	   al.,	   2007,	   Masemola	   et	   al.,	  
2004a,	   Streeck	   et	   al.,	   2009b,	   Schieffer	   et	   al.,	   2014,	   Rolland	   et	   al.,	   2008,	  
Honeyborne	   et	   al.,	   2007,	   Borghans	   et	   al.,	   2007).	   	   Interestingly,	   insights	   have	  
recently	  emerged	  from	  the	  STEP	  trial	  showing	  that	  vaccine	  recipients	  with	  T-­‐cell	  
responses	   targeting	   three	   or	   more	   Gag	   epitopes	   pre-­‐infection	   showed	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significantly	   lower	  plasma	  viremia	  compared	  to	  subjects	  without	  Gag	  responses	  
following	   infection,	   thus	   further	   confirming	   the	   role	   of	   Gag	   responses	   in	  
controlling	  viremia	  (Janes	  et	  al.,	  2013).	  	  
During	  the	  52	  week	  follow	  up	  period	  we	  also	  observed	  that	  although	  many	  of	  the	  
acute/early	  HIV-­‐1-­‐specific	  IFN-­‐γ	  ELISPOT	  CD8+	  T-­‐cell	  responses	  targeting	  Gag	  and	  
Pol	  persisted,	  the	  majority	  of	  acute	  and	  early	  T-­‐cell	  responses	  targeting	  Env,	  Nef	  
and	   other	   regulatory	   proteins	   waxed	   and	   waned	   over	   time	   and	   could	   not	   be	  
detected	   at	   the	   last	   time	   point	   evaluated.	   Indeed,	   although	   the	   earliest	   T-­‐cell	  
responses	  against	  epitopes	   in	  Gag	  and	  Pol	  were	  subdominant	   in	  relation	  to	  Nef	  
(fewer	   than	   the	   epitopes	   targeted	   in	   Nef),	   many	   of	   these	   responses	   were	  
maintained	  during	  the	  first	  year	  of	  infection.	  	  Our	  findings	  are	  in	  line	  with	  reports	  
from	  studies	  showing	  that	  targeting	  of	  dominant	  epitopes	  within	  highly	  variable	  
regions	   of	   the	  HIV-­‐1	   proteome	  often	   result	   in	   rapid	   escape	   and	   limited	   fitness	  
cost	   to	   the	   virus,	   although	   we	   could	   not	   directly	   confirm	   this	   in	   this	   study	  
because	  Nef	  was	  not	  sequenced.	   	  However,	   in	  T-­‐cells	  targeting	  more	  conserved	  
and	   fitness	   constrained	   HIV-­‐1	   regions	   escape	   is	   slow	   and	   although	   these	  
conserved	   epitopes	   are	   targeted	   in	   acute	   infection,	   responses	   are	   often	  
subdominant	  (Liu	  et	  al.,	  2009b,	  Goonetilleke	  et	  al.,	  2009,	  Mlotshwa	  et	  al.,	  2010,	  
Martinez-­‐Picado	   et	   al.,	   2006,	   Schneidewind	   et	   al.,	   2007,	   Liu	   et	   al.,	   2013).	  	  
Although	   many	   of	   the	   persistent	   responses	   targeted	   epitopes	   in	   Pol,	   these	  
responses	  did	  not	  have	  a	  significant	  impact	  on	  viral	  load	  set	  point.	  	  However,	  the	  
preservation	  of	   an	   acute	  CD8+	  T-­‐cell	   response	  against	   even	  a	   single	   epitope	   in	  
Gag	  had	  a	  demonstrable	  impact	  on	  viral	  load	  set	  point.	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Interestingly,	   some	   of	   the	   early	   T-­‐cell	   responses	   which	   where	   no	   longer	  
detectable	  when	   using	   overnight	   ELISPOT	   assay	  were	   detectable	  when	   PBMCs	  
were	   stimulated	  with	   corresponding	   peptides	   and	   cultured	   for	   10	   days	   before	  
measuring	  IFN-­‐γ	  secretion	  via	  the	  ELISPOT	  assay.	  	  The	  presence	  of	  these	  cultured	  
ELISPOT	  central	  memory	  type	  T-­‐cell	  responses	  targeting	  epitopes	  in	  Pol,	  Env,	  Nef,	  
Regulatory	  and	  Accessory	  proteins	  were	  not	  significantly	  associated	  with	  viral	  set	  
point.	   However,	   cultured	   ELISPOT	   Gag-­‐specific	   responses	   correlated	   with	   low	  
plasma	  viremia,	   thus	   further	  providing	  evidence	  on	   the	   favourable	   role	  of	  Gag-­‐
specific	   T-­‐cell	   responses	   in	   the	   control	   of	   viral	   replication.	   This	   is	   in	   line	   with	  
earlier	  studies	  conducted	  in	  human	  and	  non-­‐human	  models	  demonstrating	  that	  
central	  memory	   cells	   are	   critical	   determinants	   of	   cytotoxicity	   in	   HIV	   and	   other	  
infectious	  diseases	   (Migueles	  et	   al.,	   2008,	  Calarota	  et	   al.,	   2008,	  Ndhlovu	  et	   al.,	  
2012).	  	  	  
	  
When	  we	  sequenced	  Gag	  in	  order	  to	  assess	  the	  impact	  of	  T-­‐cell	  responses	  on	  the	  
viral	  landscape,	  our	  results	  revealed	  that	  the	  majority	  of	  epitopes	  that	  stimulated	  
T-­‐cell	  responses	  remained	  invariant	  over	  the	  first	  year	  after	  infection,	  consistent	  
with	   data	   from	   previous	   studies	   (Liu	   et	   al.,	   2013,	   Goonetilleke	   et	   al.,	   2009,	  
Mlotshwa	  et	  al.,	  2010).	  	  Although	  the	  contribution	  of	  T-­‐cells	  specific	  for	  epitopes	  
that	   did	   not	   mutate	   over	   the	   first	   year	   of	   infection	   is	   hard	   to	   assess,	   the	  
significant	  negative	  association	  between	  the	  breadth	  of	  responses	  against	  these	  
invariant	   epitopes	   and	   viral	   load	   set	   point	   suggests	   that	   these	   responses	   are	  
important.	   	   Moreover,	   these	   data	   are	   consistent	   with	   the	   observation	   that	  
invariant	  epitopes	  occurring	  in	  conserved	  regions	  of	  HIV-­‐1	  (mainly	  Gag)	  are	  rare	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during	  the	  first	  year	  of	  infection	  since	  escape	  mutations	  might	  have	  too	  great	  a	  
fitness	  cost	  for	  the	  virus.	  
In	   order	   to	   decrease	   the	   incidence	   of	   HIV	   acquisition	   after	   sexual	   exposure	  
and/or	  to	  contain	  virus	  replication	  at	  an	  initial	  site	  of	  infection,	  an	  effective	  AIDS	  
vaccine	   will	   most	   likely	   need	   to	   elicit	   high	   levels	   of	   fully	   functional	   T-­‐cell	  
precursors	   that	  migrate	   to	   relevant	  mucosal	   tissues	  and	  are	  also	   competent	   to	  
respond	  to	  HIV	  infection	  and	  expand	  into	  effector	  cells	  more	  rapidly	  than	  occurs	  
in	   natural	   HIV	   infection	   (Garber	   and	   Feinberg,	   2006,	   Blankson	   et	   al.,	   2002,	  
Reynolds	  et	  al.,	  2005).	  Our	  data	  suggest	  that	  in	  order	  to	  combat	  viral	  replication	  
more	  rapidly	  than	  occurs	  in	  natural	  infection,	  HIV	  vaccines	  would	  need	  to	  induce	  
greater	   breadth	   of	   CD8+	   T-­‐cell	   responses	   which	   can	   recognize	   numerous	   Gag	  
epitopes	  resulting	  in	  lower	  levels	  of	  viremia	  and	  a	  slower	  disease	  progression.	  	  In	  
a	  recent	  study,	  monkeys	  were	  vaccinated	  with	  replicating	  RhCMV	  vectors	  before	  
challenge	  with	  SIV	  and	  the	  breadth	  of	  responses	  to	  Gag	  epitopes	  were	  strongly	  
associated	   with	   the	   striking	   control	   of	   SIV	   observed	   in	   50%	   of	   the	   challenged	  
monkeys,	   an	   effect	   attributed	   to	   the	   robust	   CD8+	  T-­‐cell	   responses	   that	   was	  
induced	  by	  the	  vaccine	  since	  SIV	  specific	  antibody	  responses	  were	  weak	  with	  no	  
neutralization	  activity	  (Hansen	  et	  al.,	  2013).	  It	  is	  noteworthy	  to	  point	  out	  that	  this	  
RhCMV	  vaccine	  did	  not	   include	  Env	  as	  an	   immunogen	  and	   thus,	   the	  protection	  
could	   not	   have	   been	   mediated	   by	   anti-­‐Env	   antibodies.	   However,	   one	   of	   the	  
hurdles	   limiting	  the	  success	  of	  CD8+	  T-­‐cell	  responses	   is	  the	  tendency	  for	  HIV	  to	  
evade	  these	  responses	  through	  sequence	  evolution	  (Price	  et	  al.,	  1997,	  Goulder	  et	  
al.,	  1997a,	  Reece	  et	  al.,	  2013,	  Mudd	  et	  al.,	  2012).	   	  Studies	  have	   illustrated	  that	  
vaccinations	  can	  alter	  immune	  targets	  patterns	  (Vogel	  et	  al.,	  2002,	  Rodriguez	  et	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al.,	  2002,	  Hansen	  et	  al.,	  2013),	  thus	  vaccine	  approaches	  that	  can	  re-­‐direct	  CD8+	  
T-­‐cell	  responses	  to	  focus	  on	  particular	  conserved	  epitopes	  with	  high	  fitness	  costs	  
following	  escape	  should	  be	  considered.	   	  Although	  effector	  T-­‐cell	  responses	  may	  
be	   necessary	   to	   circumvent	   the	   rapid	   spread	   and	   the	   establishment	   of	   viral	  
reservoirs	   during	   acute	   infection,	   our	   data	   also	   suggest	   that	   generation	   and	  
maintenance	  of	  a	  substantial	  Gag-­‐specific	  central	  memory	  pool	   is	   still	  desirable	  
for	  viral	  control.	  The	  pivotal	  role	  of	  central	  memory	  responses	   in	  the	  control	  of	  
viral	  replication	  have	  been	  validated	  in	  an	  SIV	  vaccine	  study	  which	  demonstrated	  
that	   vaccine-­‐induced	   virus-­‐specific	   CD8+	   central	   memory	   T-­‐cell	   responses,	   not	  
the	   CD8+	   effector	   T-­‐cell	   response	   inversely	   correlated	   with	   the	   level	   of	  
SIVmac251	   replication,	   (Vaccari	   et	   al.,	   2005).	   	   Thus	   in	   conjunction	   with	   the	  
induction	  of	  Gag-­‐specific	  effector	  T-­‐cell	   responses,	  vaccination	  regimens	  should	  
also	  be	   focused	  on	  programming	  and	  maintaining	  Gag-­‐specific	   central	  memory	  
CD8+	  T-­‐cells	  able	  to	  expand	  adequately	  upon	  virus	  encounter.	  	  
	  
Robust	   Gag-­‐specific	   CD8+	   T-­‐cell	   responses	   have	   been	   shown	   to	   control	   viral	  
replication	  and	  reduce	  or	  abort	  disease	  in	  non-­‐human	  primate	  models,	  however,	  
it	   is	   still	   unclear	   whether	   CD8+	   T-­‐cells	   can	   actually	   eliminate	   an	   established	  
infection	   completely	   in	   the	   HIV-­‐1	   model	   (Liu	   et	   al.,	   2009a,	   Buchbinder	   et	   al.,	  
2008,	   Hansen	   et	   al.,	   2009,	   Hansen	   et	   al.,	   2011,	   Hansen	   et	   al.,	   2013).	  	  
Nonetheless,	   a	   non-­‐sterilizing	   vaccine	   may	   be	   beneficial	   as	   reductions	   in	   set	  
point	   viral	   loads	  will	   provide	  benefit	   to	  an	   infected	   individual	  by	   slowing	  down	  
the	  rate	  of	  disease	  progression	  while	  simultaneously	  reducing	  the	  probability	  of	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transmitting	   the	   infection	   to	  others,	   and	   thus	  provide	   the	  additional	  benefit	  of	  
reducing	  infection	  at	  the	  population	  level	  (Mellors	  et	  al.,	  1995,	  Gray	  et	  al.,	  2001).	  	  
	  
5. Impact	  of	  acute	  immune	  activation	  on	  HIV-­‐1	  disease	  progression	  
We	   show	   that	   three	   cytokines	   IL-­‐10,	   IP-­‐10	   and	   IL-­‐12	   were	   associated	   with	  
changes	  in	  viral	  load	  set	  point	  and/or	  CD4+	  T-­‐cell	  dynamics	  during	  the	  first	  year	  
of	   HIV-­‐1	   infection.	   	   Both	   human	   and	   non-­‐human	   primate	   studies	   suggest	   that	  
cytokine	   profiles	   during	   acute	   infection	   impact	   viral	   set	   point	   and	   disease	  
progression	   (Ansari	   et	   al.,	   2002,	  Mueller	   et	   al.,	   2008,	   Campillo-­‐Gimenez	   et	   al.,	  
2010,	   Roberts	   et	   al.,	   2010,	   Stacey	   et	   al.,	   2009).	   The	   notion	   that	   disease	  
progression	   can	   be	   influenced	   by	   cytokines	   during	   acute	   HIV-­‐1	   infection	   is	  
intriguing	  and	  raises	   the	  question	  of	  whether	  cytokines	  expressed	  during	  acute	  
HIV	   infection	   can	   be	   targeted	   through	   vaccination	   or	   immunotherapeutics	   to	  
alter	  viral	   set	  point	  or	   to	  preserve	  CD4+	  T-­‐cells.	  The	   rationale	  for	  HIV-­‐1-­‐specific	  
therapeutic	  vaccines	  stems	   from	   the	   observation	   that	   the	   severe	   immune	  
deficiency	   caused	   by	   HIV-­‐1	   infection	   is	   related	   to	   the	   levels	   of	   immune	  
dysfunction	  or	   immune	  activation	   seen	   in	  HIV-­‐1	   infection	   (Autran	  et	   al.,	   2004).	  	  
These	   immunotherapeutic	   vaccines	   thus	   aim	   to	   augment	   a	   host’s	   immune	  
response	   to	  HIV-­‐1	   so	   that	   viral	   proliferation	   and	   immune	  damage	   is	   slowed	  or	  
blocked	   (Ha	  et	  al.,	  2008,	  MacGregor	  et	  al.,	  1998,	  Autran	  et	  al.,	  2004).	   	  There	   is	  
also	  the	  anticipation	  that	  any	  immune	  response	  to	  a	  therapeutic	  vaccine	  strong	  
enough	   to	   control	   established	   infection	   would	   also	   be	   effective	   in	   preventing	  
initial	  infection	  in	  HIV-­‐naive	  subjects	  (Autran	  et	  al.,	  2004).	  	  It	  has	  been	  proposed	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that	   one	   of	   the	   reasons	   that	   current	   therapeutic	   vaccination	   strategies	   fail	   to	  
sustain	   or	   resurrect	   T-­‐cell	   responses	   is	   because	   they	   do	   not	   improve	   the	  
immunosuppressive	  environment	  which	  may	  be	  the	  result	  of	  increased	  levels	  of	  
anti-­‐inflammatory	  cytokines	  such	  as	  IL-­‐10	  (Brooks	  et	  al.,	  2008).	  
	  	  
Cytokines	   provide	   one	   of	   the	   most	   targeted	   factors	   used	   to	   investigate	  
alterations	  of	  viral	  kinetics,	  the	  recruitment	  of	  viral	  targets,	  and	  the	  development	  
of	   anti-­‐viral	   immunity	   (Katsikis	   et	   al.,	   2011).	   	   Blocking	   key	   suppressive	   factors	  
such	  as	   IL-­‐10	  could	  allow	   immune-­‐mediated	  control	  of	  persistent	  viral	   infection	  
and	  thus	  render	  ineffective	  vaccines	  more	  efficient	  at	  improving	  T-­‐cell	  immunity	  
(Brooks	  et	  al.,	  2008).	   Indeed,	   interventional	  studies	  to	  block	   IL-­‐10/IL-­‐10Rα	  have	  
been	  proposed	  as	  a	  potential	  adjuvant	  to	  vaccination	  regimens	  or	  as	  a	  strategy	  
to	   enhance	   underlying	   immunity	   in	   chronic	   viral	   infections,	   such	   as	   HIV	  
(Blackburn	  and	  Wherry,	  2007,	  Brooks	  et	  al.,	  2008).	  	  Similarly,	  IL-­‐12	  administration	  
in	   rhesus	   macaques	   acutely	   infected	   with	   SIV	   lowered	   viral	   set	   point	   by	   100-­‐
fold	  and	  also	  slowed	  disease	  progression	  (Ansari	  et	  al.,	  2002)	  and	  in	  vitro	  and	  in	  
vivo	  responses	  to	  IL-­‐12	  are	  usually	  maintained	  during	  late	  SIV	  infection	  (Villinger	  
et	   al.,	   2000,	   Watanabe	   et	   al.,	   1998).	   	   Based	   on	   the	   current	   findings,	   we	  
hypothesize	   that	   the	  use	  of	   cytokine	   adjuvants	   for	   therapeutic	   vaccines	   during	  
acute	   HIV	   infection	   may	   boost	   HIV-­‐specific	   immune	   responses	   or	   imprint	   an	  
immune	   response,	   which	   would	   alter	   viral	   load	   set	   point	   in	   the	   host	   whilst	  
preserving	  CD4+	  T-­‐cells.	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HIV-­‐1	  infection	  is	  associated	  with	  chronic	  immune	  activation	  ultimately	  resulting	  
in	   the	   functional	   exhaustion	   of	   T-­‐cells	   and	   this	   defect	   in	   responding	   T-­‐cells	   is	  
linked	  to	  the	  inability	  of	  the	  host	  to	  eliminate	  the	  persisting	  pathogen	  (Wherry	  et	  
al.,	   2003).	   Exhausted	   virus-­‐specific	   CD8+	  T-­‐cells	   up-­‐regulate	   PD-­‐1	   expression	  
during	   chronic	   HIV-­‐1	   infection	   and	   this	   expression	   correlates	  with	   viral	   load	   in	  
blood	  plasma	  of	  HIV-­‐infected	  patients.	  However,	  we	  show	  that	  the	  activation	  of	  
this	  PD-­‐1	  inhibitory	  pathway	  in	  acute	  HIV-­‐1	  infection	  is	  associated	  with	  a	  slower	  
disease	   progression	   and	   this	  may	   due	   to	   the	   inhibitory	   impact	   of	   PD-­‐1	   on	   the	  
detrimental	   effects	   of	   immune	   activation	   (Estes	   et	   al.,	   2008).	   Ha	   et	   al.	   (2008)	  
have	   suggested	   the	   use	   of	   therapeutic	   vaccination	   strategies,	   in	   combination	  
with	   blockade	   of	   the	   PD-­‐1	   pathway	   as	   treatment	   for	   chronic	   HIV-­‐1	   infection.	  
Although	  we	  are	  limited	  by	  the	  small	  sample	  size,	  our	  data	  suggest	  that	  using	  this	  
immunotherapeutic	   two-­‐pronged	   approach	   during	   acute	  HIV-­‐1	   infection	  would	  
require	   activation	   of	   the	   PD-­‐1	   inhibitory	   pathway	   in	   order	   to	   dampen	   early	  
immune	  activation.	  This	  may	  possibly	   lead	  to	  the	  containment	  of	   the	  spread	  of	  
virus	   thus	   limiting	   its	   pathogenic	   effect	   on	   CD4+	   T-­‐cells	   resulting	   in	   enhanced	  
viral	  clearance	  and	  a	  less	  rapid	  disease	  progression.	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6. Future	  directions	  
Despite	   the	   hurdles	   that	   HIV	   presents	   to	   vaccine	   development,	   the	   historic	  
success	  of	  vaccines	  for	  other	  pathogens	  argue	  that	  HIV	  vaccine	  research	  must	  be	  
continued	  and	  accelerated	  (Plotkin,	  2009).	  	  T-­‐cell	  vaccine	  approaches	  to	  HIV	  have	  
dominated	  much	   of	   the	   vaccine	   research	   agenda	   over	   the	   last	   decade	  mainly	  
because	   there	   is	  an	  abundance	  of	  data	   from	  HIV-­‐infected	   individuals	   indicating	  
that	   CD8+	   T-­‐cells	   are	   key	   in	   viral	   control	   and	   also	   because	   of	   the	   inability	   to	  
stimulate	  broad	  neutralizing	  antibodies	  through	  vaccination.	  However,	  evidence	  
from	   many	   other	   vaccine-­‐preventable	   infectious	   diseases	   demonstrates	   that	  
although	   antibody	   titers	   correlate	   with	   protection	   from	   infection,	   CD8+	   T-­‐cell-­‐
mediated	   immune	   responses	   are	   essential	   for	   protection	   against	   disease	  
suggesting	  that	  a	  dual	  approach	  is	  still	  warranted	  in	  HIV-­‐1	  vaccine	  development	  
(Plotkin,	  2013,	  Plotkin,	  2010,	  Schiffner	  et	  al.,	  2013).	  	  	  
	  
Despite	   the	  extensive	   characterization	  of	  CD8+	  T-­‐cell	   responses	   induced	  during	  
acute	  and	  chronic	  HIV	   infection,	   there	  still	   remains	  a	  general	   lack	  of	  consensus	  
regarding	   the	   association	   of	   these	   responses	   with	   effective	   control	   of	   virus	  
replication	  and	  in	  fact	  a	  clear	  “correlate	  of	  immunity”	  based	  on	  any	  existing	  CD8+	  
T-­‐cell	  measurements	   is	  still	   lacking	  (Ogg	  et	  al.,	  1998,	  Addo	  et	  al.,	  2003,	  Betts	  et	  
al.,	  2001,	  Goonetilleke	  et	  al.,	  2009,	  Gray	  et	  al.,	  2009).	  	  	  Although	  the	  reasons	  for	  
this	  have	  been	  deemed	  as	  multifaceted,	  others	  attribute	  this	  to	  limitations	  of	  the	  
most	   commonly	   employed	   ex-­‐vivo	   cytokine-­‐production	   assays	   mainly	   the	  
ELISPOT	   (used	   in	   the	   current	   study)	   (Wilson	   et	   al.,	   2000,	   Gray	   et	   al.,	   2009).	  	  
	   151	  
Currently,	  interferon-­‐γ	  ELISPOT	  assays	  rank	  among	  the	  most	  validated	  assays	  for	  
HIV-­‐1	   vaccine	   trials	   because	   of	   ease	   of	   reproducibility,	   high	   sensitivity	   and	  
quantitative	   precision	   in	   mapping	   the	   targeting	   and	   magnitude	   of	   CD8+	   T-­‐cell	  
responses	   particularly	   in	   samples	   with	   low-­‐frequency	   responses	   (Dubey	   et	   al.,	  
2007,	   Fu	   et	   al.,	   2007,	   Valentine	   and	  Watkins,	   2008,	   Saade	   et	   al.,	   2012).	   	   The	  
major	   limitation	   of	   ELISPOT	   is	   that	   it	   does	   not	   provide	   information	   on	   the	  
phenotype	  of	  the	  responding	  T-­‐cell	  or	  its	  antiviral	  function	  and	  properties	  (Yang,	  
2003,	  Valentine	  et	  al.,	  2008,	  Ogg	  et	  al.,	  1998,	  Addo	  et	  al.,	  2003,	  Betts	  et	  al.,	  2001,	  
Goonetilleke	  et	  al.,	  2009,	  Gray	  et	  al.,	  2009).	   	  Future	  studies	  should	  pay	  greater	  
attention	   on	   qualitative	   features	   of	   CD8+	   T-­‐cell	   responses	   and	   the	   qualitative	  
features	  most	   closely	   associated	  with	   immunologic	   control	   of	   HIV,	   such	   as	   the	  
ability	  of	  HIV-­‐specific	  CD8+	  T-­‐cells	   to	   increase	  their	  contents	  of	  proteins	  known	  
to	   mediate	   cytotoxicity	   appears	   to	   be	   a	   critical	   means	   by	   which	   HIV-­‐specific	  
cytotoxic	   capacity	   is	   regulated	   (Wherry	   et	   al.,	   2005,	   Migueles	   et	   al.,	   2002,	  
Migueles	  et	  al.,	  2008).	  	  	  
One	  of	  the	  findings	  in	  this	  study	  is	  that	  the	  immune	  response	  is	  narrowly	  directed	  
during	  acute	  HIV	  infection.	  	  An	  effective	  vaccine	  would	  need	  to	  stimulate	  a	  broad	  
CD8+	  T-­‐cell	   response	   to	   multiple	   epitopes	   that	   are	   highly	   conserved	   and	   to	  
common	   variants	   of	   the	   founder	   virus	   epitope	   sequence	   as	   this	   would	   limit	  
escape	  options	  (McMichael	  et	  al.,	  2010).	  	  Thus	  future	  studies	  should	  also	  aim	  to	  
establish	  mechanisms	  responsible	  for	  the	  narrow	  CD8+	  T-­‐cell	   immune	  response	  
during	  acute	  HIV-­‐1	  infection.	  	  The	  relevance	  of	  immune	  activation	  pathways	  and	  
acute	  phase	   cytokines	   in	  directing	  or	   influencing	  T-­‐cell	   signalling	  pathways	   and	  
responsiveness	   should	   also	   be	   investigated.	   	   	   Answers	   to	   these	   questions	  may	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enable	   better	   vaccine	   design	   and	   immune	   measurement	   assays,	   which	   could	  
significantly	  advance	  the	  field.	  
The	   initial	   analysis	   of	   the	   STEP	   trial	   showed	   that	   neither	   protection	   against	  
infection	  nor	  control	  of	   initial	  viraemia	  despite	  the	  presence	  of	  vaccine-­‐induced	  
T-­‐cell	  responses	  (Buchbinder	  et	  al.,	  2008,	  McElrath	  et	  al.,	  2008).	  However,	  more	  
recent	  reports	  show	  that	  individuals	  with	  3	  or	  more	  Gag-­‐specific	  responses	  have	  
lower	   viral	   loads	   (Janes	   et	   al.,	   2013).	   	   These	   data	   provide	   much-­‐needed	  
momentum	   for	   the	   development	   of	   new	   approaches	   and	   for	   rigorous	   re-­‐
evaluation	  of	  current	  approaches.	  Based	  on	  our	  findings	  and	  reports	  from	  others,	  
what	   appears	   to	  be	   the	   logical	   direction	   that	   vaccine	   research	   should	   follow	   is	  
the	  application	  of	  modalities	  designed	  to	  stimulate	  effector	  memory	  and	  central	  
memory	  CD8+	  T-­‐cells,	  which	  differ	  in	  quality,	  quantity,	  phenotype,	  breadth,	  from	  
the	  vaccines	   tested	  previously,	   for	  which	  multiple	  approaches	  are	  available.	   	   In	  
order	   to	   identify	   the	   precise	   immunological	   correlates	   of	   protection	   an	  
immunological	   portfolio	   comprised	   of	   a	   multi-­‐faceted	   evaluation,	   rather	   than	  
relying	   on	   the	   measurement	   of	   IFN-­‐γ	   secretion	   should	   be	   generated	   for	   the	  
evaluation	  of	  vaccine	  efficacy.	  	  
 
Future	   studies	   should	   also	   focus	   on	   elucidating	   the	   complex	   interactions	  
between	  HIV-­‐1	  and	  cytokines	  expressed	  in	  the	  host	  during	  acute	  HIV-­‐1	  infection	  
in	   order	   to	  more	   accurately	   predict	   the	   effect	   of	   the	   cytokine	   interventions	   as	  
vaccine	   adjuvants.	   	   Moreover,	   the	   cell	   types	   and	   tissues	   expressing	   these	  
cytokines	  and	  antigens	  responsible	  for	  triggering	  these	  cytokines	  will	  have	  to	  be	  
identified.	   	   In-­‐depth	   understanding	   of	   immune	   activation	   and	   exhaustion	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pathways	   during	   acute	   HIV-­‐1	   infection	   is	   also	   much	   needed	   as	   this	   may	   help	  
uncover	   additional	   pathways	   critical	   for	   control	   of	   viral	   replication.	   	   Finally,	  
understanding	  kinetics	  of	  cytokines	  such	  as	  IL-­‐10	  or	  the	  underlying	  mechanisms	  
of	  PD-­‐1	  expression	  and	  regulation,	  and	  how	  these	  biomarkers	  affect	  the	  quality	  
and	  quantity	  of	  T-­‐cell	  responses,	  may	  not	  only	  provide	  fundamental	  insight	  into	  
the	   poorly	   understood	  mechanisms	   that	   control	   viral	   replication	   but	  may	   also	  
inform	   the	   development	   of	   novel	   immunotherapeutics	   or	   vaccine	   adjuvants	  
against	  HIV.	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